The 52 and 60 kD Ro/SS-A : antigens where are they? : do anti-Ro/SS-A autoantibodies cause cutaneous disease? by Yell, Jennifer Anne
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
THE 52 AND 60 kD Ro/SS-A 
ANTIGENS WHERE ARE THEY? 
DO anti-Ro/SS-A AUTOANTIBODIES 
CAUSE CUTANEOUS DISEASE? 
Jennifer Anne Yell 
M.B.,Ch.B.(Cape Town), MRCP (United Kingdom) 
Submitted in fulfillment of the 
requirement for the degree of 
DOCTOR OF MEDICINE 
in the 
DEPARTMENT OF DERMATOLOGY 
FACULTY OF MEDICINE 
UNIVERSITY OF CAPE TOWN 
July, 1997, revised March 1998 
n·~ ' 1 ;, •• , .. . · '' •.•• :~ 1"..twn t1ds Uee1, 
· the ri:,:',, 10 ., .. ,., ... ,,l r:e tl ,i tho~, i 1 ~ " 
or in .~,t. Copy,i~ht is f-rld b, the l, • . r. 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
CONTENTS 
1. CUTANEOUS LUPUS ERYTHEMATOSUS ................... 18 
1.1 EPIDEMIOLOGY •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 18 
1.2 PATHOGENESIS •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 19 
1.2.1 Genetic factors ............................................................................... 19 
1.2.2 Environmental factors .................................................................. 21 
1.2.3 Hormonal factors ..............................•..........•...•.•.•.......••............... 22 
1.2.4 Disturbance of immune regulation .............................................. 26 
1.2.5 Clinical Subsets ............................................................................. 29 
2. THE RO ANTIGENS ........................................................... 43 
2.1 HISTORICAL BACKGROUND •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 44 
2.1.1 1969: A novel soluble cytoplasmic antigen is described ........... 44 
2.1.2 1975: Sjogren's syndrome antibodies were described .............. 45 
2.1.3 1979: Collaboration concludes that Ro and SS-A are similar. 45 
2.2 EVIDENCE FOR P ATHOGENICITY ....................................................... 46 
2.2.1 Epidemiology ..............................................................................•.. 46 
2.2.2 Clinical ........................................................................................... 47 
2.2.3 Histology ........................................................................................ 49 
2.2.4 Immunopathology ......................................................................... 50 
2.3 THERE ARE A NUMBER OF DIFFERENT Ro ANTIGENS ....................... 52 
2.3.1 60 kD Ro ......................................................................................... 58 
2.3.2 52 kD Ro ......................................................................................... 60 
2.3.3 calreticulin ..................................................................................... 68 
2 
2.3.4 54 kD Ro ...............•....•.•.•.•..•..................•.............•.•.........••...........•• 70 
2.3.5 Cross-reacting epitopes .....................................................•.•.•.••... 71 
2.4 METHODS FOR DETECTION OF RO ANTIBODIES •••••••••••••••••••••••••••••••• 71 
2.4.1 Indirect Immunofluorescence ...................................................... 72 
2.4.2 Immunodiffusion .....................................................•..................... 74 
2.4.3 Immunoblotting ..••..............•..................................................•.•..•.. 75 
2.4.4 Imm unoprecipitation .•.•.•.•...........................................•................ 76 
2.4.5 ELISA ...................•.........•.............................................................•. 77 
3. ANTIBODY PURIFICATION ........................................... 79 
3.1 INTRODUCTION ............................................................................ 79 
3.2 METHODS ..••....•..•.....•.....••..•......................................•...••••....••••••.•. 80 
3.2.1 Recombinant Gst Ro Fusion Protein .......................................... 80 
3.2.2 Rabbit Immunisation ............................................................•.•..... 83 
3.2.3 Characterisation Of Human Sera ............................................... 85 
3.2.4 Antibody Purification ................................................................... 86 
3.2.5 Antibody Characterisation .......................................................... 91 
3.3 RES UL TS ......•..••..••....•...••••••.......•..•.•.••.•.•.......•..•.•.....•.•.•..•....•..••...... 93 
3.3.1 Multiple types of anti-52 and anti-60 kD Ro antibodies were 
purified .................................................................................................... 93 
3.3.2 Cultured keratinocytes and human epidermis express the 52-
and 60-kD Ro proteins ........................................................................... 93 
3.4 DISCUSSION ...............................................................................•... 99 
3.4.1 Multiple types of anti-52 and anti-60 kD Ro antibodies were 
pu rifled ..............................•..................................................................... 99 
3.4.2 Cultured keratinocytes and human epidermis express the 52-
and 60-kD Ro proteins ......................................................................... 102 
3 
3.4.3 No evidence that Ro autoantibodies cross-react with the 52- and 
60-kD Ro proteins ................................................................................ 103 
4. LOCATION OF RO ANTIGENS IN CELLS ................. 104 
4.1 INTRODUCTION •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 104 
4.2 METHODS ..................................................................................... 107 
4.2.1 Keratinocyte culture ................................................................... 107 
4.2.2 Immunofluorescence ................................................................... 111 
4.3 RES UL TS ........................................................................................ 113 
4.3.1 Anti 52 kD Ro autoantibodies .................................................... 113 
4.3.2 Anti 60 kD Ro autoantibodies .................................................... 114 
4.4 DISCUSSION ................................................................................. 121 
4.4.1 Anti 60 kD Ro autoantibodies .................................................... 121 
4.4.2 Anti 52 kD Ro autoantibodies .............................................••.•••. 122 
5. DO THE RO ANTIBODIES CAUSE CUTANEOUS 
DISEASE? ............................................................................... 125 
5.1 CAN Ro ANTIBODIES PENETRATE LIVING CELLS? ....... 125 
5.1.1 Introduction ................................................................................. 125 
5.1.2 Methods ........................................................................................ 127 
5.1.3 Microscopy ................................................................................... 130 
5.1.4 RESULTS ..................................................................................... 130 
5.1.5 DISCUSSION .......•..........•........................................................... 136 
5.2 DO THE Ro ANTIGENS TRANSLOCATE TO THE CELL 
SURFACE? ........................................................................................... 140 
5.2.1 Introduction ....•..........................•................................................. 140 
5.2.2 Methods ........................................................................................ 145 
5.2.3 Results .......................................................................................... 150 
4 
5.2.4 Discussion ..................................................................................... 159 
5.3 POSSIBLE ROLES PLAYED BY THE Ro ANTIGENS .......... 168 
6. PROPOSALS FOR FUTURE WORK ............................. 170 
7. PROTOCOLS NOT PREVIOUSLY DESCRIBED ....... 173 
8. PUBLICATIONS ............................................................... 179 
8.1.1 Letters ........................................................................................... 179 
8.1.2 Papers ........................................................................................... 179 
8.1.3 Abstracts ...................................................................................... 180 
9. DECLARATION ............................................................... 182 
10. REFERENCES ................................................................. 184 
5 
FIGURES 
figure 1: The facial rash of SLE may vary from telangiectasia, through malar 
erythema, through more indurated erythema ........................................ ............ 32 
figure 2: Typical bullous SLE .................... .. ........ .......... .... ....... .. ...... ... ..... .. .............. .. 34 
figure 3: Cutaneous lesions of SCLE ........ ...... .... .. ...... .. .. .... ... .. ... ...... ....... .. .. ...... ....... .. 36 
figures 4 and 5: Chronic disco id lesions ................. ..... ........ ... .. ........ ........ ....... ... ........ 3 7 
figures 6 and 7: Hair loss is a common and characteristic finding in SLE. Alopecia 
may be scarring, if preceded by DLE, or non-scarring . ... ............ .. .. ................ 38 
figures 8 to 12: Mucous membrane involvement in SLE ... ...... ......... ...... ..... .... .... .... .. 38 
figure 13: Photosensitivity .......... ......... ..... ... ........ ....... ..... .... ....... .............. .... .... .......... 40 
figure 14: lupus profundus .. ..... ..... ............................. .... ........... ... ........... ........... ......... 42 
figure 15: anetoderma associated with SLE . ...... ... ....................... ... ......... .................. .42 
figure 16: Schematic view of the 52 kD Ro protein, showing the areas against which 
various antibodies were purified .. .................................... ...................... .. ... ... .. 94 
figure 17: Schematic view of the 60 kD Ro protein, showing the areas against which 
various antibodies were purified .. ....... .... .............. ....... ... .. ... ........... .. .. ....... ...... 94 
figure 18: Western immunoblot detects the 52 and 60 kD Ro proteins .... ... ... ........ .... 96 
figure 19: Purified Ro antibodies were specific for either the 52- or the 60-kD Ro 
protein as demonstrated by ELISA. (<1) Purified human anti-52-1 b, anti-52-2, 
6 
rabbit antisera raised against whole recombinant 52 kd Ro (rab anti-52) and a 
1: 100 dilution of normal sera (normal) were reacted with a panel of antigens.97 
figure 20: Purified Ro antibodies were specific for either the 52- or the 60-kD Ro 
protein as demonstrated by ELISA. (b) Purified human anti-60-2, anti-60-4, 
anti-native 60 kD Ro (anti-n60) and rabbit antisera raised against the full-
length recombinant 60 kD Ro (rab anti-60), were similarly tested .. ...... .... ...... 98 
figure 21: The 52 kD Ro antigens are immunolocalised to the cytoplasm in normal 
cultured keratinocytes ............... ........ .. ... .... ... .. ...... ..... .... ...... .. .. .......... ........ .... 115 
figure 22: Confocal laser microphotographs reveal both nuclear and cytoplasmic 
localisation of 52 kD Ro, depending on cell confluence .. .... ........... ... ....... .. ... 116 
figure 23: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the recombinant 60-2 kD 
fragment. ............... .. .......... ... .. ....... ... .................... ............ .. .. ....... ... .... ... .. ... .... 11 7 
figure 24: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the recombinant 60-4 kD 
fragment. ........... ......... ....... ....... ............. .......... .... ..... .......... ...... .... .. ...... ........ .. 11 7 
figure 25: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the native 60 .... ... .. ..... 118 
figure 26: Confocal laser microphotographs reveal predominantly nuclear localisation 
of 60 kD Ro. Immunofluorescence of cultured human keratinocytes with 
purified human anti-60-2, anti-60-4, anti-native bovine 60 kD Ro and a 1: 100 
dilution of normal serum ... ... ... ..... .. .. ... ..... ... ... ... ... ... ........ ..... .... .... ....... ..... ...... 118 
figure 27: Confocal laser microphotographs of the double-immunofluorescent 
localisations of the 52 and 60 kD Ro confirm disparate locations of the 52 and 
60 kD Ro proteins in confluent keratinocytes ..... ............... .... ....... .. .. ..... ........ 119 
7 
figure 28: Confocal laser microphotographs of the double-immunofluorescent 
localisations of the 52 and 60 kD Ro confirm disparate locations of the 52 and 
60 kD Ro proteins in confluent keratinocytes .................................. .............. 120 
figure 29: No intracellular fluorescence was obtained for any anti-60kD antibody, for 
all perturbations ............. ..... ........................ ........ .... .. .... .... ............... ... ............ 132 
figure 30: No intracellular fluorescence was obtained for or any anti-52kD antibody, 
for all perturbations ...... ........ ....... ...... .......... ....... ......... ... ....... ......................... 131 
figure 31: No intracellular fluorescence was obtained normal serum, used as a 
negative control. ... ...... ..... .. .... .... ....................... ....... ............ .......... ..... ............ 132 
figure 32: Serum 2429 showed fluorescence incubated with viable normal 
keratinocytes for 5 min ......... ......... ........... .. ...... .. ..... ....... .. .... .... ...................... 134 
figure 33: Serum 2429 showed fluorescence incubated with viable normal 
keratinocytes for 5 mm. Positive control was serum 2429 on fixed 
keratinocytes .......... ... .. .. ...... .... ..... ....... .. ......... ................................................. 134 
figure 34: Proposed model for Ro translocation .............................. ... ...................... 144 
figure 35: The ultraviolet lamps were mounted on opposing sides of a wooden gantry 
and shielded appropriately from the operator .......................... ..... .................. 146 
figure 36: Translocation / surface fluorescence negative controls ... ... ................ .... ... 153 
figure 37: Translocation / surface fluorescence negative controls . .. .... .. ........ .. ........ .. 153 
figure 38: Translocation / surface fluorescence . No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD Ro antigens. Some speckling of 
viable keratinocytes was found when incubated with serum 2429 after 
irradiation with UVB 1. 5 mJ/cm2 and prior incubation with a 10-7 M solution 
of 17 ~ Oestradiol .... ........ .... .. .... ... .. ...... ... ....... .. ... .... .. ....... ... .......................... 155 
8 
figure 39: Translocation / surface fluorescence. No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD antigens. Some speckling of 
viable keratinocytes was found when incubated with serum 2429 after prior 
incubation with Hydrochlorothiazide 100 ng/ml. .......................................... 156 
figure 40: Translocation / surface fluorescence. No supplements, with or without 
UVR, caused trans location of the 52 or 60 kD Ro antigens. Some speckling of 
viable keratinocytes was found when incubated with serum 123, I hour post 
UVB 1.5 mJ/m2 •• •••••••••••••••••••••••••••••••••••••••••••••••••••••••• •••• •••••••••••••••••••••••••••••••• 157 
figure 41: Translocation / surface fluorescence. No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD Ro antigens. Some surface 
fluorescence of viable keratinocytes was found when incubated with whole 
autoimmune sera ... .... ....... .... ................ .................... ........... ........................... 158 
9 
TABLES 
Table 1 The Gilliam classification of skin lesions associated with LE ........................ 29 
Table 2: Cutaneous manifestations in large SLE series ............................................... 42 
Table 3: Viability of normal neonatal keratinocytes with varying doses ofUVB at one 
or twenty hours post irradiation ..................................................................... 150 
Table 4: Viability of cells after supplementation+/- UVB, at 20 hrs post irradiation151 
10 
PROTOCOLS 
Protocol 1: Large scale recombinant protein production ............................................. 81 
Protocol 2: Rabbit Immunisation .... ... .. ... .. ... ......................... ..... ............. .... ... .............. 83 
Protocol 3: SDS-PAGE ... ........................................ ... ........ .... .................... .................. 86 
Protocol 4: Summary of antibody stripping and storage of strips ............................... 88 
Protocol 5: ELISA method for purification of anti-native 60kD Ro ........................... 89 
Protocol 6: Antibody concentration ............................................................................. 92 
Protocol 7: Cell extract preparation ........................................................... .................. 91 
Protocol 8: ELISA for confirming purified antibody specificity ................................ 92 
Protocol 9: Definitive keratinocyte culture ......... .... ..... ....... ................ ........... ............ 107 
Protocol 10: Subculturing of keratinocytes ................... ....... ..................................... 108 
Protocol 11: Freezing keratinocytes .......................................................................... 108 
Protocol 12: Thawing keratinocytes frozen in Liquid Nitrogen ................................ 109 
Protocol 13: Dispase for epidermal separation ......................................................... 109 
Protocol 14: Comparing various described keratinocyte culture methods ................ 109 
Protocol 15: Immunofluorescence of fixed keratinocytes ........................ ................. 111 
11 
Protocol 16: Immunofluorescence on pre-treated DNAse and RNAse keratinocytesl 12 
Protocol 17: Assessment of viability ......................................................................... 127 
Protocol 18: Immunofluorescence on viable keratinocytes ....................................... 128 
Protocol 19: ELISA to assess surface antigen expression on unfixed keratinocytes .129 
Protocol 20: ELISA to assess surface antigen expression on fixed keratinocytes .... 129 
Protocol 21: Surface ELISA Permutations ................................................................. 130 
Protocol 22: Polyvinyl alcohol mounting medium for immunofluorescence .......... 173 
Protocol 23: Buffers used for western blotting .......................................................... 174 
Protocol 24: Buffers used for ELISA ........................................................................ 175 
12 
ACKNOWLEDGMENTS 
My interest in cutaneous lupus erythematosus was kindled more than 6 years ago 
when I became involved in the care of the cutaneous lupus erythematosus patients in 
Oxford. 
I am grateful to Dr. Susan M. Burge who first introduced me to the fascination of this 
disease as a dermatology registrar in Oxford, United Kingdom. I would like to thank 
Prof. T. Ryan and Dr. Fenella Wojnarowska for the time they have devoted to me over 
the years while working in the Oxford Dermatology department. Their 
13 
encouragement was vital in organising my Immunodermatology fellowship in North 
Carolina, USA. 
I wish to acknowledge Dr. P. McCauliffe and Prof. R. Brigamann for their consistent 
encouragement and skillful guidance of the work in the department of Dermatology, 
University of North Carolina at Chapel Hill, North Carolina, United States of 
America. I thank Mr. Lixiang Wang for his patient introduction into an American 
research laboratory and his informal molecular biology tutorials. I am most grateful to 
Mr. Sam Tesfai, department of Cell Biology, University of North Carolina at Chapel 
Hill, for his gentle guidance in the art and science of confocal microscopy. 
The Arthritis and Rheumatism Council of the United Kingdom awarded me the 
Copeman Traveling Fellowship , to fund my time in the USA and the National 
Institute of Health of the United States of America (Grant AR41445 ) met my 
laboratory expenses. 
Most of all I would like to thank my parents, my husband and my children for their 
love, encouragement and willingness to follow me around the world in pursuit of my 
interest. 
14 
ABSTRACT 
Systemic lupus erythematosus, considered a multifactorial autoimmune disease, is a 
disease affecting many systems, with associated immunological abnormalities. It has 
a striking diversity of clinical patterns, pathologies and prognoses. Genetic factors 
determine the inherited baseline, on which environmental, hormonal and infectious 
triggers act to produce autoantibodies. 
Ro antibodies have been considered pathogenic in subacute cutaneous and neonatal 
lupus erythematosus. I affinity-purified antibodies to the 52 kD Ro from immunised 
rabbits (whole 52 kD protein) and human sera (using two immunodominant regions 
of the protein). I affinity-purified antibodies to the 60 kD Ro from immunised rabbits 
(whole 60 kD protein) and human sera (using two immunodominant regions of the 
protein, as well as the total "native" protein). 
Using these purified antibodies, with immunofluorescence on normal neonatal human 
keratinocytes, I showed that the 52 kD Ro is mainly cytoplasmic and the 60 kD Ro is 
mostly nuclear, with some fine cytoplasmic staining. 
I looked at the capacity of these purified antibodies to penetrate living keratinocytes 
under various conditions (hormones, drugs and vitamins). No antibody penetration 
was found, although one whole serum gave low levels of intracellular fluorescence. 
I studied the putative membrane translocation of 52 kD and 60 kD Ro under 
conditions of stress (UV A or UVB with or without hormones, drugs, vitamins and 
heat shock). I could not identify translocation of the 52 or 60 kD antigens with 
purified antibodies, although some whole sera showed fluorescence. 
I can find no evidence that antibodies directed against the 52 and 60 kD Ro antigens 
cause cutaneous disease. 
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1.CUTANEOUSLUPUSERYTHEMATOSUS 
Systemic lupus erythematosus (SLE) is a multisystem disease with associated 
immunological abnormalities. It has a striking diversity of clinical patterns, 
pathologies and prognoses. Skin manifestations are some of the most common 
symptoms and signs in SLE. They are important in diagnosing SLE: cutaneous 
lesions account for 4 of the 11 revised American College of Rheumatology (ACR) 
criteria for the classification of SLE (Tan et al 1982). 
1.1 Epidemiology 
The incidence of SLE in the UK is 24.6 per 100 000 population per year, 3.7/100 
000/year for men and 45.4/100 000/year for women (Hopkinson et al 1993). The 
highest incidence for both men and women is in the 50-59 year age range. SLE is 
more common among Afro-Caribeans than other groups. 
Skin involvement in SLE is seen in 72-85% of patients (Dubois & Tuffanelli, 1964; 
Harvey et al 1954). Cutaneous involvement is the first manifestation of lupus in 23-
28% (Dubois & Tuffanelli, 1964; Harvey et al 1954) of patients. 
9.9% to 12% of SLE patients have been reported to have an affected first degree 
relative (Grigor et al 1978), 7% with a first degree relative with photosensitivity 
(McCauliffe et al 1992). It is estimated that first-degree relatives of patients with SLE 
have an 11 fold greater chance of acquiring SLE than the general population 
(Lawrence et al 1987). 
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1.2 Pathogenesis 
SLE is considered a multifactorial autoimmune disease. Genetic factors determine the 
inherited baseline, on which environmental, hormonal and infectious triggers act to 
produce autoantibodies. Autoantibodies, along with other mediators of tissue injury, 
including complement and inflammatory cells, are likely to cause disease. 
1.2.1 Genetic factors 
Genetic factors are important in the pathogenesis of LE. The major histocompatibility 
(MHC) class II antigen HLA-DR3 is associated with the presence of anti-Ro/SSA 
antibodies in subacute cutaneous lupus erythematosus (SCLE) (Lee et al 1983), 
neonatal lupus erythematosus (NLE) (Lee et al 1983) and Sjogren' s syndrome (Harley 
et al 1986). The presence of both anti Ro and anti-La/SS-B in SLE is associated with 
HLA-DR3 and is seen in older patients (>50 years age at onset) (Hochberg et al 
1985). A large SLE study group have subsequently shown that a strong association 
with HLA-DR3 was found for antibodies against Ro52 and La, rather than anti-Ro60 
in the absence of anti-52 or anti-La (Ehrfeld et al 1992). This suggests that the DR 
association in SLE is an epitope-specific immune response. The SLE patients with 
anti-Ro alone, had an association with HLA-DR2 and tended to be younger (<22 years 
of age at onset). No HLA association has been found in infants with NLE or 
congenital heart block (Watson et al 1984). 
Associations between an allele of the interleukin- I receptor antagonist gene (IL 1 RN) 
and several inflammatory diseases have been described. There is an increase in both 
frequency and carriage rate ofIL1RN*2 in SLE. This association is strengthened with 
extensive disease and particularly with the presence of photosensitivity and discoid 
skin lesions. Carriage of this allele seems to influence severity rather than 
susceptibility to SLE (Blakemore et al 1994). 
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Overexpression of heat shock protein 1s associated with the anti-phospholipid 
syndrome. This may be due to genetic factors, as this group of 94 SLE patients had 
an absence of the HLA allo-or haplotypes, commonly found in such a cohort (Dhillon 
et al 1994). 
A study of 121 SLE patients, 119 of whom were complement typed, showed that both 
black and white patients with SLE were far more likely to have a C4a null allotype 
than were racially matched controls. A detailed evaluation of the relationship to 
different types of antibodies was performed. Anti-ds-DNA, anti-Sm, anti-Ro and 
anticardiolipin antibodies were less common in patients with homozygous C4a 
deficiency. C4a gene deletion was found in 23.4% of patients and was associated with 
SCLE and SS in SLE patients. The presence of one or two C4a null allotypes and the 
presence of a C4a gene deletion identify subgroups of SLE patients whose 
characteristics differ in many ways from those of other SLE patients (Petri et al 1993). 
However, most people with lupus-associated genes, such as DR3, do not develop LE. 
Other triggering factors must operate. Viral infection may result in production of 
antibodies to a portion of the virus that is similar to a portion of an autoantigen, so 
that antibodies to the virus cross-react with the autoantigen. In a study of 80 SLE 
patients, 80 healthy controls, 47 rheumatic disease controls and a small number of 
patients infected with the vesicular stomatitis virus, there was significantly different 
binding to the viral proteins in the SLE patients compared with other groups. The 
reactivity of the SLE sera included binding to the internal viral matrix and the 
nucleocapsid proteins (Hardgrave et al 1993). 
In a genetically susceptible individual at high rates of generation of novel fragments, 
such as in irradiation, heat shock, bacterial or viral infection, or xenobiotic exposure, 
the appropriate MHC class II molecules may capture and present self-peptides that 
were previously cryptic (Lipham et al 1991). As in other systems, the immune 
response to this self-peptide may subsequently diversify to other areas on the self-
molecule to which the organism was previously tolerant (Mamula, 1993). Subsequent 
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re-exposure of the primed immune system to low levels of "apoptotic" autoantigen, 
such as in sun exposure, may lead to clinical flares (Casciola-Rosen et al 1994) 
1.2.2 Environmental factors 
Sunlight is a well established factor in the induction and exacerbation of LE. The 
relationship of ultraviolet irradiation (UVR) to the development of SCLE and NLE is 
well established. UVR appears to up-regulate the binding of anti-Ro/SSA antibodies 
to keratinocytes, both in vitro and in vivo (Furukawa et al 1990). 
Clinically, it has been shown that lupus patients have a lowered minimal erythema 
dose (MED) to UVB compared with normal controls. A lowered MED was found 
most frequently in SLE (64%) and least frequently in DLE (32%). Prolonged 
persistence of erythema induced by 1-2 MED was a constant finding in SCLE. 
(Wolska et al 1989) Photoreproduction of lesions after single UVB exposure was 
observed most frequently in SCLE (62.5%) (Wolska et al 1989). 
In addition, skin lesions in LE have been induced by both UV A and UVB irradiation. 
Lehmann et al showed that skin lesions clinically and histologically compatible with 
LE were induced in 64% of patients with SCLE, 42% of patients with DLE and 25% 
of patients with SLE. The action spectrum of induced lesions was within the UVB 
range in 33%, in the UVA range in 14% and in both the UVB and UVA range in 53% 
(Lehmann et al 1990). 
UV A is the predominant UV component in solar radiation. UV A and UVB irradiation 
in both hun1an and SLE derived cells in vitro shows increased sensitivity with a very 
low threshold for unscheduled DNA repair synthesis, coexisting with limited cellular 
DNA repair capacities (Golan & Boerel, 1984 ). In addition, UV A irradiation of 
murine SLE-derived cells (both morbid and pre-morbid) is accompanied by elevated 
oxygen consumption (which reflects increased accumulation of oxygen reactive 
radicals) in comparison to normal cells (Golan et al 1994). Based on this data, it has 
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been suggested that SLE-derived cells are defective in the enzymatic pathways of 
removing oxygen radical species and this may have a bearing on the lower threshold 
for the UV-induced DNA damage observed in such cells. In support of this, is a paper 
showing that peripheral blood SLE lymphocytes are hypersensitive to the toxic effects 
of hydrogen peroxide. The DNA of these cells exhibit raised levels of 8-oxo-7-
hydrodeoxyguanosine (a DNA lesion induced by reactive oxygen species) (Bashir et 
al 1993). 
The prevalence of SLE among uranium miners heavily exposed to silica, is 93 per 100 
000 (Conrad et al 1996). The only differences to non-exposed SLE patients were a 
decreased frequency of arthritis and photosensitivity and an absence of anti-Sm and 
anti-Ul-RNP antibodies. ANA were found in all definite SLE patients, with anti-
dsDNA in 44.4%, anti-Ro in 55.6% and anti-La in 22.2% (Conrad et al 1996). 
Reed et al in 1985 (Reed et al 1985) reported five patients with the clinical and 
histological features of SCLE and anti-Ro antibodies, while taking 
hydrochlorothiazide. All resolved after drug discontinuation. Anti-Ro positive SCLE 
has also been reported following hydralazine, penicillamine and glyburide 
(Sontheimer, 1989). 
1.2.3 Hormonal factors 
Sex hormones are an additional influence in LE. Concordant experimental studies 
have clearly demonstrated harmful effects of oestrogens in NZB/NZW FI mice, which 
develop an autoimmune disease similar to human SLE (Roubinian et al 1979; 
Steinberg et al 1979). The importance of oestrogen is suggested by the demography 
of LE. LE occurs more commonly in females. The female: male ratio in SLE can be 
as high as 10: 1 in menstruating women. This ratio falls to 3: 1 in non-menstruating 
girls or post-menopausal women (Kornreich, 1976). Although more males develop 
SCLE or DLE than SLE, even in these groups, women outnumber men, 70 to 80% of 
SCLE patients being female (Sontheimer et al 1979). In NLE, 75% with skin disease 
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are female, whereas the number of girls with congenital heart block only slightly 
exceeds that of boys (McCune et al 1987) 
Oestrogens can upregulate the binding of anti-Ro/SSA antibodies to cultured 
keratinocytes (Furukawa et al 1988). Clinical improvement in SLE has been reported 
following removal of the female sex organs (Yocum et al 1975). SLE may exacerbate 
with oestrogen containing oral contraceptives (Bole et al 1969). 
Chronic oestrogenic stimulation due to elevated oestradiol levels may account for the 
association of SLE and Klinefelter's syndrome (Stern et al 1977). Both male and 
female SLE patients have elevated conversion of oestradiol to 16-hydroxylated 
metabolites, which behave as active oestrogens by binding to oestrogen receptors 
(Talal, 1982). Prolactin is an immunostimulatory hormone in experimental animals 
and high serum prolactin levels are found in SLE (Lavalle et al 1987). Serum 
prolactin levels have been found to be higher in pregnant SLE patients than in 
pregnant patients with rheumatoid arthritis or normal pregnant controls (Jara-Quezada 
et al 1991 ). Oestrogens stimulate the release of prolactin by the pituitary. In turn, 
prolactin inhibits the responsiveness of the pituitary to luteinising hormone release 
hormone, as well as inhibiting the action of luteinising hormone (LH) and follicle 
stimulating hormone (FSH) on the gonads. 
It is possible that the low levels of oestradiol, testosterone and dihydrotestosterone in 
LE patients could be explained by the raised levels of prolactin. In LE, sex steroid 
hormones may be acting physiologically on a disordered immune system (Cohn, 
1979). Normal immune responses, both cellular and hurnoral , are greater in females 
than males (Cohn, 1979). There are steroid-sensitive receptors in the hypothalamus, 
implying that neuroendocrine pathways also interact with the immune system 
(Besedovsky & sorkin, 1977). Oestrogens are reported to have the dual role of 
immunosuppresants and immunostimulants (Lahita, 1984). Differences in female 
immunity as compared to male immunity, include high levels of IgM, higher antigen 
specific antibodies and greater susceptibility to infection, more autoantibodies, higher 
T helper cell levels and decreased ability to accept skin grafts (Lahita, 1996). 
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In addition, a number of studies using liver, breast cancer, oviduct, uterus, anterior 
pituitary and mammary gland cells have all demonstrated that oestrogens can 
stimulate target cell DNA replication and cell division (Aprison et al 1982; Chalbos et 
al 1982; Oka & Schimke, 1969). Oestrogens are known to increase the mitotic rate of 
the epidermis of rodents and man (Bullough, 1955), to enhance the growth rate of 
cultured keratinocytes (Peehl & Harn, 1980), to stimulate the synthesis, maturation 
and turnover of collagen (McCarty & McCarty, 1977). In addition, they depress cell 
mediated immunity, attenuate natural killer cell function, decrease cancer cell immune 
surveillance and inhibit the release of thymic hormones, depending on the dose, with a 
constant relative lymphopaenia (Lahita, 1996). These oestrogen effects are thought to 
occur as a result of hormone interactions with nuclear receptors which result in an 
alteration of gene expression (Clark & Peck, 1976). 
Although initially controversial (Cox, 1965; Tozman et al 1980), more recent work 
suggests that SLE does not change with pregnancy (Out et al 1989; Tincani et al 
1991). SLE and pregnancy has been extensively studied but the studies have 
concentrated on renal involvement. Worsening of SLE is uncommon in pregnancy. 
Inactive disease is not associated with disease recurrence (Tozman et al 1980). In a 
prospective study of 80 pregnant SLE patients, disease worsened in less than 13%. A 
recent study showed that skin disease did not flare during pregnancy. 66.6% 
experienced no change in their disease, with 26.6% improving. 20% flared post-
partum (Yell & Burge, 1993). 
In a 1956 study of 80 patients, 13 with DLE were identified. In these, there were no 
clear cut changes which could be related to pregnancy (Frieman & Rutherford, 1956). 
Subsequently, in a 1961 study of 134 LE patients during 191 pregnancies, 29 DLE 
patients with 38 pregnancies were identified. DLE was essentially stable during 
pregnancy: 21 experienced no change in their disease; 7 patients improved and one 
worsened. In most patients, the disease remained stable or improved post partum 
(Bruce Donaldson & de Alvarez, 1962). Rowell and Goodfield in an unreferenced 
statement describe pregnancy as a precipitant of DLE in 1 % of cases (Rowell & 
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Goodfield, 1992). In a recent series of DLE patients, 21 % worsened, 43% did not 
change and 20% improved during pregnancy. 13% presented in pregnancy (Yell & 
Burge, 1993). 
Sex hormonal levels fluctuate with the menstrual cycle. Oestradiol levels rise prior to 
ovulation, with a second peak in the luteal phase prior to menstruation. Rowell 
describes 13% of DLE patients deteriorating premenstrually (Rowell & Goodfield, 
1992). A premenstrual cutaneous flare has been described in 25% of SLE patients 
and in 16% ofDLE patients (Yell & Burge, 1993). 
In the perimenopausal period, the decrease in the length of the follicular phase, results 
in a shorter interval between menses. In addition, mean levels of plasma FSH and LH 
increase. At the menopause, cessation of follicular development results in a drop in 
the production of oestradiol and other hormones, which in turn, leads to a loss of 
negative feedback on the hypothalamic-pituitary centres. The levels of plasma 
gonadotrophins increase, with FSH levels rising earlier and to a greater extent than 
those of LH. Plasma oestrogen and androgen levels are significantly reduced. In one 
series, 15% of SLE patients presented postmenopausally (Rowell & Goodfield, 1992). 
A perimenopausal cutaneous flare has been reported in 8% of SLE patients and in 
35% of OLE patients. Presentation in the menopause occurred in 3% of SLE and 6% 
of DLE patients (Yell & Burge, 1993). 
Exacerbation of SLE after oral contraceptive use was first reported in 1966 (Pimstone, 
1966). Two further case reports suggest that a lupus diathesis may be unmasked by 
oestrogen containing oral contraceptives (Travers & Hughes, 1978; Garovich et al 
1980). A prospective controlled study of normal women receiving oral contraceptives 
compared with a group using non hormonal contraception, revealed no altered 
serology or rheumatic complaints (Tarzyy et al 1972). However, in a study of 26 SLE 
patients receiving oral contraceptives, 43% experienced disease exacerbation during 
the 3 months after initiation of therapy (Jungers et al 1982a). However the trend to use 
low dose oestrogen pills may account for the apparent decrease in lupus like side 
effects recently. This is supported by a study which showed that oral contraceptives 
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were not a factor associated with the appearance of SLE in patients diagnosed 
between 1985 and 1987 (Strom et al 1994). The progesterone components of oral 
contraceptives are not related to SLE (Jungers et al 1982b). 
1.2.4 Disturbance of immune regulation 
The enormous array of non-organ-specific autoantibodies found in SLE has been 
termed an autoimmune thunderstorm. These antibodies are, however, directed at 
relatively few macromolecules of cell components. These are often highly conserved 
polypeptides that subserve very basic cellular functions, carried out in the nucleus, 
nucleolus and ribosomes. The reasons why only 30 or so basic cellular proteins 
become the targets of an autoimmune response in patients with LE, at the exclusion of 
the other 10 000 cellular macromolecules remain unknown. Molecular mimicry may 
be one answer. Highly conserved immunogenic molecules, expressed by infectious 
pathogens can trigger an immune response in a genetically predisposed host, that 
cross-reacts with cellular antigens (Sontheimer et al 1992). 
The presence of ANA and antibodies to ds-DNA remain the mainstay of the diagnosis 
of SLE, although 5% of patients remain persistently ANA negative. Besides having 
diagnostic value, some of these antibodies are believed to be pathogenic, although 
antibody titers do not correlate with disease activity. Clinical interest has centered 
around defining subsets of SLE by antibody typing. However, the conversion of 
"serological subset" into "clinical subset" may rely more heavily on statistics than 
clinical observations. Despite these reservations, certain antibodies do appear to be 
associated with certain clinical features. 
Anti-Ro antibodies are associated with the development of SCLE and NLE. Anti-Ro 
antibodies are found in O .1 % of hospitalised patients (Maddison et al 1979), 17 .5% of 
normal people at low level (Gaither et al 1987), as well as some relatives of patients 
with autoimmune disease (Lehman et al 1984). Sera from 5000 female blood donors 
revealed a frequency of anti-Ro antibodies of 0.44% (Fritzler et al 1985). The 
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presence of antibodies in normal individuals, suggests that there are autoreactive B 
cell clones in the repertoire of normal people. It is possible that these autoreactive 
cells are un-stimulated precursors or that they are controlled by suppression rather 
than active deletion. 
There are several animal models of SLE of which the murine ones are the most 
studied. These include the (NZB X NZW)F 1 and the MRL/1. The MRL/1 strain 
demonstrates the most aggressive form of the disease which is related to a single 
autosomal recessive gene. Anti-DNA antibodies are detected early in the NZB/NZW 
mouse and precede the first histologic signs of glomerulonephritis. If these animals 
are rendered unable to produce anti-DNA antibodies, they have few signs of 
autoimmune disease (Yoshida et al 1990). The evolution of the autoantibody 
response to nucleosomes in lupus has been studied during clinical flares, as well as in 
animal models of the disease (Mohan et al 1993; Burlingame et al 1993). These 
studies indicate that the antibody response in lupus is antigen-driven and T cell 
dependent. Autoantibodies undergo isotype switching, somatic mutation and affinity 
maturation, characteristic of rechallenge of a primed immune system by antigen. The 
presence of immune complexes containing dsDNA during acute flares, suggests that 
endogenous nucleosomes may be one antigen driving the immune response in lupus 
(Sano & Morimoto, 1981 ). 
A striking feature of the different autoantigens in lupus is their lack of restriction to 
any one subcellular location. They may be exclusively nuclear, cytosolic, membrane 
associated, or distributed between the nucleus and cytoplasm under different 
conditions. It has been suggested that the total repertoire of autoantigens might be 
clustered on a limited number of distinct subcellular particles (Tan, 1991 ). It has been 
shown that autoantigens are clustered in two distinct populations of blebs at the 
surface of apoptotic cells (Casciola-Rosen et al 1994). The smaller blebs contain 
fragmented endoplasmic reticulum (ER), ribosomes and Ro. The larger blebs 
(apoptotic bodies) contain nucleosomal DNA, Ro, La and small nuclear 
ribonucleoproteins. These autoantigen clusters have in common, their proximity to 
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the ER and nuclear membranes, sites of increased generation of reactive oxygen 
species in apoptotic cells. Oxidative modification at these sites may be a mechanism 
that unites this diverse group of molecules together as autoantigens (Casciola-Rosen et 
al 1994). Apoptosis is however, a normal developmental process and alone may not 
be critical in the development of autoimmunity. 
It has been proposed that some autoreactive T cells escape tolerance induction because 
they are directed against minor (cryptic) determinants on self-antigens that are not 
efficiently generated during antigen processing (Gammon & Sercarz, 1989). These 
autoreactive cells may become pathogenic if that cryptic determinant is subsequently 
revealed (Lipham et al 1991). A number of free radical-induced modifications of 
proteins have been described that may reveal potentially cryptic determinants. These 
include fragmentation, amino acid modifications and novel sensitivity to protease 
· attack (Wolff & Dean, 1986). The strong association of particular autoantibody 
responses with specific MHC class II molecules in patients with SLE, may reflect the 
ability of these class II molecules to capture and present self-peptides to T cells 
(Reveille et al 1991 ). 
Other pathogenic factors could result from the fact that immune complexes are 
abnormally processed. One group studied the clearance of large soluble immune 
complexes (HBsAg-anti-HBsAg) radiolabelled with 1231 in 12 healthy individuals and 
10 SLE patients. Initially, clearance was more rapid in the SLE patients, with up to 
12% of the complexes released from the liver after 30 to 50 minutes. Spleen uptake 
was reduced, as was the ability to retain the immune complex in this organ. Plasma 
complement levels and red cell complement receptor type 1 numbers were reduced in 
the SLE patients (Davies et al 1992). 
Persistent B cell activation occurs in SLE. This may persist even with inactive 
disease. Lymphocyte activation at a cellular level in 13 nonactive SLE versus 15 
controls was assessed. The expression of activation markers on B and T cells was 
higher in SLE patients. The percentage of activated B cells was related to levels of 
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total lgG and lgM but not to antibodies to <ls-DNA (Spronk et al 1993). These 
findings suggest a persistently activated immune system. 
1.2.5 Clinical Subsets 
Cutaneous lupus erythematosus (LE) has been classified by Gilliam and Sontheimer 
(Gilliam & Sontheimer, 1981) into chronic cutaneous LE, subacute cutaneous LE and 
acute cutaneous LE. See table I: 
Table 1 The Gilliam classification of skin lesions associated with LE 
1 LE-specific skin disease (Cutaneous LE [CLE]) 
1.1 Acute cutaneous LE (ACLE) 
1.1.1 Localized ACLE (malar rash, butterfly rash) 
1.1.2 Generalized ACLE (lupus rash, maculopapular lupus 
rash, photosensitive lupus dermatitis) 
1.2 Subacute Cutaneous LE (SCLE) 
1.2.1 Annular SCLE (lupus marginatus, symmetric erythema 
centrifugum, autoimmune annular erythema, lupus 
erythematosus gyratus repens) 
1.2.2 Papulosquamous SCLE ( disseminated DLE, subacute 
disseminated LE, superficial disseminated LE, psoriasiform LE, 
pityriasiform LE and maculopapular photosensitive LE) 
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1.3 Chronic Cutaneous LE (CCLE) 
1.3 .1 Classical discoid LE (DLE) 
1.3.2 Localized DLE 
1.4 Generalized OLE 
1.5 Hypertrophic OLE/verrucous OLE 
1.6 Lupus panniculitis/lupus profundus (see figure 14, pg. 42) 
1. 7 Mucosal OLE 
1.7.1 Oral OLE 
1. 7.2 Conjunctiva! DLE 
1.8 Lupus tumidus (urticaria! plaque of LE) 
1.9 Chilblain LE (chilblain lupus) 
1.10 Lichenoid OLE (LE/lichen planus overlap, lupus planus) 
2 LE-nonspecific skin disease 
2.1 Cutaneous vascular disease 
2.2 Vasculitis 
2.2.1 Leukocytoclastic 
2.2.1.1 Palpable purpura 
2.2.1.2 Urticaria! vasculitis 
2.2.2 Periarteritis nodosa-like cutaneous lesions 
2.2.3 V asculopathy 
2.2.3.l Degos' disease-like lesions 
2.2.3.2 Secondary atrophie blanche (livedoid vasculitis, 
livedo vasculitis) 
2.3 Periungual telangiectasis 
2.4 Livedo reticularis 
2.5 Thrombophlebitis 
2.6 Raynaud's phenomenon 
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2. 7 Erythermalgia 
2.8 Nonscarring alopecia 
2.8.1 "Lupus hair" 
2.8.2 Telogen effluvium 
2.8.3 Alopecia Areata 
2.9 Sclerodactly 
2.10 Rheumatoid nodules 
2.11 Calcinosis cutis 
2.12 LE-nonspecific bullous lesions 
2.13 Urticaria 
2.14 Papulo-nodular mucinosis 
2.15 Cutis laxa/anetoderma 
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2.16 Acanthosis nigricans ( secondary to Type B Insulin resistance) 
2.1 7 Erythema multiforme (Rowell's syndrome) 
2.18 Leg ulcers 
2.19 Lichen Planus 
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1.2.5.1 Systemic Lupus erythematosus 
Acute cutaneous LE, said to occur in 30-50% of SLE patients, includes localized, 
indurated erythematous lesions, widespread indurated erythema and bullous LE. 
59% of patients (in a study of 73 patients, 33 had a butterfly eruption with an 
additional 10 having a transient flush) have lesions in the butterfly area of the face. 
The malar region may be preferentially involved due to its anatomical site - exposed 
to the environment, especially sunlight and susceptible to trauma. The malar dermal 
vessels are numerous, prone to flushing and superficial, accentuating telangiectasia 
(Yell et al 1996a). The high prevalence of malar rash is confirmed in children at 67% 
(Bosi Ferraz et al 1994). 
Annular erythema, particularly of the cheeks, where thermography has shown that this 
is the coolest part of the face, has been described in Sjogren's syndrome patients 
positive for Ro. This syndrome is different histologically from SCLE (Katayama et al 
1991). 
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figure 1: The facial rash of SLE may vary from telangiectasia (top), through 
malar erythema (left), through more indurated erythema (right). 
Other patterns of erythema are seen in 12%. They present with persistent 
erythematous patches, often worsened by sun, in various sites, including the "V" of 
the neck, ears, forehead and palms (Yell et al 1996a). A "non-specific rash" has 
previously been reported in 59% of SLE patients (Wysenbeek et al 1992). 
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Blistering is uncommon in SLE, occurring in < 5% of all patients. It may be due to a 
primary blistering disease in association with SLE, vasculitis, blistering of SLE 
lesions themselves, or "bullous SLE". 
A number of criteria have been suggested in an effort to delineate "bullous SLE": SLE 
fulfilling the criteria of the American College of Rheumatology, a chronic widespread 
blistering eruption, a subepidermal blister with acute neutrophil-predominant 
inflammation in the upper dermis, immunoglobulin (lg) and complement deposition at 
the BMZ on direct immunofluorescence, immune deposits ultrastructurally localised 
on or beneath the lamina densa and a clinical response to dapsone (Gammon & 
Briggaman, 1990), see figure 2, next page. 
A number of patients fulfilling these criteria have antibodies to type VII collagen 
(Barton et al 1986; Gammon et al 1985). It has more recently been suggested that 
bullous SLE should include those patients with SLE and blistering with immune 
reactants at the basement membrane zone. 
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figure 2: Typical bullous SLE. Blistering not confined to typical lesions of SLE 
(top right and left). IF on salt split skin, either dermal, common (bottom left) or 
epidermal, uncommon (bottom right). 
Subacute cutaneous LE (SCLE), said to occur in 10-15% of SLE patients, includes 
papulosquamous and annular-polycyclic lesions. Chronic cutaneous LE is estimated 
to occur in 15-20% of SLE patients. It includes classic discoid LE (DLE), 
hypertrophic OLE, lupus panniculitis, mucosa! LE and chilblain LE. 
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1.2.5.2 Subacute cutaneous lupus erythematosus(SCLE) 
1.2.5.2.1 Subacute Cutaneous Lesions 
SCLE was first described as a distinct 
subset of LE in 1979 (Sontheimer et al 
1979). They characterised a group of 27 
patients who had in common, a recurring, 
superficial, nonscarring type of cutaneous 
LE in a characteristic distribution. These 
patients had a mild systemic illness, 
marked by musculoskeletal complaints. 
Half fulfilled the ARA criteria for SLE. 
None had serious CNS or renal disease. 
figure 3, left. These lesions are usually 
widespread, symmetrical and non-scarring. 
They occur in a characteristic, photoexposed distribution, with a LE-specific 
histopathology (Bangert et al 1984). A few patients may have a combination of both 
psoriasiform and annular lesions, although most have predominantly either one or the 
other subtype (Sontheimer, 1989). In Asians, annular erythema is the equivalent of 
the psoriasiform rash (Watanabe et al 1997). Patients falling into this subset of LE, 
frequently have anti-Ro antibodies (Sontheimer et al 1982; Miyagawa et al 1996) and 
are HLA B8 DR3/2 positive (Johansson-Stephansson et al 1989). SCLE may be 
associated with other rheumatic diseases (Provost & Watson, 1993). Photoactive 
medications may induce lesions of SCLE (Reed et al 1985), as may heat (Sontheimer, 
1985). Systemic manifestations may be as varied in SCLE as in SLE and severe 
disease is not unusual. In particular, men with papulosquamous SCLE may be at 
higher risk for severe extracutaneous disease (Cohen & Crosby, 1994). 
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1.2.5.3 Chronic cutaneous lupus erythematosus 
Chronic discoid lesions are typically inflammatory plaques with scaling, follicular 
plugging, atrophic scarring, central hypopigmentation and peripheral 
hyperpigmentation, see figure 4 and figure 5 (above). 
Discoid lesions occur in discoid LE but may also be seen in 23% of SLE patients 
(Yell et al 1996a). Chronic discoid skin lesions may be the initial manifestation of 
SLE, as found by Tuffanelli and Dubois in 10.8% (56/520) (Dubois & Tuffanelli, 
1964). Discoid lesions occurred during the course of disease in 28.7% (149/520) of 
their patients. In 12% (9/73) of SLE patients, DLE was diagnosed prior to the 
development of systemic symptoms (Yell et al 1996a). It has been suggested that SLE 
patients with discoid lesions may have a more benign clinical course with less severe 
renal disease, than unselected SLE patients (Callen, 1985). A recent study of 136 
patients with DLE, described the development of SLE in 11. Most developed SLE 5 
years after the onset of the cutaneous lesions. 4 cases out of these 11, had a poor 
prognosis: renal and/or neurologic involvement (Le Bozec et al 1994). 
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1.2.5.4 Non specific cutaneous signs 
Hair loss is a coinmon and characteristic finding in SLE, occurring in about 50%. The 
variability in recording alopecia, resulted in its exclusion from the ARA criteria in 
1982. Alopecia may be scarring, if preceded by DLE, see figure 6 (below, left), or 
non-scarring. Various mechanisms have been cited, including telogen effluvium, see 
figure 7 (below right) with a systemic disease exacerbation, anagen arrest associated 
with the use of irnmunosuppressives or anticoagulants and growth retardation leading 
to "lupus hair"(Armaz-Cruz et al 1958). "Lupus hair" describes short irregular frontal 
hair, producing a disheveled appearance, a result of growth retardation, rather than 
hair breakage (Alarcon-Segovia & Cetina, 1974). 
fig. 6 fig. 7 
Chilblain lupus describes acral lesions induced by exposure to cold, with histologic 
evidence of LE (Su et al 1994). These become obvious lesions of DLE. They occur 
in 20% (15/73) of patients with SLE (Yell et al 1996a). 
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1.2.5.5 Mucosal Lesions 
Mucosal lesions were considered uncommon in SLE. However, on careful inspection, 
see Table 2, more than 50% of SLE may have mucosal lesions (Jonsson et al 1984; 
Wysenbeek et al 1992; Robson et al 1992), see figure 8 (top left, typical mouth 
ulcers), figure 9 (top right, thicker buccal plaques), figure 10 (below left, palatal 
ulceration), figure 11 (below right, DLE cheilitis) and figure 12 (bottom, 
episcleritis ). 
fig. 9 
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Photosensitivity occurs in: 32.7% (Dubois & Tuffanelli, 1964), 50% (Lee et al 1977), 
28% (Grigor et al 1978), 63% (Wysenbeek et al 1992) and 71 % (Rothfield, 1979), see 
figure 13 (below) and Table 2. It has been reported in 58% of children (Bosi Ferraz 
et al 1994). Photosensitivity, one of the major 
diagnostic criteria for SLE, is thought to be the 
result of 3 interrelated factors: susceptibility to 
ultraviolet radiation (UVR) -induced release of 
epidermal and dermal cytokines; susceptibility 
to UVR-induced release or translocation of 
sequestered antigens in the epidermis or 
dermis; and different specific immunologic 
effector mechanisms activated by cytokines 
and directed against discrete dermal or 
epidermal targets (Norris, 1993)-
Photosensitivity precedes the clinical onset of 
internal manifestations of SLE in about one 
third of patients. This may begin as sunburn 
that persists for days or weeks despite no 
further sun exposure. The macular erythema 
may evolve into discrete papules that may resemble a drug eruption. The papular 
malar erythema and butterfly eruption which are characteristic of SLE may be due to 
photosensitivity. Some patients may not notice erythema after prolonged ultraviolet 
exposure, but hours or days later may note increased arthralgia, malaise and fever. 
Dubois and Tuffanelli noticed this in 32.7% of patients (Dubois & Tuffanelli, 1964). 
No seasonal variation has been found in the incidence of photosensitivity. It is 
possible that subjects whose disease is precipitated by sun exposure, may have a 
higher threshold for the disease, than those who develop the rash without sun 
exposure. 
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Urticaria and angioedema are common cutaneous vascular reaction patterns. Two 
North American studies have described prevalences of urticaria of 7% from a 
"neighbourhood" population) (Provost et al 1980) and 22% (from a national referral 
center)(O'Loughlin et al 1978), suggesting that it is more common in patients with 
severe disease. British studies have found urticaria in 50% of SLE patients (Scott & 
Rees, 1959; Yell et al 1996a). It suggests, therefore, that urticaria is commoner in the 
British population than the American population. There is no easy explanation for the 
American figures. It has recently been suggested that chronic idiopathic urticaria may 
well be autoimmune (Hide et al 1994) and as such it is not surprising that the rate in 
SLE is high. 
The incidence of Raynaud' s phenomenon in connective tissue diseases varies from 
3% in rheumatoid arthritis to 95% in scleroderma. Raynaud's phenomenon may be 
the first manifestation of SLE (Lee et al 1977). When it is persistent and severe, 
patients develop other vascular complications. Raynaud' s phenomenon is found in 18 
- 60% of SLE patients, see Table 2. 
Dermal vasculitis has been reported in 11 to 70% (Yell et al 1996a; Alarcon-Segovia 
& Osmundson, 1965) of patients with SLE. In severe cases, vasculitis may affect any 
part of the body. Livedo reticularis, an important marker of systemic disease, has 
been reported as an initial presentation of SLE (Weinstein et al 1987), occurring in 
4% (Yell et al 1996a). Livedo reticularis may be associated with the antiphospholipid 
syndrome Weinstein et al 1987), or may be a cutaneous marker of CNS lupus 
(Y akshi, 1986). 
A number of other skin conditions have been reported in SLE, see Table 1 The 
Gilliam classification of skin lesions associated with LE, including poikiloderma, 
erythromelalgia (Alarcon-Sergovia et al 1963), acanthosis nigricans (Brown & 
Winkelmann, 1968) and anetoderma, see figure 15. 
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Lupus profundus and anetoderma are rare cutaneous manifestations of lupus 
erythematosus. 
Figure 14 (left) lupus profundus, figure 15 (right) anetoderma associated with 
SLE. 
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Table 2: Cutaneous manifestations in large SLE series 
!Yell !Dubois Estes Lee IGrigor lweinstein IWorral IPisitine1 
INo. OF CASES 73 520 150 110 1375 84 100 1464 
YEAR OF STUDY 1995 1963 1976 1977 1982 1987 1990 1991 
Skin lesion all types % 100 72 81 82 90 55 
Raynaud's 60 18.4 21 46 32 25 
Photosensitivity 63 32.7 50 28 48 37 
Mucous membran( 55 9.1 7 34 34. 36 19 
lesions 
Butterfly eruption 45 20.9 21 34 
Urticaria 44 6.9 13 5 4 
Alopecia non-scarring 40 21.3 37 38 64 
Chronic discoid lesions 23 28.6 14 28 22 11 23 
Chilblains 20.5 
IAlopecia scarring 14 3.6 
Butterfly blush 14 36.7 39 36 68 
IV asculitis 11 21 70 18 
Bullae 8 0.4 2 
Psoriasiform rash 7 2 
Facial oedema 5 4.6 
Diffuse 5 8.4 
hvoeroiITTnentation 
Livedo reticularis 4 
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2.1 Historical Background 
Anderson et al first used gel double diffusion, to detect precipitating antibodies in 
Sjogren' s syndrome (SS) (Anderson et al 1961). 
2.1.1 1969: A novel soluble cytoplasmic antigen is described 
At the time when a variety of immunological reactions with tissue components in the 
sera of patients with SLE and related disorders was being described, a novel reaction 
was identified using a specific patient serum (Clark et al 1969). This patient (Ro), 
had a syndrome closely resembling SLE, with a systemic disease characterised by 
inflammatory lupus-like lesions over the malar emmence, arthritis and 
pleuropericardial disease. This patient's serum showed none of the typical reactions 
with nuclear components. However, this serum did show complement fixation 
reactions in very high titres with saline homogenates of various human tissues. The 
Ro antigen was subsequently isolated, partially purified and characterised. It was 
derived primarily from the soluble cytoplasmic fraction of a human tissue 
homogenate. It was found in many human organs as well as the tissue of the dog. 
This antigen was acidic, pH sensitive and heat labile, suggesting it was a protein. It 
was resistant to most proteolytic enzymes, including trypsin, pepsin and 
chymotrypsin. Reversible inactivation by parahydroxymercuribenzoate indicated that 
sulfhydryl groups may be essential for antigenicity. 
This antigen was present in tissues in very small amounts. This group failed to 
demonstrate cellular localisation of the antigen with the indirect fluorescent antibody 
technique, using human, monkey and mouse tissue. They considered that this failure 
may have been due to the inaccessibility of the antigen, its low concentration, or that it 
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may be so soluble that it was removed during the washing procedures in slide 
preparation. 
They did find very high titres in complement fixation reactions with some sera, 
suggesting that antibody directed toward the Ro antigen may be present in large 
amounts and that a significant part of a patient's hypergarnmaglobulinaemia may be 
due to this antibody. They thought it extremely interesting that a tissue component 
present in extremely small amounts, could elicit the production of large amounts of 
antibody. They found antibodies to this antigen in 40% of unselected LE sera. 
2.1.2 1975: Sjogren's syndrome antibodies were described. 
In attempts to find antibodies specific for Sjogren's syndrome (SS), 3 different 
antibodies were described in 18 SS sera. These were designated A, B and C. A Wil-
2 cell line was used as a source for tissue extraction. An Ouchterlony double-
diffusion method was used to demonstrate precipitating antibodies in human sera from 
SS patients with (SS-C) or without Rheumatoid Arthritis (RA) (SS-A and SS-8). 
There was complete non identity between SS-A, B and SS-C. The SS precipitating 
systems were not related to precipitating antibodies to native or denatured 
deoxyribonucleic acid (DNA), Smith (Sm), ribonucleoprotein (RNP) or small 
nucleoprotein (snRNP) (Alspaugh & Tan, 1975). This group suggested that at least 
one or more of the precipitins may be antibodies against cytoplasmic or non-nuclear 
components. 
2.1.3 1979: Collaboration concludes that Ro and SS-A are similar 
Double diffusion in agar gel and preparation of calf thymus extract, human spleen 
extract and Wil-2 cell extract were performed, exchanging both extracts and prototype 
sera between the two laboratories. This confirmed immunologic identity between sera 
containing anti-Ro and anti-SS-A, anti-La and anti-SS-B and confirmed immunologic 
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distinction between the Ro(SS-A) and La(SS-B) systems. In addition, they showed 
agreement between Ro and SS-A and La and SS-B with respect to their 
physicochemical properties, including acidic nature, behaviour in diethylaminoethyl 
(DEAE) - cellulose chromatography and an approximate molecular weight using gel 
filtration (Alspaugh & Maddison, 1979). 
However, they did point out interesting discrepancies, including a difference in 
findings with regard to cellular localisation. Ro was considered cytoplasmic, based on 
demonstration of these systems only in cytoplasmic extract of fresh calf thymus and 
production of cytoplasmic fluorescence of calf thymocytes. On the other hand, 
nuclear localisation of SS-A and SS-B was provided by similar fluorescence studies 
using Wil-2 cells as tissue substrate. 
2.2 Evidence for Pathogenicity 
2.2.1 Epidemiology 
Although the Ro particle is a relatively minor ribonucleoprotein, about 1-5 X 105 
copies per cell (Wolin & Steitz, 1984 ), it is a potent antigen. The concentration of 
anti-Ro in an individual serum may reach 30 mg/di, constituting a significant 
proportion of the total antibody concentration (Harley et al 1986). Anti-Ro antibodies 
are associated with the development of SCLE and NLE. Ro / SS-A antibodies are 
produced by most patients with subacute cutaneous and neonatal lupus erythematosus. 
It has been considered likely that these antibodies and the antigens against which they 
are directed, are pathogenic in SCLE and NLE (Buyon et al 1989; Sontheimer, 1989). 
In addition, anti-Ro antibodies may play a pathophysiologic role in the development 
of congenital heart block in neonatal lupus (Alexander et al 1992). More than 96% of 
SS patients have anti-Ro antibodies (Harley et al 1986). The levels of antibodies are 
much higher in patients with purpura, leucopaenia, lymphopaenia and increased 
polyclonal gammaglobulins than in those without these conditions (Harley et al 1986). 
About 10 % of normal controls had anti-Ro antibodies, in low titre (Harley et al 
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1986). Using immunoblotting, the positivity rates of Ro and/or La auto-antibodies 
were higher in sera from Japanese patients with SLE compared with titres reported for 
Caucasians but not in sera from healthy volunteers (Inagaki et al 1989). This may be 
due to a racial difference in HLA distribution and may explain some differences in the 
common signs, symptoms and laboratory anomalies in SLE between races (Inagaki et 
al 1989). Japanese SLE patients have a lower incidence of photosensitivity, sicca 
syndrome and NLE (Inagaki et al 1989). 
2.2.2 Clinical 
Anti-Ro antibodies are related to several clinical autoimmune disorders (McCauliffe, 
1997b): 
63% -82% of patients with SCLE (Sontheimer et al 1982; Deng et al 1984; Lopez-
Longo et al 1997). 
Virtually all patients with NLE (Laxer et al 1990; Brucato et al 1995). 
75% of patients with homozygous complement (C) C2 and C4 deficiency with SLE-
like disease (Provost et al 1983). 
80% of patients with primary Sjogren's syndrome (Hochberg et al 1985). 
62% of ANA-negative SLE Maddison et al 1981). 
SLE with interstitial pneumonitis (Hedgepeth & Bouluare, 1988). 
100% of patients with hypergammaglobulinaemic purpura with SLE (Senecal et al 
1995). 
A few patients with primary biliary cirrhosis and secondary SS (Domer et al 1996a). 
A 10-year follow up of one hundred anti-Ro antibody positive patients indicates that 
these patients have a diverse clinical presentation and that this anti-Ro response may 
persist for years. Some patients appear to have a static disease process for years. On 
the other hand, 65% had a progressive course. 
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At least 25% demonstrated a dynamic change in clinical presentation with the 
development of SS and/or a progressive ' rheumatoid-like' arthritis. Interstitial 
pulmonary disease and vasculitic insults occurred frequently in these patients. Renal 
disease occurred in 19 and in 47% of these, no anti-dsDNA antibodies were detected. 
Cutaneous manifestations were prominent, with photosensitivity and a malar rash 
being most common. 20% had discoid lesions, 20% had SCLE lesions (Simmons-
O'Brien et al 1995). 
Unlike anti-Ro antibody positive SCLE patients, anti-Ro antibody positive lupus 
patients with SS appear to have a more guarded prognosis. These SS/LE patients 
have an increased frequency of pulmonary, neurological, and renal disease compared 
to SCLE patients (Provost et al 1997). 
Photosensitivity is one of the major criteria for the classification of systemic lupus 
erythematosus (Tan et al 1982). A comparative survey of 36 blacks and 56 whites 
with SLE in Johannesburg, showed photosensitivity in only 19% of blacks, compared 
to 71 % of whites (Sutej et al 1989). A strong negative association with anti-Ro 
antibodies was noted as only 4% of the Ro-positive patients were photosensitive, 
compared with 55% of Ro-negative patients. The authors postulated a 'blocking' 
factor in blacks with SLE which blocked the photosensitivity caused by the interaction 
of Ro with UVR. 
Anti-Ro antibodies can cross the placenta, by the 12th week of gestation (Deng et al 
1987) where they are implicated in causing NLE. Isolated congenital heart block 
occurs in 1 in 15 000 to 22 000 live births. Skin lesions in affected infants are 
clinically similar to those of SCLE. In several months, as the maternally acquired 
antibodies are cleared from the infant's circulation, the skin lesions resolve. Anti-Ro 
maternal antibodies may also be associated with hepatitis and thrombocytopaenia as 
part of NLE (Laxer et al 1990; Watson et al 1988). Although controversial, despite 
having anti Ro autoantibodies, most of the mothers of offspring with congenital heart 
block remain healthy, with largely minor symptoms (arthralgia, dry eyes and 
photosensitivity) many years after delivery (Press et al 1996; Brucato et al 1995). 
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2.2.3 Histology 
A direct immunofluorescence pattern of in vivo epidermal IgG binding that is 
associated with anti-Ro (Lee et al 1989; Velthuis et al 1989) has been suggested as 
displaying the same type of pattern as that obtained in vitro at the keratinocyte cell 
surface after UVB exposure (Furukawa et al 1990). 
A different group has described basal fluorescence in human skin using a monoclonal 
Ro-antibody. This antibody reacts with a 60k.D polypeptide in extracts from human 
spleen and a 60 and 48k.D protein in extracts of human skin (Mayet et al 1988). This 
group suggested that, particularly in SCLE, cross-reaction of the Ro-antibody with one 
of the lower molecular weight keratins happens in that area of the human epidermis 
which histologically shows cellular destruction. 
This is supported by the demonstration of fine granular IgG deposits in the epidermal 
basal layer with both nuclear and cytoplasmic localisation in 16/51 biopsies from 
spontaneously evolved lesions of SCLE and in 7 /18 from UVR irradiated skin 
(Nieboer & Velthuis, 1991). In UVR irradiated skin, this was exclusively in the areas 
of extreme basal cell degeneration. 
Using monocyte effectors, anti-Ro sera causes profound antibody dependent cellular 
cytotoxicity (Norris et al 1984 ). This may be related to the mononuclear cell -
associated tissue change seen in cutaneous lupus lesions. 
In an in vitro electrophysiological and immunocytochemical experimental model 
contrasting neonatal and rabbit cardiac tissue, it was found that sera and IgG-enriched 
fractions from anti-Ro antibody-positive mothers of infants with NLE and congenital 
heart block, bind to neonatal rather than adult rabbit cardiac tissue. In addition, they 
alter the transmembrane action potential (Alexander et al 1992). The additional 
presence of anti-La antibodies was not additive nor synergistic. Sera containing other 
antibody specificity's, anti-native DNA, cardiolipin, Sm and nuclear RNP, failed to 
stain the neonatal cardiac tissue or produce alterations in membrane polarization. 
49 
Chapter 2 
The Ro antigens 
A further study using IgG fractions of sera from SLE patients with anti-Ro or La, with 
preparations of adult rabbit hearts and ventricular myocytes from young rabbit hearts, 
showed that anti-Ro or anti- La but not normal sera nor anti-RNP, induced cardiac 
conduction abnormalities similar to those observed in NLE (Garcia et al 1994). 
2.2.4 Immunopathology 
A number of papers from the same group, have shown that UVR induces Ro/SSA 
antigen expression on keratinocyte surfaces in vitro (LeFeber et al 1984), that targets 
coated with this antigen were lysed by mononuclear cells in the presence of antibodies 
(Norris et al 1984) and, in vitro, that human skin grafted onto nude mice bound 
Ro/SSA antibodies. This was increased by UV-irradiation (Lee et al 1989). 
The effects of UVR on Ro expression of skin fibroblasts in vitro has shown an lgM-
positive immunofluorescence in the nucleus, using 'monospecific' serum (Wollina et 
al 1991 ). Similar studies were performed on normal, uninvolved psoriatic and 
involved psoriatic skin (Wollina et al 1991). Psoriatic skin showed binding of anti-Ro 
after UV A. Normal and noninvolved psoriatic skin gave nuclear staining only after 
psoralens and UV A. Cells preincubated with anti-Ro serum, and subsequently UV A 
or PUV A treated, showed strong cytoplasmic fluorescence. Unfixed frozen normal 
skin and lesional psoriatic skin, showed no florescence with high dose UVB (103 to 2 
X 105 J/m2) but fluoresced after high dose UV A or PUV A (Wollina et al 1991 ). 
2.2.4.1 animal experiments 
To more directly determine if anti-Ro antibodies induced NLE skin disease, Lee et al 
immunoaffinity purified human Ro autoanibodies using purified Ro antigen from 
bovine spleen. These were given intravenously to immunodeficient mice engrafted 
with human skin. The human Ro autoantibodies, bound to the human basal 
keratinocytes. This binding was markedly augmented by UVR (Lee et al 1989). 
Antibody bound to the human skin graft, in a pattern of distribution indistinguishable 
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from that seen in lesions of anti-Ro SCLE donors (Lee et al 1989). In most areas, the 
epidermal staining appeared mainly cytoplasmic, with some nuclear staining. In 
occasional areas, there was accentuation of IgG deposition at the basement membrane. 
Davis et al demonstrated that UVB irradiation of guinea pigs which had been 
passively sensitised by intradermal injections of anti-Ro positive or negative sera, 
produced elevated cutaneous blood flow, only in animals that had received anti Ro 
positive sera (Davis et al 1989). 
2.2.4.2 translocation experiments 
It is proposed that UVR may augment the release of epidermal and dermal 
inflammatory mediators and may disorder local and systemic immunity. In addition, it 
has been postulated that it may induce new antigens within the epidermis or at the 
basement membrane zone, or may induce the redistribution of normally sequestered 
antigen, from within the epidermal cell to the cell surface (Norris, 1993). This 
mechanism of translocation has been suggested as causal in the cutaneous lesions of 
SCLE and NLE (Jones, 1992b ). 
The binding of anti-Ro antibodies to the cell surface after ultraviolet irradiation 
(UVR) and oestradiol treatment, was described by the same group (Lefeber et al 
1984; Furukawa et al 1990; Jones, 1992a; Furukawa et al 1988). They proposed that 
UVR or oestradiol, induced translocation of these antigens to the keratinocyte plasma 
membrane, exposing them to possible binding by extracellular antibodies. Further 
work on Ro translocation (Jones, 1992a) assessed whether injurious, metabolic, 
inflammatory, immunological or hormonal stimuli would induce Ro expression, or 
modulate that found in response to UVB. 
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2.3 There are a number of different Ro antigens 
In 1981, Lerner et al showed that human Ro autoimmune sera precipitated a new class 
of small RNAs, the human cytoplasmic RNA (hYRNA) (Lerner et al 1981). RoRNPs 
in all mammalian cells examined, comprise one of several different but closely related 
RNA molecules. 
In most nucleated cells there are at least 5 major RNAs: hYl , hY2 (a degradation 
product of hYl), hY3, hY4 and hYS (Boire & Craft, 1989), which range in length 
from 84 to 112 nucleotides. hYS RNA is significantly over-represented on Ro RNPs 
relative to hYl and hY3, although the mechanism responsible for this pattern of 
expression is unknown. h YS RNA occupies a large fraction of the 60 kD Ro protein 
in human Ro RNPs, has an atypical sequence motif and biochemical properties, not 
found on other Y RNAs and constitutes an RNA antigen in certain autoimmune 
patients. The four human Y RNA genes are arranged on chromosome 7q36 (Maraia et 
al 1996). 
Indirect evidence indicates that each RoRNP probably contains a single h Y RNA 
molecule (Wolin & Steitz, 1984). Physicochemical studies on native RoRNPs 
indicate that -the particles segregate into three distinct subpopulations, one containing 
hY5, another containing hY4 and a third containing hYl , hY3 and hY4 (Boire & 
Craft, 1989). 
Initially, it appeared that the 60kD Ro polypeptide was the sole stable protein 
component in the complex and that the La protein associated with h Y RN As only in a 
transient manner, just as it associates with all RNA polymerase III transcripts (Rinke 
& Steitz, 1982). However, it was then shown that h Y RNAs in their mature forms 
were about 30% precipitable by anti-La sera (Wolin & Steitz, 1984). A further group 
were able to distinguish biochemically certain RoRNPs in which La was a stable 
component (Boire & Craft, 1990). 
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Both the 60 and 52kD Ro are associated with four (hYl, hY3, hY4, hY5) RNA 
species (Peek et al 1993; Ben-Chetrit et al 1988). Ro found in foetal red blood cells 
apparently associates with only 2 RNA species (Rader et al 1989), while in platelets, 
only hY3 and hY4 could be detected (Hoh & Reichlin, 1991a). Additionally, there are 
species differences in the structure of the Ro complex, with only 2 RNA species, mYl 
and mY2, identified in the mouse (Wolin & Steitz, 1983). 
Earlier data suggested that Ro autoimmune sera immunoprecipitated h YRNA. Protein 
was needed for this; this was shown to be a 60kD protein (Wolin & Steitz, 1984). 
Later, Ro antibodies were identified that specifically immunoprecipitated hY5RNA 
and a 60kD protein but not other types of h YRNA (Boire & Craft, 1989). They 
concluded that some Ro autoimmune sera contain antibodies directed at a 
conformational epitope that is expressed only on Ro-h Y5RNA particles but absent on 
h YI , 2, 3 and 4 containing particles. 
Additionally, anti-Ro antibodies from SLE and SS sera eluted from Western blots of 
human cell extracts, indicated that a 52-kD protein, in addition to a 60-kD Ro, is 
associated with h Y RNA in nucleated cells (Ben-Chetrit et al 1988). While 60kD Ro 
has been shown to be directly associated with the h Y RN As in complexes, 52kD Ro 
has not been shown to directly contact any of the h Y RN As. However, 52-kD protein-
specific antibodies affinity purified from SLE and SS patient sera, were able to 
immunoprecipitate RoRNPs along with the corresponding h Y RNAs 1-5 (Ben-Chetrit 
et al 1988). 
It has been suggested that, in fact, the 52kD Ro is not a detectable component of the 
RoRNP complex under some conditions, even though it reacts with Ro autoimmune 
sera (Kelekar et al 1994). Kelekar et al analysed HeLa cell extracts by glycerol 
density gradient fractionation, to determine the distribution of the individual protein 
and RNA components of RoRNPs. They found that 52kD Ro was not detectable in an 
RNP complex with the 60kD protein under a variety of conditions. Pretreatment of 
cell extracts with ribonuclease affected gradient migration of the 60kD Ro but not the 
52kD protein, suggesting that the latter is not complexed to RNA. The migration of 
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the h Y RN As in these gradients closely followed that of 60k.D and not 52k.D Ro 
(Kelekar et al 1994 ). They suggested that other workers had shown 
coimmunoprecipitation of the 60kD when using affinity purified 52k.D antibodies 
from patient antisera (Ben-Chetrit et al 1988) because certain autoimmune patient sera 
may not react against a protein immobilized on a membrane, while they would 
recognise it in solution. In other words, patient Ro antisera determined to be 
monospecific for 52kD Ro by Western blotting may contain antibodies to 
discontinuous epitopes on 60kD Ro that escape detection with this technique. 
Further weight to this suggestion was added by a study of 12 patients sera, selected as 
a cross-section of anti-Ro associated disease states (Saitta et al 1994). They combined 
solution phase immunoprecipitation assays with solid phase ELISA and immunoblot 
experiments with recombinant Ags, to dissect the heterogeneity within the anti-60k.D 
response and its relationship to the anti52kD response. Characterisation of the 
different serum reactivities along the length of the protein, allowed the identification 
of seven autoepitopes. These included both continuous and discontinuous 
determinants. The pattern of epitope recognition correlated with both the anti-60kD 
Ro antibody titer and the concomitant presence of antibodies to the 52k.D Ro protein. 
It did not correlate with clinical diagnosis or HLA-DRJDQ genotypes in this small 
group of patients. 
The 52kD Ro component was first described by Ben-Chetrit et al (Ben-Chetrit et al 
1988). They showed a 52-kD protein in addition to the 60-kD protein, present in the 
sera of 80% of patients with detectable Ro precipitins. In addition, this study showed 
that these antigens contained different and unique epitopes which did not generate 
cross-reactive antibodies. However, this group suggested that the 52 and 60-kD 
antigens in their native state, may exist as a complex or as associated particles. 
Besides the proteins mentioned above, Ro RNPs may contain additional components, 
as the presence of single copies of the Ro proteins, together with the La protein and 
one RNA molecule, cannot account for the molecular masses of 230 to 350kD of Ro 
RNPs, observed in gel filtration (Boire & Craft, 1990). 
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It has since been found that Ro autoantibodies react with at least four distinct proteins, 
of 3 different molecular weights, 52-, 54- and 60kD (Rader et al 1989). The 60 and 
52kD antigens have been cloned (Chan et al 1991b; Chan et al 1991a). These 52 and 
60 kD proteins are structurally dissimilar (Itoh et al 1991 ). The 54 and another 60 kD 
protein are thought to be variants of these 52 and 60 kD Ro proteins respectively. The 
54kD Ro has been detected only in red blood cells and their nucleated precursors (ltoh 
et al 1991 ). The 60kD Ro in lymphocytes and red blood cells are distinct but related. 
Most patient autoantibodies which bind to the 60kD Ro lymphocyte polypeptide, cross 
react in most but not all cases with the 60kD red blood cell Ro. Similarly, antibodies 
binding to the lymphocyte 52kD Ro cross react in most cases with the red blood cell 
54kD Ro. The 54 and 60kD red blood cell proteins are antigenically distinct from the 
previously described 52kD and 60kD Ro's respectively. Thus, the four isoforms of 
Ro fall into two non-cross-reacting families (Itoh et al 1990). More recently, a novel 
52kD Ro protein was detected in human platelets, which further increase the 
heterogeneity found in human Ro RNP complexes (ltoh & Reichlin, 1991a). 
The intricacy of the Ro polypeptide-RNA complex is further complicated by its 
association with the 48-kD La protein forming a larger assembly (Peek et al 1993; 
Deng et al 1985). The La protein does not share antigenic determinants with the Ro 
peptides and the genes encoding them show no homology (Chambers & Keene, 1985). 
The La component is complexed to a spectrum of RN As that includes precursor forms 
of 5S rRNA and tRNA, certain small viral RN As and the Ro associated RN As (Rinke 
& Steitz, 1982). 
A number of papers have emerged attempting to unravel the link between the 52 kD 
Ro, 60 kD Ro and La antibody development. A case report described a patient with 
typical Sjogren's syndrome and high titer anti-Ro antibodies, who subsequently 
developed anti-La antibodies, suggesting that anti-La antibodies may follow anti-Ro 
antibodies (Satoh et al 1996). 
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Immunization of mice with recombinant mouse La resulted in a specific, isotype-
switched autoantibody response, which was initially directed toward the La C sub-
fragment (aa 111-242) but rapidly spread to involve the La A (aa 1-107) and La F (aa 
243-345) regions of the La antigen. Intrarnolecular spreading of the anti-La antibody 
response was further demonstrated by the appearance of autoantibodies to multiple, 
non-overlapping antigenic regions of La, after immunization of mice with the 107-aa 
La A sub-fragment. Moreover, immunization of mice with recombinant mouse or 
human La also elicited specific anti-60-kDa Ro IgG antibodies in all strains tested. 
Mice immunized with 60-kDa Ro produced a high titer anti-Ro antibody response, 
which was also associated with intermolecular spreading, resulting in the specific 
appearance of anti-La autoantibodies. These findings show that the development of 
autoantibodies to multiple components of the La/Ro ribonucleoprotein complex may 
follow initiation of immunity to a single component. In addition, the data reveal the 
incomplete nature of immune tolerance to La and Ro despite their endogenous 
expression in all nucleated cells. These observations are likely to account for the 
coexistence of anti-La/Ro antibodies in autoimmune disease and suggest a general 
explanation for the appearance of mixed autoantibody patterns in systemic 
autoimmune disorders (Topfer et al 1995). 
The physical association of Ro52 with the Ro/La RNP has remained controversial, 
implying that antibodies to the 52 kD Ro are not a consequence of intermolecular 
spreading and may be triggered independently of the anti-60 kD Ro response. 
To examine this relationship of the immune response to the 52 kD Ro and 60 kD Ro, 
mice were immunized with recombinant 52 kD Ro, 60 kD Ro, or La, and examined 
for autoantibody production. Immunization with 52 kD Ro resulted in rapid, high titre 
Ab production to the 52 kD Ro, followed 7 to 14 days later by lower titer 
autoantibody production to 60 kD Ro. Immunization with 60 kD Ro led to anti-60 kD 
Ro, which was also followed 7 to 14 days later by a lower titer anti-52 kD Ro 
response. Cross-reactivity of affinity-purified Abs from immune mouse sera was not 
observed (Keech et al 1996b ). 
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To determine whether immunization of healthy non-autoimmune mice with 52-kD Ro 
induces a secondary antibody response to other components of the 48-kD La-60-kD 
/Ro RNP complex and vice versa, female BALB/c mice were immunized with 
recombinant human 48-kD La, 52-kD Ro, or 60-kD Ro proteins, or the polypeptide 
control, each purified by Ni2+ affinity chromatography (Tseng et al 1997). Mice 
subsequently received booster injections with the same antigen every 10-21 days. 
Immune responses were measured by ELISA, immunoblotting of recombinant 
antigens, and immunoprecipitation of 35S-methionine-labeled in vitro translation 
products. 
Immunization with 48-kD SS-B/La resulted in anti-48-kD SS-B/La antibodies within 
45 days, followed 10 days later by a secondary response to 52-kD SS-A/Ro, as 
measured by ELISA: Antibody spreading to 60-kD Ro was not detected. 
Immunization with 52-kD Ro resulted in rapid high-titer anti-52-kD Ro responses 
within 27 days. Spreading to 48-kD SS-B/La occurred in only 1 mouse and 60-kD Ro 
was detected in a minority of the mice after prolonged antigen exposure. 
Immunization with 60-kD Ro led to anti-60-kD Ro responses within 37 days, 
followed 3 months later by low-titer anti-48-kD SS-B/La and anti-52-kD Ro 
antibodies. All primary immune responses were confirmed by immunoblotting and 
immunoprecipitation. While immunoblotting of the recombinant proteins revealed 
reciprocal intermolecular spreading in the majority of mice, immunoprecipitation 
showed that predominant spreading was generated after immunization with 48-kD SS-
B/La, which consistently resulted in antibodies to 52-kD Ro (Tseng et al 1997). 
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2.3.1 60 kD Ro 
In 1988, the cloning of a gene encoding a 60kD Ro antigen was reported (Deutscher et 
al 1988). The next year, a cDNA sequence was reported that appeared to be a 
homologous gene, or a differentially spliced version of the same gene (Ben-Chetrit et 
al 1989). Both these sequences encode 60kD proteins that are virtually identical 
except for the carboxy terminal amino acids. More recently, these were confirmed as 
different versions of the 60kD protein, both of which exist in cells (Chan et al 1991 b ). 
They are thought to arise from differential splicing of the same gene transcript. The 
60kD sequence published by Deutscher et al may be the most abundant type of 60kD 
Ro protein in cells. 
A region of the 60kD Ro amino acid sequence showed a resemblance to the RNP 
consensus motif found in most RNA-binding proteins (Deutscher et al 1988). In 
addition, 60kD Ro contained a potential zinc binding finger motif, distinct from the 
\ RNP consensus region, which may participate in the interaction with human Y RNAs 
\ or other proteins. This zinc finger is not typical of other zinc finger proteins and is 
( not conserved in other species (Wang et al 1996; O'Brien et al 1993). The 60kD Ro 
may bind h Y RNA through the RNP consensus motif and interact with other proteins, 
such as the 52kD Ro protein through the Zinc finger (Deutscher et al 1988). 
There is no extensive sequence homology between the 60kD protein and other 
published protein sequences (McCauliffe & Sontheimer, 1993b ). However, six 
segments of this protein have limited homology to different portions of a vesicular 
stomatitis virus (VSV) nucleocapsid protein. Five of these homologous regions have 
significant reactivity to human Ro autoimmune sera by ELISA. In a study of 80 SLE 
patients, 80 healthy controls, 47 rheumatic disease controls and a small number of 
patients infected with the vesicular stomatitis virus, there was significantly different 
binding to the viral proteins in the SLE patients compared with other groups. The 
reactivity of the SLE sera included binding to the internal viral matrix and the 
nucleocapsid proteins (Hardgrave et al 1993). This suggests that an immune response 
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initially directed at the VSV, or a similar viral protein, might cross-react with the 
60kD Ro protein by way of its cross-reacting epitopes (Scofield & Harley, 1991). 
Many features of VSV are consistent with it playing a role in causing anti-Ro 
associated disease, see (Scofield & Harley, 1991) discussion for a review of the 
literature supporting this. 
The shared antigenic sequences between the 60kD Ro and the nucleocapsid protein of 
the VSV, plus the possibility that viral infection can alter the normal cellular 
distribution of Ro antigens, (Tesar & Armstrong, 1986) suggests that virus infection 
might have a dual impact on the Ro autoimmune response 
Anti-60kD Ro peptide Fab fragments from infiltrating salivary gland lymphocytes in a 
SS patient, have been cloned (Suzuki et al 1997). This group generated three human 
antibody Fab fragments by using a phage-display technique. Sequence analysis 
demonstrated that two of the three Fab clones (E-42 and E-60) used homologous 
heavy chains derived from the germline VH gene DP73 in combination with different 
light chains which were derived from germline V kappa gene L6 and V lambda gene 
DPL23. The third Fab clone (E-56) used another heavy chain derived from the 
germline VH gene DP3 l in combination with the identical light chain as that of E-42. 
All three Fab clones revealed a high number of somatic mutations that probably 
occurred in antigen selection. This suggests that this patient's salivary gland 
lymphocytes have restricted usage of VH and VL genes of anti- Ro antibodies. 
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2.3.2 52 kD Ro 
A 52-kD protein in addition to the 60-kD protein, present in the sera of 80% of 
patients with detectable Ro precipitins was found (Ben-Chetrit et al 1988). On SDS-
immunoblot, the 52-kD protein appears to be the predominant SS-A/Ro component 
recognised by sera from patients with SS and, in particular, mothers of children with 
congenital heart block (Buyon et al 1994; Buyon et al 1989; Ben-Chetrit et al 1990). 
Neonatal lupus is strongly associated with antibodies reactive with Ro and/or La 
proteins, independent of maternal disease activity or classification. The subclass 
distribution of anti-48 kDa La and anti-52 and 60 kDa Ro antibodies in the maternal 
and neonatal circulation, in pregnancies affected and unaffected by the development 
of congenital heart block was compared. Sera were obtained from 32 mothers (during 
34 pregnancies 23 complicated by CHB and 11 healthy) demonstrated to have anti-Ro 
and/or La. Maternal and neonatal autoantibodies were evaluated for subclass 
distribution by ELISA. All 4 subclasses of anti-Ro and La antibodies crossed the 
placenta and were detectable in sera obtained from the umbilical cord. IgG 1 and 
IgG3 were the major subclasses represented in the 48 kDa La and 52 kDa Ro 
responses. All subclasses, including IgG2 and lgG4, were observed in about one-third 
of the anti-52 kD Ro and 48 kD La responses. In contrast, anti-60 kD antibodies 
were, with rare exception, confined to IgG 1. Except for anti-48 kD La IgG3 
antibodies, no significant differences were observed between affected and unaffected 
pregnancies in the ratio of maternal to neonatal levels of any of the antibody 
subclasses. Overall, there were no significant differences in the subclass profiles 
between mothers whose children had heart block and those who did not. The IgG 
subclasses of anti-48 kDa La(SSB) and anti-52 and 60kD Ro do not account for the 
susceptibility of one fetus versus another for the development of CHB. Anti-60 kD Ro 
antibodies were more restricted in subclass distribution than anti-52 kD Ro(SSA) or 
48 kDa La(SSB) responses (Tseng et al 1996a). 
60 
Chapter 2 
The Ro antigens 
One study sought to determine whether the fine specificity of antibody profiles 
remains stable or evolves over time and whether these findings relate to clinical status. 
Sera from 23 mothers whose children had neonatal lupus (22 heart block, one skin) 
were evaluated by SDS-immunoblot. For each mother two samples were available at 
least 13 months apart; the mean duration of time between testing was 45 months+/-
27 S.D. (range 13-108 months). Twenty-two of the 23 initial profiles were identical to 
the results obtained in a later sample. The health status of seven (30%) of 23 mothers 
changed after the birth of the affected infant but the immunoblot specificity of the 
antibodies remained unchanged. SLE was the initial and final diagnosis in the only 
mother whose profiles differed, with development of weak reactivity to 48 kD SSB/La 
in addition to the 52kD Ro after 14 months. The fine specificity of anti-Ro/ La 
antibodies as assessed by immunoblot was highly stable for years. Progression of 
clinical status was not associated with a concomitant change in antibody profile 
(Tseng et al 1996b ). 
Reactivity to the denatured 52kD Ro component seems characteristic of these mothers 
(Brucato et al 1995). These mothers present with an increased prevalence of DR3, 
B44/DR5, DR3/DQ2 and Al/Cw7/B8/DR3/DQ2. 
A recent study has shown that IgG-enriched fractions and anti-52-kD Ro antibodies 
affinity-purified from sera of mothers whose children have CHB induce complete 
atrioventricular (AV) block in the human fetal heart perfused by the Langendorff 
technique and inhibit L-type Ca2+ currents at the whole-cell and single-channel level. 
Immunization of female BALB/c mice with recombinant 52-kD SSA/Ro protein 
generated high-titer antibodies that crossed the placenta during pregnancy and were 
associated with varying degrees of AV conduction abnormalities, including complete 
AV block, in the pups (Boutjdir et al 1997). 
Congenital heart block, associated with antibodies to Ro and La, is most often 
detected between 18 and 24 weeks of gestation, yet the maternal heart is unaffected. 
An alternatively spliced 52-kD Ro messenger RNA (mRNA) derived from the 
skipping of exon 4 which encodes a smaller protein, 52beta (MW 45 kD) is 
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recognized by CHB maternal antisera. Reverse transcriptase-polymerase chain 
reaction was performed using primers flanking exon 4 and mRNA from 22 human 
foetal hearts (age 11-25 weeks) and 3 adult hearts. The brain, kidney, liver, lung, and 
spleen were similarly evaluated in a 15-week, an 18-week, and a 24-week foetus. 
Expression of 52beta was greatest and 52alpha lowest between 14 and 16 weeks of 
gestation. In foetal hearts ages 22-25 weeks and adult heart, the 52beta transcript was 
markedly diminished and 52alpha clearly dominated. The 52beta mRNA was 
observed in a 15-week brain, kidney, lung, and spleen; however, its expression 
relative to 52alpha was greatest in the heart. Since expression of the alternative 
product 52beta is maximal at the time of cardiac ontogeny when maternal antibodies 
gain access to the foetal circulation, just prior to the clinical detection of 
bradyarrhythmia, a role for 52beta in the development of CHB is implicated. Although 
other foetal tissues express 52beta, there may be differences in accessibility of antigen 
or regenerative capacities (Buyon et al 1997). 
It is not clear which of the Ro antigens are most important in pathogenesis. Certainly, 
antibodies directed against both the 52 and 60-kD proteins are present in patient sera. 
In one study, antibody to the 52-kD antigen without concomitant antibody to the 60-
kD antigen was seen only in patients with primary SS, whereas antibody to the 60-kD 
antigen without concomitant antibody to the 52-kD antigen was seen only in SLE 
patients. Although this group found that antibodies to Ro are detected in both SS and 
SLE, they showed that there is a dissociation of immune responses to the 2 antigens, 
suggesting that this may be due to differing events initiating the autoimmune process 
in these diseases (Ben-Chetrit et al 1990). This dissociation of immune responses has 
not been observed in many subsequent reports. 
In a study comparing 17 SCLE patients with 15 DLE patients, high titre, precipitating 
antibodies to Ro were found to be typical of SCLE, both anti-52 and anti-60 and 
unusual in DLE. Low titre, nonprecipitating antibodies to Ro were common in DLE 
and could be an indication of pathogenic factors shared with SCLE. However, low 
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titres of anti-Ro do not confer a significant risk for SCLE skin lesions (Lee et al 
1994b). 
In a study of maternal antibody response to the components of the Ro antigen in NLE, 
using immunoblotting, it was found that 80% of 20 sera had antibodies to Ro (Buyon 
et al 1989). Most had antibodies to the 52kD component. In contrast, antibodies to 
the 60kD Ro were least represented and not significantly increased in frequency 
among mothers of children with NLE, compared to a group of 31 mothers with 
autoimmune diseases, such as SLE, with healthy offspring. The Ro52 and La/SS-B 
were abundant in cardiac tissues from fetuses aged 18 to 24 weeks. 
On the other hand, an abstract assessing the auto-antibody specificities in 20 maternal 
NLE sera found 20/20 had antibodies to 60k0 Ro, 18/20 had antibodies to 52kD Ro , 
9 had antibodies to La and 1 had antibodies to UlRNP. Titers of anti-60kD Ro were 
significantly lower in NLE skin disease sera than in the NLE heart block sera. They 
speculated that the low titers of anti-60kD Ro may be the result of a high affinity of 
these antibodies for the skin, leading to a consequent lowering of circulating titers. 
Alternatively, it may reflect a lower threshold for the development of skin disease 
compared with heart block (Lee et al 1994a). 
A study comparing Japanese annular erythema of Sjorgren's syndrome and American 
SCLE, by ELISA, showed that these two syndromes share several types of anti-52 and 
anti-60 antibodies. However, these antibodies were found significantly more often 
and in significantly higher titers in sera from patients with Sjorgren's syndrome who 
did not manifest these skin diseases. The failure to identify disease-specific Ro 
autoantibodies in SCLE and annular erythema of SS sera, suggests that additional 
factors influence the development of these skin diseases. However, similarities in the 
Ro autoantibody responses and in the clinical features suggest that these two skin 
diseases might arise from a similar pathogenic process (McCauliffe et al 1996) 
A molecular definition for the 52-kD component has been provided by the isolation of 
cDNA clones encoding full length 52-kD Ro independently by two groups (Chan et al 
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1991 a; Itoh et al 1991 ). The complete 52-kD protein consists of 4 7 5 amino acid 
residues with a deduced molecular weight of 54 000. The deduced protein structure 
contains three distinct domains: an N-terminal region rich in Cys/His amino acid 
residues that may form DNA/RNA-binding motifs known as zinc fingers, a central 
region containing a leucine zipper motif (coiled coils) with potential for 
intermolecular dimerisation and a C-terminal "rfp-like" domain that is shared by 
several other proteins (Chan et al 1991a). The zinc finger DNA binding motif 
consists of regularly spaced cysteine and / or histidine residues that bind divalent 
cations (typically zinc). This gives rise to "finger-like" structures that enable the 
protein to bind DNA. There is some speculation that such metal binding domains 
facilitate protein folding that allows interaction with other macromolecules. There are 
innumerable exan1ples of zinc finger containing proteins interacting with double-
stranded DNA in a sequence specific fashion. Some evidence suggests that this 
domain may also participate in binding single stranded DNA, RNA or perhaps protein 
(Berg, 1990). 
Antigenic regions on the 52-kD Ro were evaluated by immunoprecipitation of [35S]-
radiolabelled in vitro translation products. This was the first study to describe at least 
two antigenic determinants on the 52kD Ro protein: one immunodominant and the 
other recognised by a more "restricted" subset of anti-52kD Ro Abs. 95% of 99 sera 
containing anti-52kD antibodies by ELISA, reacted with a large fragment spanning 
amino acids (aa) 1-291 (Buyon et al 1994). Two antigenic regions were identified: aa 
169-291 containing the leucine zipper, that was recognised by 83% of the anti-52kD 
sera tested and aa 1-78 containing the zinc finger domains, that was recognised by 
only half the sera. No sera immunoprecipitated the N-terminal fragment exclusively. 
Recognition of both or one region was not unique to any clinical subset of patients. 
Reactivity with both epitopes was demonstrated significantly more often in sera with 
high titers of Abs to the 60k0 Ro by ELISA in association with the anti-52kD 
response, compared with anti-52kD responses associated with low titers of anti-60kD 
antibodies. 81 % of 16 sera that recognised the N-terminal epitope were from patients 
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with the combination of HLA-DRbl *0301, DQAl *0501 and DQB1 *0201 alleles, 
compared with 30% of 10 that recognised only the central epitope (Buyon et al 1994). 
A further study determining the reactivity of recombinant 52 and 60 kD Ro proteins 
with sera from NLE, SCLE and SS patients, using CIE and ELISA, showed that 75% 
of NLE, 56% of SCLE and 83% of SS sera reacted with the 52kD protein (McCauliffe 
et al 1994). 75% of NLE, 63% of SCLE and 83% of SS sera reacted with the 60kD 
fusion protein. 17% of NLE, 25% of SCLE and 8% of SS sera were non reactive to 
both full length fusion proteins. Similar results were obtained for Chinese patients 
(Tsay et al 1996). ELISA studies with recombinant 52 and 60kD Ro protein 
fragments revealed at least 2 major epitopes on each Ro protein. A fragment of the 
52kD Ro protein, containing the putative leucine zipper motif, reacted with I 00% of 
ID defined Ro positive SS sera (McCauliffe et al 1994). It is interesting that this 
leucine zipper containing fragment is more reactive to the ID defined Ro positive NLE 
and SS sera than the full length 52kD fusion protein. An epitope is probably partially 
masked by the folding of the full length protein but more accessible to antibody 
binding in the partial length fragment. 
Confirmation of the fact that anti-52 kD Ro autoantibodies in different autoimmune 
diseases preferentially recognize epitopes on the central region of the antigen, has 
appeared more recently. Sera were obtained from 20 patients with SLE, 10 with 
primary SS, 15 children with CHB, 6 healthy anti-52 kD Ro positive infants born to 
mothers with SLE and 7 anti-52 kD Ro positive patients with primary biliary cirrhosis 
I secondary SS. Epitope mapping was performed using different fusion proteins in 
ELISA and immunoblot. All sera reacted with whole recombinant antigen as well as 
with the protein carrying the amino acid sequence 1-245. The proportion of positive 
sera against the 52kD Ro fusion proteins tested was found in descending order in 
patients with CHB, down to primary SS, the healthy infants group, patients with SLE 
and finally primary biliary cirrhosis / secondary SS. In general, CHB and primary SS 
sera exhibited the broadest reactivity against the recombinant protein compared to the 
limited and lower reactivity of sera from patients with primary biliary cirrhosis. Sera 
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from infants with CHB had significantly higher antibody levels to aa 1-245 compared 
to SLE sera and to sera from healthy infants born to SLE mothers, as well as to serum 
samples from patients with primary biliary cirrhosis/SS. The strongest antigenicities 
recognized by anti-52 kD Ro autoantibodies were located within the aa 197-245 
region. Further antigenic sites preferentially recognized by SS, CHB, and healthy 
infant sera were located within AA 153-196. The central region aa 153-245, was a 
major immunogenic region, containing a strong antigenic epitope between aa 197-245. 
The antibody response was directed at this major antigenic region regardless of the 
underlying autoimmune disease (Domer et al 1996b ). 
The 52kD Ro has homology with the human ret finger protein(rfp ), the regulatory 
protein, T-lymphocyte, 1 gene (rpt-1) and bovine butyrophilin. The rfp gene was 
originally described as part of the ret transforming gene (Takahashi & Cooper, 1987). 
The ret gene encodes a protein that consists of the amino terminal zinc finger portion 
of rfp, fused to a truncated tyrosine kinase. Later, when the gene that encodes this 
zinc finger containing portion of ret was isolated, it was called the rfp gene for ret 
finger protein (Takahashi et al 1988). Rfp is expressed at high levels in a variety of 
tumour cell lines, in mouse testis and in embryos. It is low or undetectable in other 
tissues, including brain, thymus, lymph node, muscle, kidney, liver, lung and ovary. 
Rfp may play a functional role in cells that are rapidly dividing, mitotically or 
meiotically. 
Rpt-1 was first described as a protein selectively expressed by resting but not 
activated CD4+ inducer T cells. Rpt-1 is a 41kD nuclear protein that down regulates 
gene expression of IL-2 receptor a -chain gene and human immunodeficiency virus 
type 1 genes (Chan et al 1991a). 
The carboxy terminal portion of the 52kD Ro shares +- 50% aa sequence identity with 
butyrophilin, thought to be involved in membrane stabilisation of milk-fat formation 
in mammary glands (Jack & Mather, 1990). The 52kD Ro may therefore be 
membrane associated. Ro has been shown to be membrane associated in apoptotic 
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keratinocytes (Casciola-Rosen et al 1994). Whether it was Ro52 and/ or Ro60 was 
not clearly delineated. 
It has been suggested that anti-52-kD autoantibodies appear to preferentially recognize 
the denatured rather than the native 52-kD Ro (Itoh & Reichlin, 1992). Another 
group, using a series of truncated 52-kD autoantigens, produced as beta-galactosidase 
fusion proteins in Escherichia coli, the B cell epitope distribution was probed with 18 
anti-Ro-positive sera by irnrnunoblotting and by ELISA (Kato et al 1995). Nearly all 
the antigenicity of the molecule was found to be linked to its leucine zipper region. In 
a further study using 9 of the 18 sera, the antigenicity of the molecule was found to be 
mainly formed by multiple conformational epitopes, and one of these epitopes 
appeared to be universally recognized by all the sera tested. The recognition of 
multiple epitopes indicates that the Ro 52-kD antigen itself drives the autoimmunity to 
this molecule. Further, it was suggested that the concentration of the antigenicity at 
the leucine zipper region may explain why anti-52-kD antibodies preferentially 
recognised the denatured protein rather than its native form. However, a different 
group (Buyon et al 1994), evaluated antigenic regions on the 52 kD Ro by 
irnrnunoprecipitation of radiolabeled in vitro translation products. Two antigenic 
regions were identified: an immunodominant aa 169-291 region, containing the 
leucine zipper and the aa 1-78 region, containing the zinc finger domain, recognised 
by a more restricted subset of antibodies. 
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2.3.3 calreticulin 
McCauliffe at al isolated a cDNA from an Epstein-Barr virus transformed cell line 
that was thought to encode a protein reactive with human Ro autoimmune sera 
(McCauliffe et al 1990). The encoded 46 kD protein migrated aberrantly at 60 kD and 
was shown to be calreticulin (CR) (McCauliffe et al 1990). Additional studies have 
failed to validate calreticulin' s reactivity with Ro autoimmune sera, although it is 
reactive with some LE patient sera (Rokeach et al 1991 ; Routsias et al 1993 ). This 
criticism has been based predominantly on the !ability of native calreticulin 
autoantigenic activity to denaturing conditions such as SDS-P AGE and the failure of 
prokaryotic forms of recombinant calreticulin to react preferentially with anti-Ro 
patients sera in Western blot and ELISA, as well as bind with hY RNA (Rokeach et al 
1991). McCauliffe could later not confirm that CR was reactive with Ro 
autoantibodies nor that it was a component of the Ro ribonucleoprotein complex 
(McCauliffe & Gardner, 1992). 
CR is a highly conserved calcium-binding protein. It resides mainly in the 
endoplasmic reticulum, where it may be involved in protein assembly (McCauliffe & 
Sontheimer, 1993 b ). Analysis of the CR promoter region shows a number of potential 
regulatory sites also found in the human GRP78, GRP94 and protein disulfide 
isomerase promoters (McCauliffe et al 1992). This suggests that these have similar 
transcriptional regulation and that their gene products, while structurally distinct, may 
have similar functions or co-functions (McCauliffe et al 1992). These observations 
are interesting in that all four of these genes encode acidic proteins that localise to the 
endoplasmic reticulum. 
The sequence of calreticulin has significant homology to lambda Ral-1, a recombinant 
cDNA clone corresponding to a major antigen of the nematode, Onchocera volvulus, 
the infectious agent in onchocerciasis. Onchocerciasis patients produce antibodies 
that cross-react with the 46-kD CR autoantigen (Lux et al 1992). 
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It has been suggested that some form of post-translational modification such as 
phosphorylation with or without RNA binding, is necessary to produce the 
configuration of calreticulin that is recognised by anti-Ro antibodies (Sontheimer et al 
1993). This is based on the observation that calreticulin binds to stem loop structures 
on the rubella virus genomic DRNA, only after its protein has been phosphorylated 
through a mechanism of autophosphorylation. A segment of the amino terminus of 
calreticulin has considerable homology to an RNA-binding motif employed by a 
member of the SR family of splicing factors. In addition, anti-Ro antibodies may 
precipitate a rubella virus RNA that is bound at the 5' end, to a pair of 60 and 52 kD 
proteins of unknown identity (Pogue et al 1993). 
Further work suggests that approximately 10% of cellular calreticulin molecules are 
associated with h Y RNA. This subpopulation of calreticulin has been suggested as 
binding Ro antibodies (Lieu et al 1994). Further work showed that unphosphorylated 
human rCR bound to in vitro transcribed forms ofhYRNA, the RNA backbone of the 
Ro RNP particle. This interaction appeared to be mediated by binding through the N-
and C-terminal domains of CR, but not by the central pro line-rich domain. In addition, 
it was suggested that CR can facilitate the binding of the 60-kDa polypeptide 
component of the Ro RNP to h YRNA. In addition, CR and the 52-kDa Ro 
polypeptide appeared to be capable of interacting through direct protein-protein 
binding. Through these molecular interactions and its known functional role as a 
chaperone, it was suggested that CR plays a supportive role in the formation of the Ro 
RNP complex (Cheng et al 1996). 
It was however, considered that a considerable proportion of cellular calreticulin 
molecules, perhaps including secreted forms of calreticulin, do not appear to have the 
conformational structure resulting from post-translational modification with or 
without h Y RNA binding that would allow them to interact fully with Ro 
autoantibodies (Kawashima et al 1994). 
In addition, complete congenital heart block is associated with anti-calreticulin 
autoantibodies. Anti-calreticulin autoantibody responses in serum samples from 18 
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infants with CCHB, their mothers and in a control group of 11 anti-Ro or anti-La 
positive infants without heart block and their mothers were analysed. Specific 
ELISA's were performed. Nine out of 18 sera with CCHB contained IgG anti-
calreticulin antibodies. Four sera of those with IgG antibodies also had IgM 
antibodies. One serum contained anti-calreticulin IgM antibodies only. In the non-
CCHB group two sera were positive for IgG and one serum was positive for IgM anti-
calreticulin antibodies. Sera of healthy infants were negative both for anti-IgG and 
anti-lgM calreticulin antibodies. Calreticulin is involved in calcium storage and 
therefore anti-calreticulin antibodies might influence the development of CCHB. The 
finding of lgM autoantibodies and the observed differences in antibody response in 
infants and mothers support the hypothesis of a fetally mediated and passively 
acquired autoimmune disease (Orth et al 1996). 
More recently, a subpopulation of human calreticulin that is reactive with human Ro 
autoimmune sera was identified in a nucleic acid-enriched Wil-2 cell fraction derived 
by anion exchange column chromatography. Further resolution of this fraction by gel 
filtration size separation demonstrated that the appearance of CR (true mol. weight 
46kD) coincided with the emergence of Ro ribonucleoprotein (mol. weight > 250 kD) 
antigenic activity and increasing 260 nm ultraviolet absorbance. This high nucleic acid 
fraction could be further partitioned into four small RNA-containing Ro antigenic 
sub-fractions by a second passage over the anion exchange column. CR was enriched 
in one sub-fraction and present in the other three sub-fractions as well. No CR was 
found in the RNA-free fraction of the repartition eluate. These results represent the 
first direct demonstration that CR, a high-affinity calcium binding protein, exists in a 
form that is directly associated with all four varieties of native, human Ro 
ribonucleoprotein particles (h Yl-5) (Lieu & Sontheimer, 1997). 
2.3.4 54 kD Ro 
Since the description of the 52kD component, (Rader et al 1989) described two 
human erythrocyte-specific Ro components of 60 and 54 kb. These were 
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immunologically related to the previously described 60 and 52 kD species 
respectively. This 54kD isoform was found in nuclei free platelets and red blood 
cells. It is unclear why mature red cells carry varying forms of Ro (Rader et al 1989). 
This has not been confirmed: a further group showed that the main reactivity of Ro 
sera was to a 52 kD, rather than a 54 kD protein in red cells (Manoussakis et al 1993), 
although a small percentage of sera detected a 54 kD red cell protein. An autoantigen 
defined by a band on western immunoblotting is less defined than one which has been 
cloned and characterised. 
2.3.5 Cross-reacting epitopes 
Controversy exists as to whether the 52kD protein is associated with the 60kD protein 
and h Y RNA. It has been demonstrated that antibodies from Ro autoimmune sera 
specific for either a 52kD or 60kD protein on Western blot, immunoprecipitate hY 
RNA from cell extracts. However, antibodies specific for the 52kD protein, 
precipitated a small amount of 60kD protein, along with h Y RNA and the 52kD 
protein. A number of groups would agree that the 52 kD Ro protein is a component of 
the Ro RNP complex (ltoh et al 1991; ltoh & Reichlin, 1991 b; Ben-Chetrit et al 
1988). 
Some investigators have suggested that a major denaturation resistant epitope on the 
52 kD Ro protein is cross reactive with the 60kD Ro protein (ltoh et al 1992). They 
suggest that it is not really a target of the Ro autoimmune response but simply is 
detected because of its shared epitope with the major immunogen. 
2.4 Methods for detection of Ro antibodies 
There are a range of assays to detect ANA. The first method of Ro detection was gel 
double diffusion. Newer assays are increasingly sensitive. When highly purified or 
recombinant autoantigens are used in versatile assays such as ELISA, 
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2.4.1 Indirect Immunofluorescence 
The most widely used procedure for ANA screening, is the indirect 
immunofluorescence test (Tan, 1967). The standardisation of IF-ANA has been 
difficult and several recommendations have been made to improve testing procedures, 
including a quality assurance program to detect Ro antibodies. The inability to detect 
Ro antibodies may account for a significant percentage of so called ANA-negative 
SLE cases (Lopez-Robles et al 1986; Maddison et al 1981; Deng et al 1984). Most 
clinical laboratories are using ID, CIE or a purified native 60kD Ro ELISA to detect 
Ro autoantibodies in patients sera (McCauliffe et al 1997b ). 
The detection of 60kD Ro is hindered by its low cellular abundance. Two studies 
have used a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 
cells for IF. In the first, the Ro60 (60kD) Ro gene was transfected and over-expressed 
into HEp-2 cells (Keech et al 1994). They used a mixture of Ro60 transfectants and 
untransfected HEp-2 cells (HEp-Ro60) as a substrate for IF-antinuclear antibody 
testing in a hospital laboratory. Screening of 240 routine serum specimens identified 
14 Ro transfectant-positive sera which were confirmed by 
counterimmunoelectrophoresis. 3 of these sera were ANA-negative on untransfected 
cells and regular HEp-2. A comparison of HEp-Ro60 and regular HEp-2 showed 
strong concordance of the different ANA patterns between the 2 substrates. No 
increase in background staining was observed on the Ro transfectants when reacted 
with normal human sera. A comparison between HEp-Ro60 and CIE for 53 sera from 
patients with primary Sjogren's syndrome showed that HEp-Ro60 were a sensitive and 
specific substrate for detection of anti-Ro antibodies. Masking of positive Ro 
transfectants was observed rarely in sera containing multiple ANA specificities, but 
the Ro60 staining on these transfectants were unmasked at higher serum dilutions. 
Dr. Tom Gordon holds a US patent for this transfected cell assay and has asked a 
company to market the product. Dr. Fritzler used the commercial product to 
determine the sensitivity and specificity of this assay (Fritzler & Miller, 1995). 
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Seventy-three sera with Ro autoantibodies as determined by double immunodiffusion 
and immunoblotting were tested by IF on a HEp-2 cell substrate that had been 
transfected with a full-length cDNA encoding a human 60kD Ro autoantigen. 
Controls included 30 normal human sera and 50 sera with a variety of other 
antinuclear antibodies. Prototype human and rabbit sera directed against the 60 kD Ro 
antigen produced intense speckled nuclear and nucleolar staining of transfected cells. 
Sixty-nine of 73 (95%) SS-A/Ro positive sera also produced this characteristic 
staining pattern. The endpoint autoantibody titers on transfected cells was fivefold 
greater than on un-transfected cells. The 30 normal human sera and the 50 sera with 
other antinuclear antibodies did not produce this characteristic staining. Six of 32 
(19%) unselected sera that were sent for autoantibody testing had reactivity with 
transfectants by IF. Four of the six sera were confirmed to have anti-Ro antibodies by 
ID and 5/6 IB. By contrast, only three of these sera were scored as having a staining 
pattern compatible with SS-A/Ro antibodies by IIF on standard HEp-2 substrates. 
2.4.1.1 Fixation 
In addition, methods of fixation are important. Conventional cell fixation for ANA 
testing does not allow full visualisation of all proteins, such as CR, that reside in the 
ER. ER proteins can be seen better with IF with detergent permeabilisation of fixed 
cells or unfixed cells exposed to 9% sucrose (McCauliffe & Sontheimer, 1993b). 
Acetone fix for 1 - 10 minutes on KB or HEp-2 cells, with SS-A containing sera, 
produced discrete nuclear speckles and no cytoplasmic staining. However, when the 
same cell lines were used with either ethanol or methanol, the intensity of staining 
with anti SS-A sera dropped from 2+ to trace, as the fixation time increased from 1 to 
10 minutes (Bylund & Nakamura, 1991 ). Periodate-lysine-paraformaldehyde (PLP) or 
2% glutaraldehyde caused a different, non-specific immunofluorescent pattern of the 
entire cell, with anti SS-A sera (Harmon et al 1984). Using a variety of unfixed 
tissues, Lopez-Robles et al found mainly nuclear, with occasional cytoplasmic, 
fluorescence and suggested that Ro could be a mobile complex, whose location 
depends on the cell cycle (Lopez-Robles et al 1986). 
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2.4.1.2 Substrates 
The Ro antigen is found in very low concentrations in mouse, rat, rabbit, hamster and 
chicken cells (Harmon et al 1984) and tissue culture cells are more sensitive 
substrates than tissue sections (Deutscher et al 1988). In addition, tissue culture cell 
nuclei contain certain nuclear materials that are not present in the nuclei of resting-
phase cells. The presence of an ANA in certain patients with SCLE that binds to 
human HEp-2 cells but not to mouse kidney sections, suggests that this particular type 
of ANA reacts with a nuclear antigen present in HEp-2 cells but in low or absent 
concentrations in mouse kidney cells (Sontheimer et al 1992). 
2.4.2 Immunodiffusion 
Immunodiffusion, gel double diffusion (Ouchterlony) (ID), is the classical, simple 
method of detection of anti-Ro antibodies. Agar is used as a support medium. Wells 
are cut into the agar. Into the center well is placed the antigen, an extract of human 
spleen (HSE). The outer wells contain the test and reference sera. If the test serum 
contains an antibody reactive against an antigen in HSE, a precipitin line will form 
between the test and the antigen wells. If the test and reference sera have identical 
antibody systems, the precipitin line formed between the reference serum and the 
antigen wells will merge into a continuous line, with the precipitin line formed 
between the reference serum and the antigen wells (line of immunologic identity). 
Antibodies are detected by using double diffusion in 0.5% agarose. Precipitin lines 
form after interaction with Ro and dilutions of sera (Ben-Chetrit et al 1988). These 
precipitin lines are stained with Coomasie blue and compared against reference sera. 
This is a native assay (Bo ire et al 1991 ). This technique does not differentiate 
between antibodies to the 52 and 60-kD antigens (Ben-Chetrit et al 1988). With this 
technique, anti-Ro antibodies can be detected in 25% (Sontheimer et al 1992) to 57% 
(Ben-Chetrit et al 1990) of patients with SLE. Virtually no normal individuals have 
anti-Ro antibodies with immunodiffusion. 
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Counter-immunoelectrophoresis (CIE) is a more sensitive Ro autoantibody detection 
method (McCauliffe et al 1997b ). In one study, CIE was found to be reliable, with a 
specificity of 100% and a sensitivity of 89% (Manoussakis et al 1993 ). It has not yet 
been determined which of the molecules reactive with Ro autoimmune sera are 
responsible for the immunoprecipitation, seen in immunodiffusion assays. It has been 
observed that non-reducing SDS-PAGE of eluted precipitins from CIE showed the 
precipitins to be composed of a 60kD protein (Rader et al 1989). 
An improved method for the detection and identification of antibodies against 
extractable nuclear and cytoplasmic antigens has been described: 
counterimmunoelectrophoresis with serum pre-diffusion (SPD ) (Walravens et al 
1997). In this technique, serum is allowed to diffuse freely into the gel before pouring 
the antigenic extract in its trough ( or wells) and starting the electrophoresis. Both the 
immunoprecipitations and the interaction with reference sera are strongly intensified 
by serum pre-diffusion, leading to higher sensitivity and specificity for the detection 
of anti- Ro, anti- La, anti-UlRNP, anti-Sm, anti-Jol and even anti-Scl-70 antibodies. 
The optimal serum pre-diffusion time was 2 h. To evaluate the relevance of SPD for 
the clinical laboratory, 92 antinuclear antibody (ANA) positive sera were tested on 
CIE without serum pre-diffusion and with 2 h serum pre-diffusion in identification 
tests with Ro, La, Sm, UlRNP and Jol reference sera. The precipitation lines and 
their interactions were evaluated by three independent observers. It was observed that 
serum pre-diffusion considerably improved the efficiency of CIE for antibody 
identification. 
2.4.3 Immunoblotting 
Electrophoretic blotting is performed using the method of Towbin (Towbin et al 
1979). Proteins are separated by SOS-PAGE (Laemmli, 1970) and electrophoresed to 
a nitrocellulose sheet. These are then blocked to inhibit non specific binding. The 
nitrocellulose sheets are then incubated with dilutions of sera. This assay generally 
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uses denatured polypeptide versus native protein, although some proteins may be able 
to refold depending on experimental conditions. 
Western blot analysis has high specificity (95% for the 52 kD Ro [Ro52], 97% for 
Ro60) for Ro autoantibody detection but low sensitivity (36% for Ro52 , 17% for 
Ro60) (Manoussakis et al 1993). One study showed 51/90 SLE sera (57%) Ro 
positive by ID. In Western blotting, of the same population, 24 (47%) possessed 
antibodies against both the 60 and 52-kD antigens, while 9 (18%) reacted only with 
the 60-kD protein. 18 (35%) were non-reactive by Western blot, although positive by 
ID (Ben-Chetrit et al 1990). In addition this biases for high affinity antibodies (Buyon 
et al 1989). Immunoblotting may fail to detect anti-60 kD antibodies in some sera 
because of the denaturing of the protein that takes place prior to electrophoresis and 
the importance of conformational epitopes in some sera. Thus, immunoblotting 
should not be relied on as the sole method for evaluating the presence or absence of 
anti-60kD Ro. 
However this is to some degree controversial. One group (Zimmermann et al 1996) 
has found that IB is the most sensitive method for detection of anti-La and may help to 
characterize clinically distinct subgroups of anti-Ro positive patients with SLE. They 
suggest that determination of anti-Ro by IB may increase the prognostic value of this 
autoantibody. 
2.4.4 Immunoprecipitation 
In this technique, radiolabelled cell extracts are used as a source of antigen, against 
which patients' sera adsorbed to protein A-Sepharose beads, are immunoprecipitated 
(Lerner et al 1981 ; Francoeur & Mathews, 1982). A RNA immunoprecipitation assay 
detects Ro autoantibodies with greater sensitivity than CIE but is impractical for 
routine diagnostic work (Manoussakis et al 1993; Meilof et al 1990). This assay 
likewise detects native antigen. 
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In a study comparing 5 methods of Ro antibody detection, RNA precipitation was the 
most specific and sensitive of the assays (Manoussakis et al 1993). This is based on 
the sensitive detection of radiolabelled small h Y-RNA particles precipitated by anti-
Ro antibodies. Whole cell extracts are prepared from radiolabelled HeLa cell 
cultures. RN As are extracted from the pellets with phenol and analysed on 10% 
polyacrylamide-7M urea gels. Bands are visualised by x-ray autoradiography in the 
presence of intensifying screens. 
Owing to its complexity and the use of large amounts of radiolabelled reagents, this 
assay has little value for routine laboratory serological work (Manoussakis et al 1993), 
although protocols that do not need radioactivity exist (Forman et al 1985). 
2.4.5 ELISA 
Using an ELISA based on affinity purified Ro antigen, 50% of patients with SLE are 
found to have elevated levels of this autoantibody specificity (Sontheimer et al 1992). 
Some have found this test to be less specific than immunodiffusion (Manoussakis et al 
1993; Meilof et al 1990), whereas others have found ELISA with purified native 
60kD Ro protein to be more specific than ID (McCauliffe et al 1997b ). Recombinant 
60kD Ro protein ELISAs appear to be less sensitive in detecting Ro autoantibodies 
than are native 60kD Ro ELISAs, ID and CIE. One benefit of this new technology is 
the ability to measure antibody binding levels to individual epitopes. These are 
limited portions of an autoantigen's amino acid sequence that represent single 
antibody binding sites. Certain patterns of clinical disease may be linked to 
autoantibody production against individual autoepitopes rather than whole 
autoantigenic molecules (Sontheimer et al 1992). Certainly, it has been shown that 
commonly employed Ro serologic assays detect anti-60kD Ro autoantibodies but fail 
to detect anti-52 kD Ro autoantibodies, that can be detected using a recombinant 
52kD Ro ELISA (McCauliffe et al 1997b ). ELISA for anti-60 is preferably done 
using native 60 rather than denatured 60. In addition, human, rather than bovine 60 is 
required in some cases, as reactivity with 60-kD Ro from other species may be weak 
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or absent (Lee et al 1994b ). On the other hand, the autoantibody response to Ro52 
appears to be due to largely epitopes present on the denatured or recombinant 
molecule (Lee et al 1994b ), although a study evaluating Ro52 antigenic regions by 
immunoprecipitation in a relatively non-denaturing system, confirmed similar results 
to those obtained with ELISA (Buyon et al 1994). 
SS sera are more likely to contain anti-52 and anti-60kD Ro autoantibodies, or anti-
52kD Ro autoantibodies alone, than anti-60kD Ro autoantibodies alone (McCauliffe 
et al 1997b; Ben-Chetrit et al 1990; Ricchiuti et al 1994; St.Clair et al 1994; Slobbe et 
al 1991 ). The 52kD Ro ELISA assay is a better assay for detecting Ro autoantibodies 
in SS sera, than commonly employed serologic techniques (McCauliffe et al 1997b ). 
A study looking at the reactivity of recombinant 52 and 60kD Ro proteins with sera 
from SCLE, NLE and SS patients, found that the ID assay and the recombinant Ro 
ELISA together are more sensitive in detecting Ro antibodies than either assay alone 
(McCauliffe et al 1994 ). Eight ( 5 7%) of 14 ID defined Ro negative NLE, SCLE and 
SS sera were reactive with both the 52 and 60kD Ro fusion proteins by ELISA. 
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3.1 INTRODUCTION 
The early controversy about the location of Ro, could be explained by the later 
recognition of different Ro proteins. These initial studies used "generic Ro" sera, that 
may have contained both anti-52 and anti-60 kD Ro antibodies, or only anti-52, or 
only anti-60 kD Ro antibodies. Later studies attempting to differentiate the position of 
the 60 kD Ro from the 52 kD Ro were flawed in their purification of anti 52kD Ro 
antibodies. 
Slob be et al in their immunofluorescence study (Slobbe et al 1991 ), immunoaffinity 
purified antibodies monospecific for either the Ro60 or La antigen, using recombinant 
antigen, coupled to a CNBr-activated Sepharose 4B, yielding monospecific anti-La 
and anti-Ro60 antibodies from patients and monospecific rabbit anti-Ro60 antibodies. 
Anti-Ro52 antibodies were not purified. Rather, a serum was used, which did not 
contain detectable levels of anti-Ro60 or anti-La antibodies on immunoblot. They 
then passed this serum repeatedly over a Ro60-column, in an effort to remove anti-
Ro60 antibodies. The western blot showing the specificity of the Ro52 antibodies 
however, revealed a band running just above 60 kD. 
The subsequent paper by Kelekar et al, used 60 or 52-kD rabbit antiserum produced 
against partially purified recombinant forms of the corresponding proteins 
overexpressed in E coli (Kelekar et al 1994). No further characterisation details were 
given. Ben-Chetrit et al, in their paper describing the 52 kD antigen, used anti-52kD 
antibodies which precipitated both a 52 kD and also a 60 kD component (Ben-Chetrit 
et al 1988). Perhaps this explains the similar bright nuclear staining they found with 
both anti-52 and anti-60 kD antibodies. It is possible that the results one obtains, may 
be dependent in part, on the sera from which one purifies the antibody. It has been 
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shown that a number of patients with anti-Ro antibodies also have rheumatoid factor 
(Scofield et al 1991 ; James et al 1990). 
Where there are two different Ro antigens, it is necessary in efforts to unravel 
physiological and disease processes, to have purified antibodies to work with. In 
addition these antibodies need to target the relevant epitopes, whether conformational 
or not. For this reason it was important to purify antibodies to the major regions of 
Ro52 and Ro60. For double immunofluorescence, antibodies from two different 
species were needed. 
3.2 METHODS 
3.2.1 Recombinant Gst Ro Fusion Protein 
3.2.1.1 Isolation of 52 and 60 kD Ro encoding clones 
cDNA clones encoding the entire 52 and 60 kD Ro proteins were isolated by the 
polymerase chain reaction (PCR) using Wil-2 8-cell cDNA (ATCC CRL 8885) and 
synthetic oligonucleotides corresponding to published sequences (Deutscher et al 
1988; Chan et al 1991 a; ltoh et al 1991 ). Ro cDNA fragments that encode different 
portions of the antigens were also produced by PCR using the isolated cDNA clones 
as templates. These cDNA were subsequently used to make protein fragments of the 
52 and 60 kD Ro antigens. This work was performed by Dr. Daniel P McCauliffe. 
3.2.1.2 Expression vector construction and sequencing 
The 52 and 60kD Ro encoding cDNA were ligated into the pGEX-2T vector 
(Pharmacia, Piscataway, NJ) so that full length and partial length glutathione S-
transferase (GST)-Ro fusion proteins could be generated. dsDNA sequence analysis 
of each construct was performed by the Sanger dideoxy method with modified T7 
DNA polymerase (Sequenase) according to the manufacturer's recommendations 
(United States Biochemical Corp., Cleveland, Ohio, USA) and compared to published 
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sequences (Deutscher et al 1988; Chan et al 1991a; Itoh et al 1991; Ben-Chetrit et al 
1989). This work was performed by Dr. Daniel P McCauliffe. 
3.2.1.3 Recombinant protein production and purification 
Recombinant GST-Ro fusion proteins were expressed in JM 109 cells (ATCC 53323) 
and purified using glutathione linked agarose (Sigma) as described (Smith & 
Corcoran, 1990). The 52 and 60 kDa GST fusion proteins could be cleaved from GST 
with thrombin as described (Smith & Corcoran, 1990). However, previous work has 
shown that the GST portion of the fusion protein does not interfere with Ro antibody 
binding to the recombinant Ro proteins (McCauliffe et al 1994). Large scale 
recombinant protein production was performed using the following protocol: 
Protocol 1: Large scale recombinant protein production 
On the first day, 150 ml of liquid broth (LB)/ ampicillin (ampicillin: add 150µ1 of 
stock to final cone. of 50µg/ml) was seeded with the bacteria containing plasmid of 
interest and grown overnight in a 37°C shaker. During this process, 31 of LB was 
prepared in three 21 flasks and autoclaved. In addition, the glutathione agarose was 
prepared by adding 249 mg of glutathione agarose to 20 ml of PBS, letting it sit at 
room temperature for about one hour and then spinning it for 10 min. in a Dorvall RT 
6000 centrifuge at 2 500 RPM. The wash was repeated twice. After the third wash, 
the agarose pellet was resuspended in 3ml of PBS, to bring up the total volume to 6 
ml. 
On the second day, 1 ml of 50 mg/ml ampicillin stock was added to each one litre of 
broth. Each flask was seeded with 50 ml of overnight culture and grown for an 
optimal 4 hours at 3 7°C. Then 1 ml of 1 OOmM IPTG was added to each flask and 
grown for one hour. During this hour, the following were prepared on ice: 6 
centrifuge bottles, rinsed with ddH20, six 50 ml tubes, four scintillation tubes and the 
PBS/protease inhibitor solution (30 ml 1 X PBS + 900µ1 500 mM EDTA + 450 µl 100 
mM PMSF [added only to one bottle as viable for only 1/2 hr, during 2nd 
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centrifugation] + 300µ1 OTT + 300µ1 IM OTT + 450µ1 Triton X-100). Then the 
cells/media were poured into six 250 ml Nalgene centrifuge bottles, balanced and 
centrifuged for 10 minutes in a Sorvall GSA rotor at - 5 500 RPM (5 OOOGs). One 
flask was put into the -20°C freezer. The supernatant was decanted and the 
centrifugation was repeated with the rest of the cells/media in the same bottles. Each 
cell pellet was then resuspended on ice in 4 - 5 ml of ice cold PBS/protease inhibitor 
solution and poured into four 20 ml scintillation tubes. This solution was sonicated 
on ice with a 13 mm probe at a setting high enough to clarify the cells in about 30 sec 
but low enough to avoid frothing. [setting 5, 20 sec. thrice] . The sonicate was spun 
for 10 min. in a Sorvall SS-34 rotor at 6500 rpm (- 5000 G). The supematants were 
transferred to a clean 50 ml tube and the 6 ml solution of glutathione agarose was 
added. This was mixed gently on a rocker for about 6 min. at room temperature and 
centrifuged for 10 min. in a Dorvall RT 6000 centrifuge at 2 500 RPM. The 
supernatant was aspirated with a vacuum. 30 ml PBS/protease inhibitor solution was 
added to the pellet and rocked for 6 min. at 4 °C. The centrifugation was repeated, 
followed by two washes with 1 X PBS. The supernatant was decanted, aspirated and 
the agarose pellets were washed once with 20 ml ice cold 1 % Triton-X/PBS solution. 
The pellets were washed once with 20 ml. ice cold IX PBS, transferred to a 15 ml 
tube, spun and the excessive supernatant removed , to - 5 ml. The 2 tubes were 
combined to - 10 ml, spun and aspirated to 6 ml. Using a 1 ml pipette, the 50 ml 
bottles were washed to remove remaining agarose and this was transferred to 6 ml. A 
sample was then taken for western blotting It was aliquoted and stored at -70°C. 
*For thrombin cleavage, after the addition of the ice cold 1 % Triton-X/PBS solution 
as above, the agarose pellets were washed once with 30ml ice cold thrombin wash 
buffer, followed by a wash with 30ml ice cold thrombin cleavage buffer without 
calcium. This was then spun and the excessive supernatant was removed, to a final 
volume of 6ml. 
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3.2.2 Rabbit Immunisation 
New Zealand white rabbits were immunized with recombinant 52 and 60 kD fusion 
proteins, linked to glutathione - agarose, according to established protocols (Oettinger 
et al 1992). This work was performed, in part, by Mr. L Wang. In total 6 rabbits were 
immunised. The sera from three rabbits were used to purify antibodies used in these 
experiments. 
In more detail, the following methodology was applied: 
Protocol 2: Rabbit Immunisation 
RABBIT#! 52-1-b 
The rabbit was immunised subcutaneously with 1 mg of recombinant 52-1-b protein 
(0.5 ml agarose, 0.5 ml Normal saline and 0.5 ml complete Freund' s medium). 22 
days later, a further 1mg ofrecombinant 52-1-b protein (1 ml [agarose + supernatant] , 
0.5 ml incomplete Freund' s medium) was injected. 17 days later, 4 ml of blood was 
drawn. 15 days later, the rabbit was immunised with > 1 mg of recombinant 52-1-b 
protein (1 ml [agar + supernatant, 1 ml incomplete Freund' s medium). 13 days later, 
the rabbit was bled. 16 days later the rabbit was re-immunised with - 800 µg of 
recombinant 52-1-b protein (0.5 ml agar and 0.5 ml incomplete Freund's medium). 
13 days later, 15 ml blood was drawn. 34 days later, 15 ml blood was drawn. 19 days 
later the rabbit was re-immunised with - 500 µg of recombinant 52-1-b protein (0.5 ml 
agar and 0.5 ml incomplete Freund's medium). 17 days later, 35 ml of blood was 
drawn. The next day, 100 ml blood was drawn and the rabbit was sacrificed. 
RABBIT #2 whole 52 
The rabbit was immunised subcutaneously with - 200 µg of recombinant whole 52 
protein (0.5 ml agar, 0.5 ml Normal saline and 0.5 ml complete Freund' s medium). 
22 days later, a further - 150 µg of recombinant whole 52 protein(! ml [agar + 
supernatant, 0.5 ml incomplete Freund' s medium) was injected. 17 days later, 4 ml of 
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blood was drawn. 15 days later, the rabbit was immunised with - 500 µg of 
recombinant whole 52 protein (1 ml (agar + supernatant, 1 ml incomplete Freund's 
medium). 13 days later the rabbit was bled. 16 days later the rabbit was re-
immunised with - 500 µg of recombinant whole 52 protein (0.5 ml agar and 0.5 ml 
incomplete Freund' s medium). 13 days later, 15 ml blood was drawn. 34 days later, 
15 ml blood was drawn. 19 days later the rabbit was re-immunised with -400 µg of 
recombinant whole 52 protein (1 ml agar and 1 ml incomplete Freund' s medium). 27 
days later, 20 ml of blood was drawn. 36 days later the rabbit was re-immunised with 
- 100 µg of recombinant protein (50 µg whole 52 and 50 µg 52-2, 1 ml agar and 1 ml 
incomplete Freund' s medium). 16 days later, 10 ml of blood was drawn. 81 days 
later the rabbit was re-immunised with - 150 µg of recombinant protein (50 µg whole 
52, 50 µg 52-1 and 50 µg 52-2, 1 ml agar and 1 ml incomplete Freund's medium). 21 
days later, 12 ml of blood was drawn. 7 days later, 25 ml of blood was drawn. 18 
days later the rabbit was re-immunised with - 150 µg of recombinant protein (50 µg 
whole 52, 50 µg 52-1 and 50 µg 52-2, 1 ml agar and 1 ml incomplete Freund's 
medium). 22 days later, 30 ml of blood was drawn. 6 days later the rabbit was re-
immunised with - 150 µg of recombinant protein (50 µg whole 52, 50 µg 52-1 and 50 
µg 52-2, 1 ml agar and 1 ml incomplete Freund' s medium). 14 days later, 100 ml of 
blood was drawn and the rabbit was sacrificed. 
RABBIT #3 whole 60 
The rabbit was immunised subcutaneously with - 100 µg of recombinant whole 60 
protein (0.5 ml agar and 0.5 ml complete Freund's medium). 23 days later, a further 
- 150 µg of recombinant whole 60 protein (0.5 ml agar and 0.5 ml incomplete 
Freund' s medium) was injected. 13 days later, 15 ml of blood was drawn. 34 days 
later, 12 ml of blood was drawn. 42 days later, the rabbit was immunised with - 300 
µg of recombinant whole 60 protein (1 ml (agar + supernatant, 1 ml incomplete 
Freund's medium). 27 days later, 20 ml of blood was drawn. 36 days later the rabbit 
was re-immunised with - 500 µg of recombinant whole 60 protein (0.5 ml agar and 0.5 
ml incomplete Freund's medium). 16 days later, 20 ml blood was drawn. 32 days 
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later the rabbit was re-immunised with -200 µg of recombinant protein (50 µg whole 
60, 50 µg 60-1, 50 µg 60-4 and 50 µg 60-2, 1 ml agar and 1 ml incomplete Freund's 
medium). 27 days later, 20 ml of blood was drawn. 17 days later, 25 ml of blood was 
drawn. 32 days later the rabbit was re-immunised with -200 µg of recombinant 
protein (50 µg whole 60, 50 µg 60-1, 50 µg 60-4 and 50 µg 60-2, 1 ml agar and 1 ml 
incomplete Freund's medium). 22 days later, 5 ml of blood was drawn. 16 days later 
the rabbit was re-immunised with -200 µg of recombinant protein (50 µg whole 60, 
50 µg 60-1, 50 µg 60-4 and 50 µg 60-2, 1 ml agar and 1 ml incomplete Freund's 
medium). 14 days later, 100 ml of blood was drawn and the rabbit was sacrificed. 
3.2.3 Characterisation Of Human Sera 
A number of whole sera from well documented patients were used, in addition to the 
specific antibodies. Autoimmune patient sera were collected from the University of 
North Carolina sera bank in the division of rheumatology. Patients notes were 
reviewed to verify patient diagnosis. A diagnosis of NLE was based on the presence 
of congenital heart block and / or characteristic skin lesions in an infant born to a 
mother with Ro antibodies. A diagnosis of SCLE required the presence of 
characteristic skin lesions by clinical and histopathological examination. A diagnosis 
of primary SS was based on the presence of the sicca complex ( dry eyes and dry 
mouth) in the absence of another connective tissue disease. ID defined Ro negative 
SCLE sera were provided by Dr. Richard Sontheimer, Southwestern Medical Center, 
Dallas, Tx, U.S.A. 
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In addition, a number of sera were chosen after assessing their antibody yield on both 
immunoblotting and ELISA: 
2429 SS. Immunodiffusion (ID) positive for SSA. ELISA positive for native 
60kD Ro, recombinant 52kD Ro, recombinant 60kD Ro and La. 
93-1 Glyburide induced SCLE. ID positive for SSA. + native 60 
2109 Subacute cutaneous LE. ID Ro negative 
123 Neonatal LE. ID positive for SSA. ELISA positive for native SSA, negative 
for recombinant 52kD Ro, recombinant 60kD Ro and La. 
92-1, C2 Subacute cutaneous LE. Paired sera from same patient, one month apart. 
C2 antinuclear factor (ANF) negative, 92-1 ANF positive. 
3.2.4 Antibody Purification 
3.2.4.1 Anti-52 kD Ro 
3.2.4.1.1 SDS-PAGE and Western Blotting 
Ro fusion proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then transferred to polyvinylidine difluoride paper 
(Immobilon-P, Millipore Corp., Bedford, MA.), electrophoretically with a semi-dry 
transfer unit (Semi-phor TE70, Hoefer Scientific Instruments, San Francisco, CA.) 
(Harlowe & Lane, 1988) according to the following protocol: 
Protocol 3: SDS-P AGE 
Prior to pouring the gel, the glassware and spacers were cleaned with 70 - 95% ETOH 
and Kimwipes. The plates were then fixed together using the alignment card and 
fitted into the casting stand. The resolving gel was made with ddH20 3.35 ml + 
Tris(8.8) 2.5 ml + 1 % SDS 100µ1 + 30% acrylamide 4 ml, then degassed, followed by 
the addition of 50µ1 1 % APS and 5µ1 Terned. The resolving gel was added carefully 
from the top. The plates were filled and immediately overlaid with water using a · 
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needle and syringe. When the gel had polymerised (about one hour) the water was 
removed from the surface and the stacking gel poured with the comb in place. Once 
polymerised (about 30min), the comb was removed and the wells rinsed with distilled 
water. 
The samples to be run on the gels were prepared by adding 2 ml of sample buffer (for 
2 double gels) to the recombinant protein and mixing on a rocker at room temperature. 
The molecular weight markers, 1 Oµl / single and the samples were loaded onto the 
relevant lanes of the gel. The gels were then fitted into the upper chamber of an 
electrophoresis tank (Biorad) and the top and bottom chambers filled with cooled 
running water. The gels were then run at 200mA for 30 -45 mins. 
Western Blotting 
Just prior to the completion of gel electrophoresis, the PDF (polyvinylidine difluoride) 
paper and 4 sheets of filter paper, cut to the size of the gels, were soaked for a few 
seconds in Methanol, then ultrapure water, then transfer buffer. Once electrophoresis 
was complete, the gel was removed from the tank. The glass plates were separated. 
The plate holding the gel was then immersed in buffer and overlaid with a sheet of 
nitrocellulose. On top of this was added one sheet of filter paper, followed by a piece 
of cellophane, then a sheet of filter paper, then the second gel, then two sheets of filter 
paper. 
The resulting sandwich (held between two plastic plates) was then placed in the 
transfer unit (Semi-phor TE70, Hoefer Scientific Instruments, San Francisco, CA.). 
The proteins were then transferred to the poly (vinylidine difluoride) paper by blotting 
at 150 mA/gel for about 50 mins. Coomassie blue dye was then added to the glass 
chamber. Two ends were cut off the PDF paper and stained. The rest of the PDF 
paper was then blocked with 4 g milk powder in 80 ml ELISA coating buffer for 1.5 
to 2 hrs. It was then removed, and strips from Coomassie blue were added to find the 
protein. The protein strips were then cut out and stored in SOB and Ampicillin. 
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3.2.4.1.2 Reduction 
From preliminary experiments it was realised that to keep the antigenicity of 52-1 b, a 
reducing agent was necessary. The best reducing agent was DTT, which prevents 
denaturation by stopping the formation of disulphide bonds. The 52-1 b strips needed 
to be incubated overnight in DTT, before being washed repeatedly and using for 
antibody purification. 
3 .2.4.2 Stripping 
The PDF strips were incubated with human Ro autoimmune sera, or rabbit anti-sera, 
overnight at 4°C and then washed three times with a large volume of lX PBS at room 
temperature. The PDF strips were stripped of the bound antibodies with 0.2 M 
glycine (pH 2.8), for 10 minutes, as described below. A number of preliminary 
experiments were performed to determine the best stripping agent for each antibody, 
as assessed by specific activity in ELISA and western blot. The following agents were 
used for 2, 5, 10, 15 and 30 minutes: 0.1 M Glycine (pH 1.8), 0.2M Glycine (pH 2.8), 
Glycine pH 2.5 and Trimethylamine. 
Protocol 4: Summary of antibody stripping and storage of strips 
Strips were stored in 50 ml tubes with 20 ml SDB, to cover the strips completely, with 
25 µl Ampicillin at 4°C. The 52-lb strips were stored in 20 ml SDB + 200 µl DDT 
overnight, then washed 4 times with 1 X PBS the next morning, before storing as for 
other strips. SDB was made with 0.5 ml Tween 20, 2.5 g bovine serum albumin (BSA 
0.25% ), 1.0 g goat gamma globulin (0.1 % ), 1.0 g sodium azide (0.1 % ), 1 X PBS to 1 
liter ( dilute 1 OX PBS 1: 10 in H20), filter sterilised. 
Antibody purification The strip was taken out of the storage tube and washed twice 
with 1 X PBS. The storage tube was kept. 12-20 ml fresh SDB was added to the 
strips then -40-50 µl serum. The tube was rotated overnight at 4°C. The liquid 
phase (unbound fraction) was saved in a labeled tube for ELISA. The strips were 
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washed in 25 ml wash buffer (0.5 ml Tween 20 (0.05%) in 1 liter sterile 1 X PBS). 
After the final wash, all the wash buffer was poured out. 
Antibody stripping - 7 ml 0.2 M Glycine (pH 2.8) was added and rotated at room 
temperature for 5 min. After decanting and saving the first glycine wash, -5 ml 
additional glycine was added to the strips and rotated at room temperature for - 5 min. 
The liquid phase was saved and combined with the other - 7 ml glycine wash. The 
strip was briefly spun to collect any remaining liquid. Immediately -0.9 ml of 1 M 
Tris (hydroxymethyl)-aminomethane (pH 9.5) was added. This was mixed well and 
checked with pH paper to ensure that the pH = 8, if not, more Tris was added. After 
the final glycine wash had been removed, the strips were washed twice with 1 X PBS, 
then stored as described above. 
3.2.4.3 Human Anti-native 60kD Roantibodies 
3.2.4.3.1 Novel ELISA method 
Protocol 5: ELISA method for purification of anti-native 60kD Ro 
24 wells of a 96-well microtiter plate were coated with bovine Ro (Immunovision, 
Springdale, AK) diluted to 8 units/ml in coating buffer. These were incubated 
overnight at 4 °C, blocked for one hour (0.25% bovine serum albumin and 0.1 % goat 
gamma globulin in 1 X PBS) and incubated with a high titer anti native 60 kD Ro 
containing autoimmune serum, diluted 1 :5000, for one hour. After two washes, the 
bound antibodies were stripped from each well with glycine 0.2M, pH 2.8 for five 
minutes. The pH was immediately equilibrated to pH 8.0, with IM Tris, pH 9.5. The 
antibodies from each well, were pooled and concentrated (Spin-X UF concentrator, 
Costar, Cambridge, MA), according to the following protocol: 
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Protocol 6: Antibody concentration If the antibodies were to be kept for later use 
on fixed cells, a preservative, Sodium Azide was added. If the antibodies were to be 
used on viable cells, for the penetration experiments, no preservative was added. 
centrlcon # 30 
concentrator 
Wash centrlcon by spinning In buffer of choice 
before adding your protein. 
Can block with 0.5% BSA. 
add material to 
be concentrated 
(2 ml total) 
repeat procedure 
until all material 
has been 
concentrated ( 
add more 
material to be 
concentrated 
keep 
concentrator 
~--,-.,, upright 
t spin In SS-34 rotor at -6,000 
RPM X 30 min. 
Maximum SS-34 RPM: 
#3 = 7,000 
-··ztubes 
#10 and #30 = 6,000 
#100 = 2,500 
waste vial 
After final 
concentrating spin 
place cap on top 
and Invert 
remove waste vial 
and spin concentrated 
material Into the cap 
with SS-34 rotor at 
2,500 RPM X 2 min. 
throw away 
this fraction 
transfer cone. 
to MCT. 
~ 
~"-> Q 
concentrate 
Invert and rinse with 
- 200 ul of serum 
dil. buf. 
replace emptied 
and Invert. 
Spin in SS-34 
rotor at 2,500 
RPM X 2 min. 
after the spin 
transfer rinse to MCT 
with original concentrate. 
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3.2.5 Antibody Characterisation 
3.2.5.1 Verification of antibody specificity 
3.2.5.1.1 Immunoblotting 
3.2.5.1.1.1 Skin extract preparation 
Protocol 7: Cell extract preparation 
A human skin extract was prepared from a freshly isolated plastic surgery specimen. 
The dermis was separated from the epidermis with 1 M NaCl, as previously described 
(Woodley et al 1984). The epidermis was then snap frozen in liquid nitrogen and 
pulverised. The pulverised epidermis was suspended in a lysis buffer (50mM NaCl, 
0.3% Nonidet P-40, 1 OmM dithiothreitol, 15rnM ethylenediamine tetraacetic acid) 
containing protease inhibitors [1.4mM phenylmethanesulfonyl fluoride, pepstatin (2.5 
µg/ml) , leupeptin (0.5µg/ml) and aprotinin (0.4 µg/ml)]). The supernatant fraction 
was collected by centrifugation. Serial dilutions of this extract were subjected to 
SDS-PAGE and Coomassie blue staining to determine the relative amount and 
integrity of protein in the extract. Extracts with the least protein degradation were 
used for western blot analysis. Wil-2 cell (A TCC CRL 8885) and cultured human 
keratinocyte extracts were similarly made by suspending XI06-7 cells in 1ml of lysis 
buffer followed by sonication with three 20 sec bursts. 
3.2.5.1.1.2 Western Blot analysis 
Western blot analysis was performed on the human skin extract (Martinez-Lavin Met 
al 1979), a cultured keratinocyte and a human Wil-2 cell extract (ATCC CRL 8885), a 
human lymphoblastoid cell line, known to express both the 52 and 60 kD Ro proteins 
(McCauliffe et al 1994) and GST (negative control protein). They were subjected to 
SDS-PAGE and then transferred to PVD paper, in a miniblot apparatus (Miniblotter 
28, Immunetics, Cambridge, MA) as described in Protocol 3. The blot was then 
developed with bromochloroindoyl phosphate and nitro blue tetrazolium (Sigma) as 
described (Harlowe & Lane, 1988). 
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3.2.5.1.2 ELISA 
Protocol 8: ELISA for confirming purified antibody specificity 
Recombinant proteins and native bovine Ro antigen were coated on 96-well microtiter 
plates at 2-5 µg/ml concentration as previously described (Winston et al 1990), see 
protocol in Appendix. Antibodies were incubated. Antibody binding was detected 
using goat antihuman IgG antibodies conjugated with alkaline phosphatase (sigma 
Chemical Co, St. Louis, MO, USA). P-nitrophenyl phosphate (Sigma) substrate was 
added and colour development measured at 405 nm by a microplate reader (Vmax, 
Molecular Devices, Corp. , Menlo Park, CA, USA). Antibodies were judged reactive if 
their optical density values were at least 2 standard deviations above the mean value 
of 15 ID defined Ro negative autoimmune sera. The autoimmune control sera were 
obtained from patients with SLE [9 (4 anti-Sm, I anti-Ul RNP, 4 anti-Sm and anti-Ul 
RNP)] , rheumatoid arthritis (3), dermatomyositis (2) and mixed connective tissue 
disease (I anti-Ul RNP). 
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3.3 RESULTS 
3.3.1 Multiple types of anti-52 and anti-60 kD Ro antibodies were 
purified 
Rabbit antibodies were purified against full length recombinant 52 and 60 kD Ro 
proteins. Human autoantibodies were affinity purified against two different 
recombinant 52 kD Ro fragments [52-lb (amino acids 1-98) and 52-2 (amino acids 
138-340)], see figure 16, pg. 94 and two different recombinant 60 kD Ro fragments 
[60-2 (amino acids 139-326) and 60-4 (amino acids 410-538)], see figure 17, pg. 95. 
Each of the four fragments had previously been shown to contain at least one major 
Ro epitope [52-2, 60-2, 60-4: (McCauliffe et al 1994); 52-lb (Yell et al 1996b)]. 
Human antibodies were also purified against the native 60-kD Ro protein, which 
contains one or more epitopes not expressed by the recombinant Ro proteins 
(McCauliffe et al 1994). 
3.3.2 Cultured keratinocytes and human epidermis express the 52-
and 60-kD Ro proteins 
The specificities of the purified antibodies were demonstrated by immunoblot, see 
figure 18, pg. 96 and ELISA, see figure 19, pg. 97, figure 20, pg. 98. 
None of the purified Ro autoantibodies reacted with both 52- and 60-kD Ro proteins. 
There was no convincing evidence of cross-reactivity between the anti-52 and anti-60 
kD Ro antibodies by immunoblot. Furthermore, the ELISA results of the entire panel 
of Ro antibodies failed to validate the existence of the previously described cross-
reactive epitope shared by the 52 and 60 kD Ro proteins (Itoh et al 1992). 
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figure 16: Schematic view of the 52 kD Ro protein, showing the areas against 
which various antibodies were purified. Human autoantibodies were affinity 
purified against two different recombinant 52 kD Ro fragments (52-lb (amino 
acids 1-98) and 52-2 (amino acids 138-340)). 
Purified anti-52 kD Ro autoantibodies 
Zinc fingers L~ucine Butyrophi_lin-like 
zipper domain 
NHzi@@@s2-1~ I 52-2-~00H 
1) anti-52-1 b 
2) anti-52-2 
3) anti-52 (whole) 
human 
human 
rabbit 
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figure 17: Schematic view of the 60 kD Ro protein, showing the areas against 
which various antibodies were purified. Human autoantibodies were affinity 
purified against two different recombinant 60 kD Ro fragments [60-2 (amino 
acids 139-326) and 60-4 (amino acids 410-538)]. Human antibodies were also 
purified against the native 60-kD Ro protein, which contains one or more 
epitopes not expressed by the recombinant Ro proteins (McCauliffe et al 1994). 
Purified anti-60 kD Ro autoantibodies 
hYRNA 
Zinc finger 
1) anti-60-2 
2) anti-60-4 
3) anti-n60 (conformational) 
4) anti-60 (whole) 
human 
human 
human 
rabbit 
OOH 
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figure 18: Western immunoblot detects the 52 and 60 kD Ro proteins in human 
skin extract (SE), cultured normal human keratinocyte extract (KE) and Wil-2 
cell extract (WE). Autoimmune sera (AS) was used as a negative control. Each 
extract was subjected to SDS-PAGE, transferred to PVDF paper and then incubated 
with a 1 :25 dilution of Ro-negative autoimmune control sera (AS), purified human 
anti-60-2 antibodies (60) and human anti-52-2 antibodies purified from two different 
autoimmune sera (52 and 52'). 
SE KE WE 
52' AS 60 52 52' 
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figure 19: Purified Ro antibodies were specific for either the 52- or the 60-kD Ro 
protein as demonstrated by ELISA. (a) Purified human anti-52-lb, anti-52-2, 
rabbit antisera raised against whole recombinant 52 kD Ro (rah anti-52) and a 1: 100 
dilution of normal sera (normal) were reacted with a panel of antigens. Purified 
antigens: n60, native 60 kD Ro;whole 60, full length recombinant 60 kD Ro;60-2, 
recombinant 60-2 fragment (aa139-326);60-4, recombinant 60-4 fragment (aa 410-
538); whole 52, full length recombinant 52 kD Ro; 52-1, recombinant 52-1 fragment 
(aa 1-178); 52-2, recombinant 52-2 fragment (aa 138-340); La, native La/SS-B 
autoantigen; and GST, recombinant glutathione S-transferase, which was a component 
of each recombinant fusion protein in this antigen panel. 
Purified Anti-52 kD Ro Antibodies 
(Specificity by ELISA) 
- antl-52·1b ~ anU-52·2 - rab anU·52 - Normal 
n80 whole 80 60-2 80-4 whole 52 52· 1 b 52·2 La GST 
AnllgalS 
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figure 20: Purified Ro antibodies were specific for either the 52- or the 60-kD Ro 
protein as demonstrated by ELISA. (b) Purified human anti-60-2, anti-60-4, anti-
native 60 kD Ro (anti-n60) and rabbit antisera raised against the full-length 
recombinant 60 kD Ro (rah anti-60), were similarly tested. Purified antigens: n60, 
native 60 kD Ro;whole 60, full length recombinant 60 kD Ro;60-2, recombinant 60-2 
fragment (aa139-326);60-4, recombinant 60-4 fragment (aa 410-538); whole 52, full 
length recombinant 52 kD Ro; 52-1 , recombinant 52-1 fragment (aa 1-178); 52-2, 
recombinant 52-2 fragment (aa 138-340); La, native La/SS-B autoantigen; and GST, 
recombinant glutathione S-transferase, which was a component of each recombinant 
fusion protein in this antigen panel. 
Purified Anti-60 kD Ro Antibodies 
(Specificity by ELISA) 
- anll-6().2 - anll-60-4 - anll-n60 - rab d-60 
n60 whole 80 8().2 80-4 whole 52 52· 1 b 52·2 La GST 
Antigens 
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3.4 DISCUSSION 
3.4.1 Multiple types of anti-52 and anti-60 kD Ro antibodies were 
purified 
A 52-kD Ro protein was first found in addition to the 60-kD protein, in the sera of 
80% of patients with detectable Ro precipitins (Ben-Chetrit et al 1988). In addition, 
this study showed that these antigens contained different and unique epitopes which 
did not generate cross-reactive antibodies. However, this group suggested that the 52 
and 60-kD antigens in their native state, may exist as a complex or as associated 
particles. Ro autoantibodies have been shown to react with at least four distinct 
proteins, of 3 different molecular weights, 52-, 54- and 60kD (Rader et al 1989). The 
60 and 52kD antigens have been cloned (Chan et al 1991b; Chan et al 1991a) and are 
structurally dissimilar (Itoh et al 1991 ). 
Considerable evidence has implicated passive immunisation with anti-Ro antibodies 
in the pathogenesis of NLE. However, the low frequency of the disease in infants 
born to mothers seropositive for anti-Ro, suggests that significant qualitative 
differences exist among humoral anti-Ro responses. Further definition of these 
qualitative differences has been possible with epitope mapping. This has been applied 
to a number of autoimmune responses. Theoretically, a dominant autoepitope may 
represent an important stimulus for initiation or maintenance of an autoantibody 
response. 
Methods of identifying B cell epitopes with short synthetic peptides have been 
criticised (Horsfall et al 1991 ). Based on molecular modeling of antibody-antigen 
interactions, greater than 90% of epitopes are thought to be conformational and 
dependent on discontinuous sequences and therefore unlikely to be identified with 
short synthetic peptides (Blundell et al 1987; Laver et al 1990). Recombinant fusion 
proteins have been used to identify conformational epitopes that are missed with 
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synthetic peptides. ELISA studies with recombinant 52 and 60kD Ro protein 
fragments revealed at least 2 major epitopes on each Ro protein (Tsay et al 1996). 
The first study to describe at least two antigenic determinants on the 52kD Ro protein, 
showed one immunodominant and the other recognised by a more "restricted" subset 
of anti-52kD Ro antibodies. 95% of 99 sera containing anti-52kD antibodies by 
ELISA, reacted with a large fragment spanning amino acids (aa) 1-291 (Buyon et al 
1994). Two antigenic regions were identified: aa 169-291 containing the leucine 
zipper, that was recognised by 83% of the anti-52kD sera tested and aa 1-78 
containing the zinc finger domains, that was recognised by half the sera. 
Confirmation of the fact that anti-52 kD Ro autoantibodies in different autoimmune 
diseases preferentially recognize epitopes on the central region of the antigen, has 
appeared more recently. The strongest antigenicities recognized by anti-52 kD Ro 
autoantibodies were located within the aa 197-245 region. Further antigenic sites 
preferentially recognized by SS, CHB, and healthy infant sera were located within aa 
153-196. The central region aa 153-245, was a major immunogenic region, 
containing a strong antigenic epitope between aa 197-245. The antibody response was 
directed at this major antigenic region regardless of the underlying autoimmune 
disease (Dorner et al 1996b ). 
The immune response to the 60kD Ro antigen is heterogeneous. Some autoimmune 
sera specifically recognise the native Ro antigen but fail to bind the corresponding 
denatured polypeptides. A number of groups have described about 15% of anti-Ro 
positive sera which do not recognise either the 52 nor 60-kD polypeptides m 
immunoblots (Elkon & Culhane, 1984; Ben-Chetrit et al 1988; Boire et al 1991 ). In 
one study (Boire et al 1991 ), after immunodepletion using the denatured 60-kD Ro 
polypeptide, all anti-Ro positive sera still contained high titers of antibodies 
recognising conformational determinants on the Ro antigen. The frequent 
immunodominance of anti-Ro antibodies targeted to conformational determinants 
suggests that native autoantigens may directly drive the autoimmune response (Boire 
et al 1991 ). Heterogeneity in recognition of autoepitopes of the 60-kD Ro protein has 
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been detected using both synthetic peptides by ELISA and denatured fusion proteins 
by immunoblot. Discontinuous epitopes exist (Saitta et al 1994). 
Several investigators have tried to identify 60kD Ro epitopes based on the reactivity 
of autoimmune sera with synthetic peptides. Scofield et al identified a major epitope 
on the 60kD Ro protein that has been localised to the sequence EYRKKMDI 
contained within my 60-4 fragment (Scofield et al 1991). They showed 28/45 (67%) 
ID defined Ro positive SS sera reacted by Western blot with a 3kD fragment of the 
60k.D Ro that contains the EYRKKMDI sequence. McCauliffe et al have found that 
42% of ID defined Ro positive SS sera react by ELISA to a recombinant 60 fragment 
containing this sequence (60-4) (McCauliffe et al 1994). They found the 60-2 
fragment more reactive, with 9/12 (75%) of ID defined Ro positive sera reactive. 
NLE, SCLE and SS patient sera all reacted with these two 60kD Ro epitopes. 
A different group has shown that a synthetic peptide corresponding to amino acid 
residues 21-41 of the 60k.D Ro protein had significant reactivity to SS but not LE 
patient sera (Barakat et al 1992). My recombinant 60k.D Ro protein starts with 
residue 24. The 60-1 fragment that contains all but three of the amino acids used to 
make the 21-41 synthetic peptide, has little reactivity with SS patient sera (McCauliffe 
et al 1994). Another group (Scofield & Harley, 1991), synthesised 531 overlapping 
octapeptides for the entire 60kD Ro sequence. 
A further group used 22-mer, synthetic peptides overlapping by eight residues, 
covering the entire sequence of the Ro60 kD autoantigen, to evaluate three groups of 
sera according to their autoantibody specificites. The first group consisted of 
monospecific anti Ro60 kD sera from four patients with SLE and one with SS, the 
second one was composed of anti-Ro60 kD+anti-La(SSB)-positive sera from four 
patients with SS and the third group included three normal sera and one anti Ro52 kD 
serum. It was found that sera from SLE patients interact with a common antigenic site 
spanning the sequence TKYKQRNGWSHKDLLRSHLKP (169-190) of the Ro60 kD 
protein. On the other hand, sera from SS patients recognise the 
ELYKEKALSVETEKLLKYLEAV (211-232) region. Determination of the minimal 
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required peptide length for optimal antibody recognition showed that the defined 
epitopes can be shortened to the NGWSHKDLLR(l 75-184) and 
KALSVETEKLLKYLEAV (216-232) sequences respectively. Inhibition experiments 
using the Ro60 kD antigen and soluble peptides corresponding to the 175-184 and 
216-232 segments further confirmed the specific antibody binding (Routsias et al 
1996). 
I have purified multiple types of anti-52 and anti-60-kD Ro antibodies. Rabbit 
antibodies were purified against full length recombinant 52-and 60-kD Ro proteins. 
Human autoantibodies were affinity purified against two different recombinant 52-kD 
Ro fragments [52-lb (amino acids 1-98) and 52-2 (amino acids 138-340)] and two 
different recombinant 60-kD Ro fragments [60-2 (aa 139 -326) and 60-4 (aa 410-
538)]. Each of the four fragments had previously been shown to contain at least one 
major Ro epitope(McCauliffe et al 1994). Human antibodies were also purified 
against the native 60-kD Ro protein, which contains one or more epitopes not 
expressed by the recombinant Ro proteins (McCauliffe et al 1994). I have previously 
used the stripping method to reuse ELISA plates for antibody testing, without 
significant loss of coated protein. This stripping technique has been previously 
published and demonstrated that the stripping procedure does not significantly 
diminish antigenic capacity ( of denaturation resistant epitopes) (Baunoch et al 1992). 
3.4.2 Cultured keratinocytes and human epidermis express the 52-
and 60-kD Ro proteins 
The specificities of the purified antibodies were demonstrated by immunoblot and 
ELISA. These antibodies identified appropriately sized proteins in keratinocyte 
extracts prepared from surgical and cultured specimens, indicating that both Ro 
proteins are expressed in normal human adult skin and in cultured human 
keratinocytes respectively, see figure 18. Multiple protein fragments were labeled 
with the anti-52-kD Ro antibodies. Whether these fragments represent protein 
degradation, different forms of the 52-kD Ro protein, or cross-reactive proteins is 
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uncertain. The smear -like nature of the fragments with a greater proportion of 
smaller fragments in the skin extract preparation, which takes longer to prepare than 
the cultured keratinocyte and Wil-2 cell extracts, would suggest that these fragments 
arise from protein degradation. 
3.4.3 No evidence that Ro autoantibodies cross-react with the 52-
and 60-kD Ro proteins 
Itoh et al previously reported that a major denaturation-resistant epitope on the 52 kD 
Ro protein is cross-reactive with the Ro autoantibodies directed against an epitope 
expressed on the native 60 kD Ro protein (Itoh et al 1992). There was no convincing 
evidence of cross-reactivity between the anti-52 and anti-60 kD Ro antibodies by 
immunoblot, see figure 18. Furthermore, the ELISA results of the entire panel of 
purified Ro antibodies failed to validate the existence of the previously described 
cross-reactive epitope shared by the 52- and 60-kD Ro proteins (Itoh et al 1992), see 
figure 19. 52-2 contains the previously described denaturation resistant epitope. 
Whether the discrepancy between my data and that of Itoh et al resulted from 
differences in patient sera reactivities, source of Ro antigen, or methodology is 
uncertain. Other studies have also failed to reveal cross-reactivity of anti-52 and anti-
60 kD Ro autoantibodies (Keech et al 1994; St.Clair et al 1994; Ben-Chetrit et al 
1988; Peek et al 1993 ). 
103 
4. LOCATION OF Ro ANTIGENS IN CELLS 
4.1 Introduction 
Anti-52 and anti-60 kD Ro autoantibodies are produced by the vast majority of 
patients with SCLE and NLE (McCauliffe et al 1994). Although there is substantial 
evidence that these autoantibodies are pathogenic in these two diseases (McCauliffe, 
1997a; Lee et al 1989), the cellular function and location of their target antigens have 
remained controversial. 
Multiple studies have characterised the cellular location of Ro antigens by 
immunofluorescence techniques but with discrepant results. These discrepancies have 
arisen in part from differences in fixation techniques (Harmon et al 1984; Peek et al 
1993), the use of non-human substrates (Harmon et al 1984) and the utilisation of 
human Ro autoimmune sera of varying specificities (Hendrick et al 1981; Maddison 
et al 1981; Harmon et al 1984; Lopez-Robles et al 1986; Miyagawa et al 1988). 
Studies using anti-Ro antibodies in IF reported both nuclear and cytoplasmic staining 
(Ben-Chetrit et al 1988; Slobbe et al 1991; Lopez-Robles et al 1986; Mayet et al 
1988), while others showed only nuclear staining (Lopez-Robles et al 1986; Harmon 
et al 1984 ), or a predominantly cytoplasmic location (Alspaugh & Maddison, 1979; 
Bachmann et al 1986; Hendrick et al 1981 ). It is interesting that purification of the 
Ro antibody system by a quantitative precipitin technique, followed by IF, has shown 
conclusively that anti-Ro antibodies showed only cytoplasmic staining when calf 
thymus, KB cells, human normal lymphocytes and cells from chronic lymphocytic 
leukaemia patients, were used as substrates. However, many whole sera when 
employed in similar experiments using KB and Wil-2 cells, produced a speckled 
nuclear fluorescence as well as cytoplasmic staining. This was especially obvious 
when La antibodies were additionally present. When, however, mouse liver, the most 
commonly used substrate at the time, was employed, with purified anti-Ro antibodies, 
neither nuclear nor cytoplasmic staining was found (Sontheimer et al 1982). 
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In 1986, a group used eight sera directed against the Ro antigen in an indirect 
immunofluorescence technique, on several mammalian tissues. They checked the sera 
for mono specificity by Ouchterlony and immunoblotting techniques, using partially 
purified Ro antigen from human spleen. They found a mainly speckled nuclear 
pattern in the nucleus of dog liver and HEp-2 cells. Cytoplasmic fluorescence 
appeared in one serum (Lopez-Robles et al 1986). 
A further group has fractionated human Jurkat and mouse 3T3 cells into a cytoplasmic 
and nuclear fraction and analysed these fragments separately. They found that the Ro 
and La protein were both present in the cytoplasm and nucleus, while the Y RNAs are 
exclusively cytoplasmic. In addition, they showed that the majority of the human Y 
stably associated with Ro60 and Ro52, as well as with the La protein. In the nucleus, 
Ro60 and Ro52 were not associated with Y RNA (Peek et al 1993) 
Antiserum specific for CR has revealed predominantly perinuclear cytoplasmic 
staining with lesser amounts of nuclear staining (McCauliffe & Sontheimer, 1993b). 
Most hY5RNA has been reported in the cytoplasmic fraction of HeLa cells (Kato et al 
1982). A different study subsequently found that more than 90% of the Ro particles 
were recovered from the cytoplasmic fraction of HeLa cells (Bachmann et al 1986). 
The Ro antigen was originally described as a saline-soluble, cytoplasmic antigen 
(Clark et al 1969). 
A further study using six monoclonal anti-Ro antibodies, showed either a cytoplasmic 
binding or a nuclear binding to HEp-2 cellular antigens (Rosario et al 1988). They 
found that the first mouse serum and 3 of the 6 monoclonal antibodies bound 
cytoplasmic antigens. One monoclonal antibody bound a nuclear antigen in HEp-2 
cells in a homogenous pattern. This binding represented that of the monoclonal 
antibodies, rather than other immunoglobulins, as it was reproduced when 
supernatants, ascites fluid, purified IgG, or hybridoma-bearing SCID mouse sera were 
tested. 
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Recent studies, with standard fixation methods, human substrate and more specific Ro 
antibodies, however, have also produced discrepant results (Bachmann et al 1986; 
Ben-Chetrit et al 1988; Slobbe et al 1991; Peek et al 1993; Casciola-Rosen et al 1994; 
Kelekar et al 1994; Peek et al 1994). Kelekar et al used immunofluorescence analysis 
of two different cell lines with monospecific antibodies against 52 and 60kD proteins 
to suggest that these two proteins are not present on overlapping sets of structures in 
vivo (Kelekar et al 1994 ). 
In a study usmg monospecific antibodies on s1m1an virus 40-transformed 
keratinocytes, Ro antigen was detected in both the nucleus and cytoplasm. Primary 
cultured adult keratinocytes showed localised immunofluorescence within the nucleus. 
When the calcium concentration of the medium was switched to 0.05 mM, these cells 
expressed cytoplasmic Ro antigens within 48 hours. Surface expression of this 
antigen could not be detected in either primary or transformed cells (Miyagawa et al 
1988). 
The interpretations of these data are even less certain because it has been reported that 
some Ro autoantibodies cross-react with the 52 and 60kD Ro proteins (ltoh et al 
1992). Slobbe et al used indirect IF to look at the intracellular location of 52 and 
Ro60, using a monospecific anti-Ro52 serum and a monospecific rabbit anti-Ro60 
serum on human HEp-2 cells. The monospecific human anti-Ro52 serum was 
determined by negativity to Ro60 and La on immunoblotting. However a cross 
reactive epitope has been found with the conformational 60 and 52 on immunoblot. 
This may well have accounted for their findings of identical localisation of both the 52 
and 60kD Ro in a diffuse cytoplasmic staining next to a strong punctuated nuclear 
staining, with nucleoli (Slobbe et al 1991 ). 
My aims were to determine the localisation of 52 and 60 kD Ro antigens in human 
keratinocytes. I also hoped to clarify the discrepancies reported in previous 
localisation studies by using a panel of anti-52 and anti-60 kD Ro specific antibodies 
and to reassess whether previous inconsistencies may have resulted from cross-
reacting antibodies. 
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4.2 METHODS 
4.2.1 Keratinocyte culture 
Keratinocyte culture has been comprehensively reviewed (Karasek, 1983; Fuchs et al 
1988). Before 1983, most keratinocyte culture media needed serum supplementation 
(Briggaman et al 1967). Improved keratinocyte growth was shown on lethally 
irradiated mouse 3T3 feeder layers in media supplemented with epidermal growth 
factor, cholera toxin and hydrocortisone (Rheinwald & Green, 1975). Ham's group 
pioneered the use of serum free media for many cell types, including MCDB-153 for 
keratinocytes (Boyce & Ham, 1983). This medium was then enriched with increased 
concentrations of a number of essential amino acids. 
A number of preliminary experiments were performed (not described here) to assess 
the best way of establishing primary human keratinocyte culture, see Protocol 14, pg. 
110. It was decided to use serum free media ab initio to decrease confounding factors. 
Protocol 9: Definitive keratinocyte culture 
Neonatal foreskins were stored in Dulbecco's modified Eagle's medium-high glucose 
(DMEM-high glucose), with 1 mM sodium pyruvate, 2% fetal calf serum (FCS), 5 
ug/ml of ketoconazole, 100 ug/ml of chloramphenicol, 100 U/ml of penicillin, 100 
ug/ml of streptomycin, 250 ng/ml amphotericin B and 20 mM HEPES (pH 7.3), for 
between one to 24 hours at 4°C. They were washed 2 - 3 times with HBSS. The 
foreskin was flattened , epidermis up and cut into pieces 3 mm2. They were then 
trypsinised overnight, in 0.25% trypsin (make fresh: weigh the trypsin, dissolve in the 
buffer, then filter) at 4°C. The next morning, the epidermal layers were coming off 
the dermal chunks. The epidermal layers were peeled off and shaken vigorously into 
Medium 154 (Cascade Biologics Inc., Portland, OR). This shaking dislodged the 
viable basal keratinocytes. The basal keratinocytes from the epidermis were 
resuspended in Medium 154 (Cascade Biologics Inc., Portland, OR) supplemented 
with human keratinocyte growth supplement. These primary cultures were incubated 
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Medium 154 (Cascade Biologics Inc., Portland, OR). This shaking dislodged the 
viable basal keratinocytes. The basal keratinocytes from the epidermis were 
resuspended in Medium 154 (Cascade Biologics Inc., Portland, OR) supplemented 
with human keratinocyte growth supplement. These primary cultures were incubated 
at 37°C 5% CO2. The medium was changed as needed. After about 5 days, the 
keratinocytes were about 50% confluent, at which stage they were subcultured. 
The following protocol was followed for subculturing: 
Protocol 10: Subculturing of keratinocytes 
The media was aspirated and the parent dish rinsed twice with HBSS emf. 5 ml of 
0.1 % trypsin solution containing 0.02% EDT A was added. The dish was put into the 
incubator and checked about 4 mins later. The cell solution was aspirated. The dish 
was rapped vigorously against the palm to remove the cells. (Total < 10 min.). 5 ml 
trypsin neutralising solution was added. This was transferred to a 15 ml tube and 
centrifuged at 1000 rpm for 3-5 min .. The supernatant was removed. The pellet was 
loosened and resuspended in 4 ml Med 154. An aliquot was added to the daughter 
flask containing Med 154. The next day, each flask was rinsed twice with HBSS emf 
and fed with Med 154. This important rinse removed dead cells and debris. 
When the cells were 60-80% confluent, they were frozen. The following freezing 
protocol was used: 
Protocol 11: Freezing keratinocytes 
Freezing medium was made up ( MED 154 with DMSO to 10%, sterile filter, store at 
4°C). The NUNC cryotubes were labeled with cell type, passage number, number of 
cells per tube and date. The keratinocytes were trypsinised as for routine subculturing 
and resuspended in HBSS emf 0.1 % FCS. The cell suspension was spun for 5 
minutes at 1000 rpm in GLC-3(200 X g). The supernatant was removed, the pellet 
was loosened and resuspended in the cold freezing medium. The cryotubes were 
placed on ice for 20 minutes to thoroughly cool them, then transferred to the -20°C 
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freezer for 2 hours, followed by the -70°C freezer overnight, then into the liquid 
nitrogen. 
These keratinocytes were thawed and seeded onto 8-chamber Lab Tek slides (Nunc 
Inc., Naperville, IL). The following thawing protocol was used: 
Protocol 12: Thawing keratinocytes frozen in Liquid Nitrogen 
The cryotube was removed from the liquid nitrogen and thawed in a 37°C water bath 
as rapidly as possible. In the hood, the cryotube was drenched with 70% ethanol to 
sterilise it. It was wiped dry with a sterile wipe. Thawed keratinocytes were diluted 
with appropriate volumes of Med 154 and the chambers were seeded. 
In an effort to increase the yield of basal keratinocytes from adult cells, Dispase, rather 
than Trypsin was used according to the following protocol: 
Protocol 13: Dispase for epidermal separation 
The skin was placed into foreskin medium and washed three times HBSS without Ca 
or Mg. With the epidermis up, it was cut into 3 mm2 pieces. It was then incubated in 
Dispase 2.4u/ml at 37°C for 3 - 5 hours. When ready, the epidermis slid off the 
dermis. The epidermis was transferred to a 15 ml centrifuge tube, containing 2 ml 
Gibco trypsin. The dermis was scraped with a scalpel to remove basal keratinocytes 
and these were added to the tube. This was incubated at 37°C in a water bath for 20 -
30 min. , shaking the tube from time to time. 10 ml Trypsin Neutraliser was then 
added and pipetted up and down to help dissociation. This was centrifuged for 8 min. 
at 1800 and resuspended in plating medium. Basal keratinocytes were seeded at 2 - 3 
X 106 cells/75 cm2 flask with 10 - 15 ml medium. They were washed at 24 - 48 hours. 
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Protocol 14: Comparing various described keratinocyte culture methods 
DAY WITH 3T3 CELLS IN SERUM FREE MEDIA 
1 Incubate foreskins for 24 hrs in foreskin Incubate foreskins for 24 hrs in foreskin 
media media 
2 a)1n petri dish, wash foreskin X 3 with a)1n petri dish, wash foreskin X 3 with 
HBSS HBSS 
b )Epidermis up, cut into 2X2mm squares b )Epidermis up, cut into 2X2mm squares 
c)Fill dish with 15 ml 0.25% trypsin in c)Fill dish with 15 ml 0.25% trypsin m 
trypsin/EDT A buffer (without EDT A) trypsin/EDT A buffer (without EDTA) 
d) incubate overnight at 4C d) incubate overnight at 4C 
3 treat 3T3 cells with Mitomycin a)remove and pool epidermal sheets 
b )vortex epidermal sheets in HBSS 
a)T/F epidermal sheets to clean dish with c)centrifuge cell suspension for 5min at 
10ml plating media 250 g 
b) shake vigorously d)resuspend in Medium 154 supplemented 
c)pipette and expel cells X5-10 with KGM and antibiotics 
d)aliquot suspension into new tissue e)seed each 25 cm2 flask with 105 cells 
culture dishes 
e)Add 2Xl06 mitomycin treated 3T3 
cells/dish 
f) add plating medium up to 15ml 
g)incubate at 37C for 3-4 days 
4 After 24 hours, wash cells with warm 
HBSS to remove dead cells before adding 
further warmed Medium 154. 
5 
6 change medium every 3-4 days to growth change medium every 2-3 days until cells 
medium are confluent, typically, 7-10 days. 
7 after one week, or when keratinocytes 
cover 50% of dish, remove 3T3 cells 
10 subculture keratinocytes before they once confluence reached, 
become confluent a)remove medium 
a)aspirate medium and rinse X2 with b)add 0.05% trypsin/0.01% EDTA for 1 
HBSS min to remove fibroblasts 
b)add 5ml 0.1% trypsin/0.02% EDTA c)discard supernatant 
c)put dish in incubator and check 4 mins d)add more trypsin to detach keratinocytes 
later (+-4-5 minutes) 
d) aspirate cell suspension e) stop trypsinisation with HBSS with 10% 
e) add 5ml trypsin neutralising soln plus 1- FCS 
2ml FCS (mixed beforehand) f)centrifuge resulting suspension for 5min 
f)T/F to a 15ml tube and spin at I OOOrpmX at 250g 
3-5min g)resuspend pellet in warmed medium 154 
g)remove supernatant h) 1 XT25 flask to 1 T75 flask 
h)resuspend pellet in 4ml KGM 1 XT75 flask to 2xTl 50 flasks 
i)add aliquot to daughter flask 
11 next day, rinse each flask with HBSS and 
feed with KGM 
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4.2.2 Immunofluorescence 
A number of preliminary experiments (not shown here) were performed to determine: 
the best fixative (3% paraformaldehyde, versus 4% paraformaldehyde, versus neat 
Acetone, versus Ethanol, versus 2% glutaraldehyde) the best permeabilising agent: 
(0.1 % Triton X in PBS, versus neat Acetone for 30 seconds, versus 0.1 % Saponin, 
versus Tween 20, diluting buffer) and the best dilutions of both primary and secondary 
antibodies. All the primary antibodies used were checked at concentrated through to 
dilute dilutions. The secondary antibodies were diluted according to manufacturer's 
recommendations with one dilution either side in addition. 
Protocol 15: Immunofluorescence of fixed keratinocytes 
The keratinocytes were fixed in 3% paraformaldehyde at 4°C for 15 minutes, followed 
by 2 brief washes with IX phosphate buffered saline (PBS). They were permeabilised 
for 5 minutes with 0.1 % Triton X in PBS, washed twice with IX PBS and then 
incubated for one hour at 4°C with the primary purified Ro antibodies. Following 
another 2 PBS washes, secondary goat anti-human IgG conjugated to Texas Red 
(Jackson lmmunoresearch Laboratories, West Grove, PA) and / or (depending on 
whether the cells were labeled singly or doubly) goat anti-rabbit lgG conjugated to 
fluorescein isothiocyanate (Sigma, St. Louis, MO), was added for 30 minutes at 4°C. 
The slides were washed twice, the chambers were removed and the slides were 
coverslipped with polyvinyl alcohol mounting media (PV A). 
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To ensure that the negative nuclear staining observed with the anti-52kD antibodies 
was not due to inability of the secondary antibody to detect the primary antibody, as it 
was bound to DNA, the experiments were repeated with pre-treatment with both 
DNAse and RNAse. The following modified IF protocol was used: 
Protocol 16: 
keratinocytes 
Immunofluorescence on pre-treated DNAse and RNAse 
The cells were washed twice with cold dulbecco PBS (X 5 min. max.) and then fixed 
in paraformaldehyde (3% in PBS) for 15 min. at room temperature. Following a 
further two washes with cold dulbecco PBS (X 5 min. max.), the keratinocytes were 
permeabilised with Triton X-100 (0.2% in PBS) for 15 mins. The cell chambers were 
then incubated with DNAse I (Pharmacia) at a concentration of 10 OOOu/ml stock, 
diluted 1 :20 for 45 min. or incubated with DTT 200 µ/ in 20 ml SDB overnight. 
Negative controls were incubated with RNAse/DNAse dilution buffer only. 
Thereafter, the keratinocytes were treated as for previous immunofluorescence 
protocols. 
4.2.2.1 Microscopy 
4.2.2.1.1 Epifluorescence microscopy 
The slides were viewed with a conventional epifluorescence microscope, followed by 
confocal microscopy. 
4.2.2.1.2 Confocal Microscopy 
Two confocal microscopy systems were used. Images were collected with a Bio-Rad 
MRC-600 laser scanning confocal microscope (Bio-Rad Ltd., Hemel Hempstead, 
Herts, UK) mounted onto a Nikon Diaphot inverted microscope, with a 1 OOX 
objective and a pinhole setting of 3 to maximise optical sectioning, at 0.8 - 0.9µm 
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krypton laser to the sample. Excitation light was attenuated with a 1 % neutral density 
filter to minimise photobleaching. 
The other confocal system used, was a Zeiss invert LSM 410, with software version 
3.50 (Gottingen, Germany) with a pinhole of 20 and a similar neutral density filter. 
The contrast and brightness adjustments were maintained at constant levels for all 
experiments and controls. Each digital image was obtained with a laser exposure time 
of 8 seconds, averaged over four, to reduce noise. Confocal images were processed 
using Adobe Photoshop 3.0 software and printed on an Epson colour printer (Epson 
America, Inc., Torrance, CA.) 
4.3 RESULTS 
The specific antibodies, described in the previous chapter, were used to determine the 
cellular locations of the 52 and 60 kD Ro proteins, by conventional epifluorescence 
and scanning confocal microscopy, including Z-series. 
4.3.1 Anti 52 kD Ro autoantibodies 
The human anti-52-1 b and 52-2 autoantibodies stained the cytoplasm in a fine 
granular pattern, see figure 21, pg. 115. There was similar nuclear staining that was 
most apparent in cells that had not yet reached confluence. Cells that had reached 
confluence often demonstrated minimal nuclear staining, see figure 22, pg. 116. To 
ensure that the poor nuclear staining observed with the anti-52kD antibodies was not 
due to inability of the secondary antibody to detect the primary antibody, as it was 
bound to DNA, the experiments were repeated with pre-treatment with both DNAse 
and RNAse. These results were the same as those obtained with the standard IF 
method. 
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4.3.2 Anti 60 kD Ro autoantibodies 
Both the human anti-60-2 and 60-4 autoantibodies strongly stained the nucleus in a 
coarse granular pattern, with no staining of nucleoli. In addition there was some fine 
cytoplasmic staining, see figure 23 pg.117, figure 24 pg. 117, figure 25 pg. 118, 
figure 26 pg. 118. 
Differences in 52 and 60 kD Ro localisation were confirmed by double 
immunofluorescence with both human and rabbit purified anti-52 and anti-60 kD Ro 
antibodies, see figure 27 pg. 119, figure 28 pg. 120. 
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figure 21: The 52 kD Ro antigens are immunolocalised to the cytoplasm in 
normal cultured keratinocytes. Normal neonatal cultured keratinocytes were fixed 
and stained as described Purified human antibodies to the recombinant 52-2 kD 
fragment (a) and the 52-1-2 kD fragment (b), both stained the cytoplasm, as viewed by 
confocal microscopy. 
52-2 kD fragment (a) 
52-1-2 kD fragment (b) 115 
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figure 22: Confocal laser microphotographs reveal both nuclear and cytoplasmic 
localisation of 52 kD Ro, depending on cell confluence. The anti-52 kD antibodies, 
showed more cytoplasmic staining (fine granular) than the 60 kD antibodies. 
Occasionally, nuclear staining, although much weaker than that obtained with the 60 
kD antibody, was present. This was most apparent in cells that had not yet reached 
confluence. Cells that had reached confluence often demonstrated minimal nuclear 
staining. Immunofluorescence of cultured human keratinocytes with purified human 
anti-52-1 b antibodies (two panels on the left) and anti-52-2 antibodies (two panels on 
the right). The two uppermost panels depict nonconfluent cells and the two 
lowermost panels show cells that have reached confluence. Scale bar, 25 µm. 
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figure 23: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the recombinant 60-2 kD 
fragment stained the nucleus brightly, as viewed by confocal microscopy. Bar, 25 
µm. 
figure 24: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the recombinant 60-4 kD 
fragment stained the nucleus brightly, as viewed by confocal microscopy. Bar, 25 µm. 
117 
Chapter 4 
Location of Ro antigens in cells 
figure 25: The 60 kD Ro antigens are immunolocalised to the nucleus in normal 
cultured keratinocytes. Purified human antibodies to the native 60 ( c ), stained the 
nucleus brightly, as viewed by confocal microscopy. Bar, 25 µm. 
figure 26: Confocal laser microphotographs reveal predominantly nuclear 
localisation of 60 kD Ro. Immunofluorescence of cultured human keratinocytes with 
purified human anti-60-2, anti-60-4, anti-native bovine 60 kD Ro and a 1:100 dilution 
of normal serum, as depicted. Bar, 25 µm. 
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figure 27: Confocal laser microphotographs of the double-immunofluorescent 
localisations of the 52 and 60 kD Ro confirm disparate locations of the 52 and 60 
kD Ro proteins in confluent keratinocytes. Double immunofluorescence of 
cultured human keratinocytes with human antibodies to the recombinant 52-2 kD 
fragment, (labeled with Texas Red-conjugated goat anti-human antibodies) seen as 
orange fluorescence and purified rabbit anti-60 kD (labeled with fluorescein 
isothiocyanate-conjugated goat anti-rabbit antibodies) seen as green fluorescence. 
Bar, 25 µm. 
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figure 28: Confocal laser microphotographs of the double-immunofluorescent 
localisations of the 52 and 60 kD Ro confirm disparate locations of the 52 and 60 
kD Ro proteins in confluent keratinocytes. Double immunofluorescence of 
cultured human keratinocytes with human anti-60-4 antibodies (labeled with Texas 
Red-conjugated goat anti-human antibodies) seen as orange fluorescence and purified 
rabbit anti-52 kD Ro antibodies (labeled with fluorescein isothiocyanate-conjugated 
goat anti-rabbit antibodies) seen as green fluorescence. Bar, 25 µm. 
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4.4 DISCUSSION 
The position of Ro in cells has been variable in numerous different experiments over 
many years. Recent localisation studies have found predominantly nuclear and minor 
cytoplasmic localisation of both the 52- and 60-k.D Ro antigens in HEp-2 and HeLa 
cells (Peek et al 1994; Ben-Chetrit et al 1988; Slobbe et al 1991; Casciola-Rosen et al 
1994). Another study, however, found predominantly cytoplasmic localisation of 60-
kD Ro and mostly nuclear localisation of 52-kD Ro in HeLa and HEp-2 cells (Kelekar 
et al 1994). Unfortunately, most of these studies relied on a single monospecific 
autoimmune sera and / or antisera with anti-52 or anti-60-k.D Ro activity. The 
specificity of these reagents was often not well defined. Monospecific anti-52-k.D Ro 
sera were defined by immunoblot analysis and may have contained anti-60k.D Ro 
antibodies as this method does not detect all anti-60-kD Ro antibodies (Boire et al 
1991 ). My immunofluorescence data are more convincing than any yet published 
because I used a panel of non-cross-reactive anti-52 and anti-60 kD Ro antibodies, as 
shown in chapter 3, all of which produced consistent yet disparate locations for the 52 
and 60 kD Ro antigens. 
4.4.1 Anti 60 kD Ro autoantibodies 
My predominantly nuclear localisation of the 60 kD Ro antigen is consistent with 
most of the earlier studies and a recent study that used monoclonal anti-60 kD Ro 
antibodies (Veldhoven et al 1995). A German group had earlier developed a 
monoclonal 60 kD Ro antibody. This and a 60k.D Ro purified from a particular SCLE 
patient serum, showed (in contrast to all other Ro antisera) nuclear speckles, diffuse 
cytoplasmic staining and, in addition, staining of the intermediate filament network 
(Mayet et al 1988). In addition, in contrast to their other Ro sera which they could not 
identify in whole epidermis, these antibodies, stained frozen sections of epidermis. 
Only a pale fluorescence was seen on non-sun exposed skin. Sun-exposed skin gave a 
bright staining of basal epidermis. The highest concentration of antigen was detected 
in the basal keratinocytes of a cutaneous lesion from the patient from whom this anti-
121 
Chapter 4 
Location of Ro antigens in cells 
60kD antibody was purified. They assumed that this specific binding observed only 
with their monoclonal and the antibody purified from one particular patient's serum, 
cross-reacted with a cytoskeletal protein or was directly interacting with an antigen 
directly related to the intermediate filament. This study had no positive control. 
In the previous chapter, I showed by immunoblot analysis that normal human 
epidermis expresses both the 52- and 60-kD Ro antigens. I have been unsuccessful, 
however, in localising the 52 and 60-kD Ro antigens in human skin biopsies by 
indirect IF, despite using different techniqu~s on sections obtained from different 
donors (data not shown). I speculate that my inability to localise antigens may be 
related to technical matters but it is possible that my skin biopsies came from 
individuals that produce low amounts of Ro antigen. An up to 2 000-fold difference 
in 60-kD Ro skin expression has been reported among individuals, recently (Niimi et 
al 1995). I have not noticed such a difference in the level of 52- and 60-kD Ro 
antigen expression in cultured keratinocytes harvested from several donors. 
Overexpression of the 60 kD Ro-encoding gene in HEp-2 and LTA-5 cells showed 
bright finely speckled nuclear staining. Those cells with the highest intensity staining 
also showed weak cytoplasmic staining. No surface expression was detected (Keech 
et al 1994). A further study has used a transfected and overexpressed human 60 kD 
Ro autoantigen in HEp-2 cells for IF. Prototype human and rabbit sera directed 
against the 60 kD Ro antigen produced intense speckled nuclear and nucleolar 
staining of transfected cells (Fritzler & Miller, 1995). 
4.4.2 Anti 52 kD Ro autoantibodies 
I have found greater cytoplasmic localisation of the 52 kD Ro than previous work. 
Most of the recent localisation studies used "monospecific" 52 kD Ro autoimmune 
sera (Ben-Chetrit et al 1988; Slobbe et al 1991; Casciola-Rosen et al 1994), or 
partially purified rabbit antisera (Kelekar et al 1994) that may have contained anti-
native 60 kD Ro or other autoantibodies that could produce nuclear fluorescence that 
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overshadowed the cytoplasmic fluorescence generated by the anti-52 kD Ro 
antibodies. The Casciola-Rosen study that found no difference in the location of 
Ro52 and Ro60 in unprovoked cultured keratinocytes, used an anti-52 kD Ro 
monospecific serum defined by immunoblot results, which may have contained anti-
60 kD Ro antibodies, as immunoblot analysis does not detect all anti-60 kD Ro 
antibodies (Boire et al 1991 ). 
Isolation of antibodies specific for each Ro antigenic polypeptide has allowed more 
precise cellular localisation of the Ro polypeptides. These results have helped explain 
the discrepancies encountered previously with immunofluorescence staining used 
whole Ro patient sera. Part of this difficulty has been due to the difficulty in 
obtaining reactive monoclonal Ro52. Anti-nuclear autoantibodies found in human 
autoimmune diseases frequently cross-react with homologous autoantigens in distant 
species, supporting the notion that autoantibodies target conserved functional 
domains. However, the 52-kD Ro protein is an exception, in that human 
autoantibodies are not known to recognize any equivalent antigen in the cells of 
rodents and other non-primate species. To understand this lack of cross-reactivity, 
one group isolated cDNAs encoding the mouse 52-kD Ro molecule. The cDNA 
encoding mouse 52-kD Ro revealed an open reading frame of 470 amino acids, with 
70% sequence identity to the human 52-kD Ro antigen. The putative leucine-zipper 
and zinc-finger motifs present in human Ro52 were conserved in the mouse protein. 
Recombinant mouse 52-kD Ro protein reacted with human autoantibodies by ELISA 
and immunoblot, but with approximately 10-fold lower reactivity than recombinant 
human 52-kD Ro protein under the same conditions. Detection of both human and 
mouse 52-kD Ro by immunoblot was dependent on antigen concentration which was 
limiting in the cell equivalents generally used in immunoblot assays. Differential 
chaotropic disruption of antibody binding suggested a lower avidity of human 
autoantibody binding to the mouse 52-kD Ro protein compared with the human 
antigen. Structural differences between the human and mouse 52-kD Ro autoantigens 
are associated with poorly conserved autoantibody activity across species (Keech et al 
1996a). Our group (work not shown here) had similar difficulties. 
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My results are supported by the work of other laboratories. In a paper focusing on 
methodology for detecting Ro and La antibodies in Japanese patients with 
autoimmune disease, Ro antigens were prepared from cultured human cell lines (KB 
and KBE). They isolated a 58kD (probably equivalent to the now well recognised 
52kD protein), in high concentration from the cytoplasmic fraction of KB cells 
(Inagaki et al 1989). 
Overexpression of the 52 kD Ro-encoding gene in HEp-2 and LT A-5 cells has 
demonstrated a predominantly cytoplasmic localization of the 52kD protein (Keech 
et al 1995). 
My immunofluorescence findings are unique in that I have shown the location of the 
52 and 60-Ro in normal human cultured keratinocytes. Human antibodies directed 
against two different recombinant 52 protein fragments showed similar 
immunofluorescence. This was true too, of the two different anti-recombinant 60 
antibodies, as well as the antibody directed against the native 60 epitope(s). The 
differences between the anti-52 kD and anti-60 kD antibodies were further confirmed 
by double labeling with human and rabbit antibodies. I would argue that the 60 kD Ro 
protein resides largely in the nucleus and the 52 kD Ro is located mainly in the 
cytoplasm. 
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5.1 CAN Ro ANTIBODIES 
CELLS? 
5.1.1 Introduction 
PENETRATE 
CAUSE 
LIVING 
The view has long been held that antinuclear antibodies cannot penetrate living cells. 
However there is evidence to suggest that this may be possible. Patients have been 
described in whom epidermal nuclear staining is present, without circulating 
antinuclear antibodies (Burrows et al 1993, Velthuis et al 1990; Parodi et al 1985; 
Herrera-Esparza & Avalos-Diaz, 1982). 
One group has made the interesting observation that deposits of lg (as shown by DIF) 
in the cytoplasm of human skin keratinocytes, are associated with high levels of serum 
antibodies to keratinocytes in the superficial epidermal cell layers (upper cytoplasmic 
antigens) and with LE (found in 22/98, 22.5%) (Ioannides & Bystryn, 1993). They 
speculate that that this may be due to antibody penetration of cells in vivo. 
Furukawa et al during their work on oestradiol's influence on keratinocyte surface 
binding of sera with Ro and La reactivity, made the observation that in some cells, 
incubated with antibody probes before fixation, antibody internalization and nuclear 
staining could be seen. They suggested that this antibody internalization could be 
minimized by shortening incubation times and performing incubations in the cold 
(Furukawa et al 1988). 
Another group have identified IgG antibodies capable of penetrating an epithelial cell 
line, COLO 16 in 5/36 (14%) ANA+ SLE patient sera (Golan et al 1993). Thirty 
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minutes following incubation of cells with dilutions of either whole sera, globulin 
fractions, or F(ab')2 fragments of lgG, - 80-90% of cells showed intranuclear lgG by 
indirect IF. The percentage of DIF-positive staining cells was directly related to the 
length of time that the sera were incubated with the cells. The binding process was 
rapid (30% of nuclei were positive after a 10-min. incubation with serum) and 95% of 
cells were positive after a 30-min. incubation. In addition, the process was 
temperature dependent. 50% of cells showed faint nuclear fluorescence after 
incubation with serum for 60 min. at 2°C, whereas 100% of cells showed intense 
nuclear staining when incubated at 3 7°C for the same length of time. Viability of the 
cells prior to assay was >98% as determined by Trypan blue staining. Penetration of 
lgG into the nuclei did not affect viability or DNA synthesis of cells in short-term 
culture. 
Other antibodies have been shown to penetrate cells, including antibodies to proteins 
3, ribosomal protein P, lymphocytes, synaptosomes and neurons (Zack et al 1996). 
Assuming that the observations of antibody penetration of cells is a true in vivo 
phenomenon, it is possible that a number of mechanisms may be involved in allowing 
immunoglobulin molecules to penetrate the cytoplasm or nucleus of living cells. The 
expression of keratin antigens on the surface of viable keratinocytes might account for 
the internalisation of such antibodies into cells (Sontheimer, 1993). 
For anti-DNA antibodies, cellular penetration and translocation to the cell nucleus 
were thought to require the presence of DNA (Zack et al 1996). Since some 
antibodies have been shown to bind membrane proteins cross-reactive with DNA, 
these proteins may be instrumental in cellular penetration. In other cases, DNA 
binding proteins usually thought of as intracellular, have been described in association 
with the membrane of some cells (Zack et al 1996). 
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5.1.2 Methods 
5.1.2.1 Cell Culture 
See Protocol 9: Definitive keratinocyte culture pg. 107. 
Neonatal foreskins were washed and trypsinised overnight at 4 °C. The basal 
keratinocytes from the epidermis were resuspended in Medium 154 (Cascade 
Biologics Inc., Portland, OR) supplemented with human keratinocyte growth 
supplement. These keratinocytes were seeded onto 8-chamber Lab Tek slides (Nunc 
Inc., Naperville, IL). They were grown to 50% confluence. 
5.1.2.2 Determination Of Cell Viability 
Protocol 17: Assessment of viability 
This was assessed by the propidium iodide (Yeh et al 1981) or trypan blue (Golan et 
al 1993) methods. 
Propidium iodide (Molecular probes, Eugene, OR) stock solution was made by 
dissolving 5 mg of propidium iodide in 100 ml of 1 % Trisodium citrate and stored in 
a brown bottle at 4°C. To make a working solution, this was diluted 1 :3 with PBS. 
Two methods were then employed: 20 µl PI was added to cells following 3rd wash 
after addition of conjugate, mixed thoroughly, mounted and read immediately, or 100 
µl PI was added to cells following the first wash after addition of conjugate, mixed, 
incubated at 4°C for 5 min., washed twice, mounted in glycerol and examined. 
The trypan blue dye exclusion test was performed by adding trypan blue 0.1. % in PBS 
at 4°C to the keratinocytes after the primary antibody incubation for 45 sec at room 
temperature, before being fixed in 3% paraformaldehyde. The mean percentage of 
viability was determined from a total count of 500 cells in three different chambers. 
127 
Chapter 5 
Do the Ro antibodies cause cutaneous disease? 
5.1.2.3 Viable cells 
Protocol 18: Immunofluorescence on viable keratinocytes 
Old media was removed. Primary antibody diluted to 75 µl in Media 154 was added 
and incubated for 30 min, or for varying durations as described below. Incubation 
took place at 4 °C or 3 7°C, in separate experiments. The keratinocytes were then 
washed with PBS for 5 min, followed by fixation in paraformaldehyde (3% in PBS) 
for 15 min. at room temperature. Following two washes with cold dulbecco PBS (x5 
min. max.). The cells were immersed in Triton X-100 (0.2% in PBS) for 5 min. at 
room temperature. Next followed two washes with cold dulbecco PBS, followed by 
incubation with 100 µI of secondary antibody at room temperature for one hour. The 
plastic chamber was removed, the slides were dipped for 10 sec in propidium iodide 
(100µ1 in 10 ml PBS) to counterstain the nucleus and mounted in PVA. The primary 
antibody was incubated on viable cells for varying time periods: 5 min. , 15 min., 1 hr, 
3 hrs, 7 hrs, 24 hrs and 48 hrs. The keratinocytes were irradiated with UVB, 1.5 and 
4.5 mJ/cm2 at 5 mins, 30 mins and one hour post irradiation. The positive control was 
the same antibody or whole serum 2429, without UVB. The negative control was 
secondary antibody alone. The following antibodies were used: 60-2 ( 1: 100), 60-4 
(1 :50), 52-1 b (1 :25), 52-2 (1 :50). These were the dilutions previously found to yield 
the best results on immunofluorescence of fixed normal keratinocytes. 
In the next stage of the experiments, all the above variables remained constant, with 
the addition of a supplement to the medium. Hydrochlorothiazide was supplemented 
at l 00 ng/ml, 200 ng/ml and 400 ng/ml for 24 - 48 hours. Media in 2 chambers of 
each slide were supplemented with Oestradiol at 10-7 M for 24 - 48 hours. Using 
colonies of 10 - 50 cells in Lab Tek chambers, Vit C was added to give a 
concentration of 27 µg /108 cells, Vit E was added to give a concentration of 2. 7 µg 
/108 cells and HCZ 100 ng/ml plus oestradiol were used together. 
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The above experiments were similarly performed on keratinocytes seeded into wells 
on an ELISA grid, as annotated later in Protocol 19: ELISA to assess surface 
antigen expression on unfixed keratinocytes. 
Protocol 19: ELISA to assess surface antigen expression on unfixed keratinocytes 
2 X 104 third passage keratinocytes were seeded onto each well of a 96-well 
microtiter, strip culture plate (Costar). They were seeded at a density of 2 X 104 cells 
in 200 µl complete medium. 3 separate cell lines were used in triplicate, on at least 3 
separate occasions. They were incubated in medium 154 (Cascade Biologics Inc., 
Portland, OR) at 37°C, supplemented with human keratinocyte growth supplement, 
until the keratinocytes in all wells were confluent. For the last 3 days of growth, any 
experimental supplements were added, in the same concentration as used for 
immunofluorescence. Viability of two columns of wells were assessed using trypan 
blue. The wells were then washed twice with 1 X PBS. The final wash was gently 
aspirated carefully and completely, using a Pasteur pipette whose tip had been pulled 
in a flame, to a fine tip. 200 µI primary antibody was incubated in each well overnight 
at 4°C. The wells were then washed X 3 with PBS, incubated with goat anti-human 
IgG for 2 - 4 hours and developed at 3 7°C for 2 - 3 hours. 
Protocol 20: ELISA to assess surface antigen expression on fixed keratinocytes 
2 X 104 third passage keratinocytes were seeded onto each well of a 96-well strip, 
microtiter culture plate (Costar) and treated exactly as described in Protocol 19: 
ELISA to assess surface antigen expression on unfixed keratinocytes. Once the 
final wash had been aspirated, the keratinocytes were fixed in 200µ1 0.25% 
glutaraldehyde, diluted fresh in PBS. They were incubated for 5 minutes at room 
temperature. The glutaraldehyde was aspirated. The wells were then washed gently 
twice with IX PBS. The plate was flicked to remove the PBS. For storage, 
200µ1/well PBS and 0.02% sodium azide were added. The plate was then stored in 
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the dark in a tight-sealed container. 200 µl primary antibody was incubated in each 
well overnight at 4°C. The wells were then washed three times with PBS, incubated 
with goat anti-human IgG for 2 - 4 hours and developed at 37°C for 2 - 3 hours. 
Protocol 21: Surface ELISA Permutations 
The permutations performed on keratinocytes for immunofluorescence, were mirrored 
in the keratinocytes assessed for ELISA, with the addition of irradiation with 160 mJ 
UVB/cm2• All keratinocytes were used one hour post irradiation. The wells 
containing the 52-1 b were incubated overnight with 10 mM DTI. Fixed versus un-
fixed cells were compared. 
5.1.3 Microscopy See 4.2.2.1 Microscopy pg: 112, 4.2.2.1.1 
Epifluorescence microscopy pg: 112, 4.2.2.1.2 Confocal Microscopy pg: 112 
5.1.4 RESULTS 
All studies were performed in triplicate, each experiment with a different cell line, for 
each of the variables studied. 
5.1.4.1 Immunofluorescence 
For every permutation on viable cells, no purified human antibodies displayed any 
intracellular fluorescence. All the anti-52 kD Ro (see figure 29, pg. 131), the anti-60 
kD Ro (see figure 30, pg. 132) autoantibodies (labeled with Texas Red-conjugated 
goat anti-human antibodies and/or fluorescein isothiocyanate-conjugated goat anti-
human antibodies) did not fluoresce. Normal serum, used as a negative control, 
likewise showed no cellular penetration (see figure 31, pg. 133). However, a single 
whole autoimmune serum, 2429, showed fluorescence under all conditions but it was 
of great interest to observe, that this occurred in only those cells staining positive for 
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trypan blue (see figure 32, pg. 134). Serum 2429 was obtained from a patient with 
Sjogren's syndrome. This serum was immunodiffusion positive for Ro, ELISA 
positive for native 60kD Ro, recombinant 52kD Ro, recombinant 60kD Ro and La. 
The positive control was whole autoimmune serum, 2429 in fixed, rather .than viable 
keratinocytes (see figure 33, pg. 135 ). To clarify these negative results, the 
experiments, with the addition of UVB or UV A were repeated on at least two separate 
occasions some months apart. The negative results were reproducible. 
figure 29: No intracellular fluorescence was obtained for or any anti-52kD 
antibody. These results were negative for all perturbations. 
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figure 30: No intracellular fluorescence was obtained for any anti-60kD 
antibody . These results were negative for all perturbations. 
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figure 31: No intracellular fluorescence was obtained for normal serum, used as 
a negative control. These results were negative for all antibodies, normal sera 
and for all perturbations 
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figure 32: Serum 2429 showed fluorescence when incubated with viable normal 
keratinocytes for 5 min. Positive control was serum 2429 on fixed keratinocytes 
(see figure 33, pg. 135). This occurred in both perturbed and no-perturbed cells 
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figure 33: Serum 2429 showed fluorescence incubated with viable normal 
keratinocytes for 5 min. Positive control was serum 2429 on fixed keratinocytes, 
shown here. This occurred in both perturbed and on-perturbed cells 
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5.1.5 DISCUSSION 
Patients have been described in whom epidermal nuclear staining is present, without 
circulating antinuclear antibodies. In a study of 22 patients exhibiting epidermal 
nuclear staining, 7 did not have a positive serum ANA at the time of biopsy for DIF. 
In addition, in 11 of 16 cases tested, antibodies to RNP were absent (Burrows et al 
1993). Other groups have reported cases of epidermal nuclear staining occurring in 
the absence of serum ANA (Velthuis et al 1990; Parodi et al 1985; Herrera-Esparza & 
Avalos-Diaz, 1982). 
I have no evidence that purified monospecific anti-52 and anti-60 Ro antibodies are 
capable of penetrating normal human neonatal keratinocytes. These studies were 
performed under a multitude of experimental stresses, including all those factors 
known to precipitate or aggravate cutaneous disease. It is possible that the previously 
reported epidermal nuclear staining occurred as a result of contamination by 
diffusable ANA in the dermis gaining access to the epidermal nuclei during tissue 
processing (Gilliam, 1975). 
Other workers agree, showing that it is associated with high titers of anti-RNP 
antibodies. Other experiments that would address this issue further, would include 
disaggregation of the blister tops into a single cell suspension, followed by extensive 
washing, cytospin fixation and staining for intracellular immunoglobulin. Another 
approach would be to formalin fix suction blister tops or intact biopsy specimens prior 
to sectioning, followed by the application of a staining protocol capable of detecting 
human immunoglobulin in formalin-fixed tissue. 
Ioannides & Bystryn in their work showing that deposits of Jg in the cytoplasm of 
human skin keratinocytes, are associated with high levels of serum antibodies to 
keratinocytes in the superficial epidermal cell and LE, speculate that that this may be 
due to antibody penetration of cells in vivo. This may possibly due to antibody 
binding to an antigen like structure on the cell surface, or to potential functional or 
cell-cycle changes in the epidermal cell membrane in SLE (loannides ·& Bystryn, 
136 . 
Chapter 5 
Do the Ro antibodies cause cutaneous disease? 
1993). These deposits were very uncommon in skin specimens from patients with 
bullous dermatoses, or non lupus skin disease (Ioannides & Bystryn, 1993). More 
details of the actual experiments performed including the conditions and durations of 
washing the epidermal suction blister tops prior to freezing and sectioning, would 
have allowed for critical analysis as to whether their findings may have occurred 
because of contamination by small amounts of extracellular immunoglobulin. 
Ioannides and Bystryn showed that the upper epidermal cytoplasmic staining pattern is 
sometimes extremely focal and spotty (Ioannides & Bystryn, 1993). If free keratin 
reactive autoantibodies from the dermis were washing onto intracellular keratinocyte 
antigens exposed by processing, one may expect this staining to be even and diffuse, 
rather than either in localised keratinocyte clumps or in scattered single keratinocytes. 
It is unlikely that specific keratin antigens are differently expressed in these targeted 
areas. 
Assuming that previous observations of antibody / cell penetration are true (Ioannides 
& Bystryn, 1993), it is possible that some keratinocytes in LE patients suffer subtle 
injury, not morphologically apparent. Such stressed keratinocytes may be unable to 
prevent circulating antibodies from leaking in. There is some precedent for anti-
keratin antibodies gaining access to stressed mammary epithelial cells in the absence 
of morphologic evidence of cell injury (Dairkee et al, 1991 ). 
However, (Ioannides & Bystryn, 1993) did not observe epidermal cytoplasmic 
staining in basal keratinocytes, the focus of injury in SLE. In addition, it is likely that 
penetration of keratinocytes by antibody would lead to some type of functional 
consequence but epidermal cytoplasmic staining was frequently observed in normal-
appearing skin. 
In the Denver experiments on 'translocation', they found that lgG from Ro and La 
positive serum, bound to UV irradiated keratinocytes in culture. They produced the 
same pattern of binding in intact human skin harvested by suction blister 24 hours 
after irradiation with UVB and then incubated as intact epidermis with serum In these 
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experiments they found that antibody bound to cell surfaces, was internalised with 
time and rapidly appeared in the nucleus if these cells were observed early enough 
(Furukawa et al 1990). I observed my cells within minutes of addition of the anti-Ro 
antibodies, without detecting intracellular penetration. It is interesting that I showed a 
very low penetration rate in those cells incubated with whole serum (in this respect, 
duplicating the Denver work, as they failed to use purified antibodies). One must 
therefore presume that either a completely different antibody present in the "Denver" 
sera penetrated cells, or more likely, as shown in the work of Casciola-Rosen et al, 
their findings may be changes associated with apoptosis, rather than penetration of 
normal cells. 
As discussed in the introduction to this chapter, the group that identified IgG 
antibodies capable of rapidly penetrating an epithelial cell line, COLO 16 in 5/36 
(14%) ANA+ SLE patient sera (Golan et al 1993), showed that the percentage of DIF-
positive staining cells was dependent on the time of sera incubation and temperature. 
Interestingly, intracellular IgG could not be detected following exposure of the cells to 
high titer reference autoantibodies of known specificities, against Ro, La, Sm, RNP, 
ribosomes or DNA. This would support my work showing no cell penetration with a 
whole range of anti-Ro antibodies, directed at the major Ro epitopes. 
Antibody uptake was relatively selective for transformed epithelial cell lines, as 
intranuclear lgG was not detected in cell lines of normal human keratinocytes, or 
those of lymphoid origin, exposed to the sera. Penetration may be limited to either the 
state of differentiation or activation of the cell. These findings suggest that a subset of 
SLE patients have IgG capable of penetrating a transformed cell line of epithelial 
origin. It supports my work that anti-Ro antibodies are incapable of penetrating 
normal human keratinocytes. 
For molecules to penetrate into the nucleus, they would need to do so through a very 
selective gatekeeper sorting mechanism, recognising specific amino acid sequences, 
not possessed by immunoglobulins. For these to penetrate into the nucleus, they 
would need to do so via a rather unconventional mechanism. One group has 
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suggested that they may be imported into the nucleus in association with a carrier 
protein such as a cell surface receptor. They, in addition suggest that, the association 
of the carrier protein with the immunoglobulin, may prevent the antigen-binding site 
of the antibody from reacting with its antigen in the nucleus accounting for the 
absence of visible cellular pathology (Golan et al 1993). The requirement for free 
DNA and the role of Fe binding for cellular penetration appears to be different in the 
various antibodies. The antibodies studied have distinct specificities for binding 
antigen and they target different cell types. Therefore, multiple mechanisms may be 
operative in cellular penetration and nuclear localisation. 
Some have argued that Fe receptor-mediated endocytosis is the mechanism by which 
UlRNP antibodies penetrate human lymphoid cells (Alarcon-Segovia et al 1978). 
Keratinocytes have been shown to express Fe and C3 receptors as a result of herpes 
virus infection (Kubota et al 1987). However, normal epidermal keratinocytes have 
not been shown to express such receptors ( Galoppin & Saurat 1981, Sting! et al 1977). 
There are a number of functional implications of immunoglobulins directed against 
specific vital intracellular components, gaining access to cells. Overall, there is little 
precedent within the conventional view of the immune system for immunoglobulins 
finding their way into healthy living cells. In favour of this is the fact that infectious 
organisms that hide in cells are dealt with by cellular rather than humoral responses. 
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5.2 DO THE Ro ANTIGENS TRANSLOCATE TO THE 
CELL SURFACE? 
5.2.1 Introduction 
5.2.1.1 Ultraviolet Radiation 
In 1984, the first report appeared of ultraviolet-irradiated, cultured keratinocytes 
which bound IgG antibodies from the sera of LE patients with either monospecific 
anti-SSA/Ro, anti-RNP, or anti-Sm activity (Lefeber et al 1984). A study of the 
viability and permeability of irradiated keratinocytes showed that this apparent cell 
membrane expression of extractable nuclear antigens was seen on injured 
keratinocytes whose cell membranes were intact but not on dead cells. Neonatal 
human keratinocyte monolayers of 10-50 cells were irradiated with 0, 0.2, or 2.0 
mJ/cm2 UVR (predominantly UVB). They chose these doses, suggesting that since 
10% of UVB light incident on Caucasian skin penetrates to the basal layer, an in vitro 
dose of2 rnJ/cm2 would be equivalent to 20 mJ/cm2 in vivo in human skin. One MED 
in Caucasians, ranges from 15 to 75 mJ/cm2 for UVB. At 8 and 24 hours after 
irradiation the cultures were examined for viability or antibody binding. Human lgG 
binding to cell surfaces was assessed by first blocking irradiated cultures with normal 
rabbit serum and then incubating with a 1: 10 dilution of monospecific antiserum 
followed by acetone fixation, second antibody incubation and sequential propidium 
iodide dip. Slides were mounted in a paraphenylenediamine-containing mounting 
medium. 
The degree of positive staining was determined qualitatively and quantitatively by 
visual counting of at least 200 cells in each specimen using a Zeiss epi-illuminated 
microscope. Cell viability in irradiated cultures was measured by ethidium bromide 
with acridine orange, propidium iodide exclusion, or fluorescein diacetate uptake. 
They found strong granular staining of unfixed irradiated keratinocytes with all six 
monospecific sera used. The percentage of positive cells ranged from 10 - 20%. 
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Irradiated cells which showed granular staining with anti-Ro or anti-RNP, also stained 
with fluorescein diacetate but less intensely than did cells without granular staining. 
This suggested that these cells were injured. 45-55% of there cells were dead. They 
interpreted these findings to suggest that UV irradiation of cultured keratinocytes 
causes cell death and irreversible membrane damage to many cells, producing a 
population of injured cells with expression of certain nuclear antigens on the cell 
membranes (Lefeber et al 1984). 
Furukawa et al from the same laboratory set out to confirm Le Feber's findings. 
Using three different protocols, they concluded that Ro autoantibodies (and anti-La 
and anti-RNP) bound to UVB (not UVA) irradiated keratinocytes (Furukawa et al 
1990). They used short-term 2% paraformaldehyde fixation of suspensions of 
cultured human keratinocytes previously incubated with monospecific antiserum 
probes for Ro. UVB (280-320 nm) induced the binding of monospecific antibody 
probes for Ro and La on keratinocytes in a dose dependent fashion. Maximal 
induction was observed at the dose of 200 mJ/cm2• UV A (320-400 nm) had no effect. 
Identical results were obtained with standard immunofluorescence techniques, 
incubating viable cells with antibody at 4°C for one hour before fixation and labeling. 
Jones, previously from the same group and continuing his work in the UK, used the 
same sera that the Denver group had used for all their work (Jones, 1992a). For 
injurious stimuli he used hydrogen peroxide. Metabolic stimuli were assessed 
because of their effects on various aspects of cellular metabolism, such as protein 
synthesis. He used cholera toxin, as it has been shown to increase DNA and 
subsequently protein synthesis in human melanocytes and keratinocytes. In addition, 
he used Phorbol- l 2-myristate-13-acetate, tumour promoters, with a number of effects 
on cellular metabolism and cell membrane function. A number of immunological 
stimuli were assessed, including gamma interferon (reportedly stimulates the 
expression of class II HLA-DR on the surface of cultured human keratinocytes and 
induces the synthesis of new proteins by cells), interleukin 1 (a cytokine produced by 
keratinocytes, monocytes and Langerhans cells, which, in the presence of antigen, 
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activates T-cells to produce IL-2 and IL-2 receptors and enhances the protein synthesis 
and cell proliferation of keratinocytes) and interleukin 2 (thought to be responsible for 
the proliferation of T cells). In addition, he used the inflammatory stimuli, leukotriene 
B4, one of the most active of the inflammatory products of the lipoxygenase and 
cyclo-oxygenase pathways of arachidonic acid metabolism. The hormonal stimuli 
used were 17-J3 oestradiol, progesterone and dihydrotestosterone. 
5.2.1.2 Drugs 
Several drugs have been shown to induce SCLE lesions, associated with Ro 
autoantibodies (Furner, 1990; Fine, 1989). The mechanism, here, is unknown. Most 
cases of drug induced SCLE have been linked with Hydrochlorothiazide. The effects 
of drugs on Ro translocation have not been studied. 
Vitamin E (Vit) has been proposed as a treatment for lupus skin disease {Ayres Jr & 
Mihan, 1971). a tocopherol (5,7,8 - trimethyltocopherol) comprises about 90% of 
tocopherols in animal tissue. Discovered in 1922, it quickly became known as the 
"fertility" vitamin and was christened tocopherol from tocos ( childbirth) and phero (to 
confer), based on the ability of Vit E to restore fertility to experimental animals on vit 
E-defi.cient diets. Tocopherols are the body's chief antioxidants, protecting the labile 
unsaturated fats, e.g.: cell membranes, from lipid peroxidation. They also enhance the 
intestinal absorption of Vitamin A. Vit E deficient mice have been shown to develop 
a defect in the formation of inter and intramolecular collagen cross-linkages and 
premature aging (Ayres Jr & Mihan, 1971). The daily recommended allowance is 30 
LU., approximately 30g (Ayres Jr & Mihan, 1971). 
In addition, no work has been done on the effect of Vitamin C (Vit C) on Ro 
translocation. Ascorbic acid acts as a cofactor by transferring electrons to enzymes 
that provide reducing equivalents. As such they are important in collagen synthesis, 
carnitine synthesis, the conversion of folic to folinic acid and dopamine to 
noradrenaline, microsomal drug metabolism, they increase intestinal iron absorption 
and play a role in adrenal steroid genesis. Vit C can also increase the effectiveness of 
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Vit E through antioxidant synergism. As for Vit E, the concentration in tissues is 
probably more real than plasma concentrations. 
5.2.1.3 Oestrogens 
The hormonal milieu may also play an important role in Ro associated disease. 
Approximately 75% of SCLE patients and infants with NLE skin disease are female. 
Oestrogen treatment of cultured keratinocytes has been reported to increase the 
expression of Ro antigens on the cell surface (Furukawa et al 1988). It is not known 
which of the Ro antigens are so displaced. 
5.2.1.4 Heat 
Some SCLE patients have found that heat can exacerbate their disease (McCauliffe & 
Sontheimer, 1993a). Heat shock-like proteins may be translocated to the cell surface, 
where they may participate in antigen presentation or be a target for gamma/delta T 
cell directed cytotoxicity. The induction of heat shock proteins has been reported to 
be a primary cellular response to tissue injury and their induction may enhance post-
traumatic tissue recovery. Interleukin-2-treated T-lymphocytes and cyclopentanone 
prostaglandin-treated HeLa cells, induce 68kD and 80kD heat-shock proteins. These 
may function in the regulation of the cell cycle or form part of a defensive reaction to 
cytokine or mediator synthesis. Immunofluorescence has demonstrated a rapid and 
reversible accumulation of the 72-kD heat shock protein within the nucleolus of heat-
stressed keratinocytes (Edwards et al 1991 ). There has been great interest in the role 
of hsp as molecular chaperones, binding and escorting molecules to the nucleus, 
cytoplasmic vacuoles, the ER and the plasma membrane during stress. In addition, 
hsp themselves may be targets of autoimmune reactivity. In human keratinocytes, hsp 
can be induced by UVR as well as heat (Edwards et al 1991; Maytin et al 1993). A 
number of investigators have shown that hsp induction is greater in peripheral blood 
mononuclear cells from lupus patients compared to normal subjects or in lymphoid 
cells from infiltrates in lupus nephritis. Lupus patients also make antibodies to hsp 
(Norris, 1993). 
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5.2.1.5 State Of Keratinocyte Differentiation And Proliferation 
Human keratinocytes grown in low calcium containing media, have greater amounts 
of cytoplasmic Ro antigen as detected by IF than those grown in high calcium 
containing media. At lower calcium concentrations, cultured keratinocytes are in a 
less differentiated, more rapidly dividing state, more like the basal keratinocytes. This 
may explain why the more rapidly proliferating basal keratinocytes are preferentially 
targeted in NLE and SCLE cutaneous disease (McCauliffe & Sontheimer, 1993b). I 
reproduced the previous experiments, on normal human keratinocytes under 
physiological doses of UV A and UVB and other physiological stresses, including 
drugs, vitamins and hormones, using the purified anti-52 and anti-60 kD Ro 
autoantibodies previously discussed in chapter 3 to unravel which of the Ro antigens 
were translocated to the cell surface, see figure 34, below. 
figure 34: proposed model for Ro translocation. 
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5.2.2 Methods 
5.2.2.1 Cell Culture 
Keratinocytes were cultured as previously described, see Protocol 9: Definitive 
keratinocyte culture pg: 107. Second passage keratinocytes were frozen in liquid 
nitrogen for later use. These keratinocytes were thawed and seeded onto 8-chamber 
Lab Tek slides (Nunc Inc., Naperville, IL). They were grown to 50% confluence. 
5.2.2.2 Determination Of Cell Viability 
See Protocol 17: Assessment of viability 
This was assessed by the propidium iodide (Yeh et al 1981) or trypan blue (Golan et 
al 1993) pg.: 127 
5.2.2.3 Ultraviolet Irradiation 
The ultraviolet lamps used were two Phillips black light lamps, mainly UV A, peaking 
at 370 nm and two FS40 lamps, mainly UVB, peaking at 305 nm (Strato-Ray Co. 
Minneapolis, MN). These were mounted on opposing sides of a wooden gantry and 
shielded appropriately from the operator. See figure 35, pg. 146. Irradiance was 
measured with a IL 1700 Radiometer (International light, Newburyport, Mass). 
Keratinocytes were irradiated with ultraviolet A (UVA) at 4.795J/cm2. They were 
then returned to the 37°C incubator. They were incubated with the primary antibody 
at one and 20 hours after UV A exposure. Keratinocytes were irradiated with 
ultraviolet B (UVB) at the following doses: 0 mJ/cm2 , 1.5 mJ/cm2 , 4.5 mJ/cm2 , 160 
mJ/cm2 , 200 mJ/cm2 and then incubated with primary antibody at one hour and at 20 
hours post irradiation. 
Viability was assessed at 20 hours post irradiation by counting the number of cells out 
of 500, that were positive for trypan blue. 
145 
Chapter 5 
Do the Ro antibodies cause cutaneous disease? 
figure 35: The ultraviolet lamps were mounted on opposing sides of a wooden 
gantry and shielded appropriately from the operator. Irradiance was measured 
with a IL 1700 Radiometer (International light, Newburyport, Mass). 
5.2.2.4 Addition Of Oestradiol, Hydrochlorothiazide, Vit E and C 
Keratinocytes were incubated in a 10-7 M solution of 17 p oestradiol. d a. tocopherol 
acetate was added to the chambers or ELISA wells, to give a concentration of 
2.7µg/10 8 cells, L Ascorbic acid was added to give a concentration of 27µg/10 8 cells. 
Hydrochlorothiazide was added to give a dose of 400 ng/ml, 200 ng/ml and 100 
ng/ml. 
146 
Chapter 5 
Do the Ro antibodies cause cutaneous disease? 
5.2.2.5 Heat Shock 
Keratinocytes at 50% confluence on chamber slides, were exposed to 42°C for 90 
minutes and then either used immediately, or allowed to recover at 37°C for 4 hours. 
Control slides were maintained at 3 7°C. These slides were stained with 2 different 
monospecific anti-52 and anti-60 kD antibodies and C2 whole sera. 
5.2.2.6 Immunofluorescence 
5.2.2.6.1 Fixed cells 
Keratinocytes were fixed as previously described, see Protocol 15: 
Immunofluorescence of fixed keratinocytes pg. 111, followed by manipulations, see 
5.2.1.1 Ultraviolet Radiation pg. 140, 5.2.1.2 Drugs pg.142, 5.2.1.3 Oestrogens pg. 
143, 5.2.1.4 Heat pg. 143. 
5.2.2. 7 Viable cells 
See Protocol 18: Immunofluorescence on viable keratinocytes pg: 128 
At varying time intervals after manipulations, see 5.2.1.1 Ultraviolet Radiation pg. 
140, 5.2.1.2 Drugs pg.142, 5.2.1.3 Oestrogens pg. 143, 5.2.1.4 Heat pg. 143, the 
keratinocytes were washed in IX PBS, stained with trypan blue to assess viability and 
then incubated at 37°C, for varying times (5 min., 60 min., 3 hr, 4 hr, 5 hr and 7 hr) 
with the primary antibodies or whole sera. This was followed by fixation in 3% 
paraformaldehyde at 4°C for 15 minutes, followed by 2 brief washes with IX PBS. 
They were permeabilised for 5 minutes with 0.1 % Triton X in PBS, washed twice 
with IX PBS and then incubated for 30 minutes at 4°C with secondary goat anti-
human lgG conjugated to Texas Red. The slides were either dipped in propidium 
iodide to counterstain the nucleus, or the nucleus was left unstained. They were then 
washed twice and coverslipped with polyvinyl alcohol mounting media. 
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5.2.2.8 Microscopy 
The slides were viewed with a conventional epifluorescence microscope, followed by 
confocal microscopy, as previously described in chapter 4. Confocal images were 
processed using Adobe Photoshop 3.0 software and printed on an Epson Stylus colour 
printer 
5.2.2.9 ELISA to assess surface antigen expression 
5.2.2.9.1 Unfixed 
2 X l 04 third passage keratinocytes were seeded onto each well of a 96-well microtiter 
culture plate (Costar), as previously described, see Protocol 19: ELISA to assess 
surface antigen expression on unfixed keratinocytes pg: 129. They were subjected to 
manipulations before fixation, as already described, see 5.2.1.1 Ultraviolet Radiation 
pg. 140, 5.2.l.2 Drugs pg.142, 5.2.1.3 Oestrogens pg. 143, 5.2.1.4 Heat pg. 143 
5.2.2.9.2 Fixed 
2 X l 04 third passage keratinocytes were seeded onto each well of a 96-well microtiter 
culture plate (Costar), as previously described, see Protocol 20: ELISA to assess 
surface antigen expression on fixed keratinocytes. They were subjected to various 
manipulations described earlier, see 5.2.1. l Ultraviolet Radiation pg. 140, 5.2.1.2 
Drugs pg.142, 5.2.l.3 Oestrogens pg. 143, 5.2.l.4 Heat pg. 143, mirroring those 
permutations performed on keratinocytes for immunofluorescence. The wells 
containing the 52-1 were incubated overnight with 10 mM DTT. 
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5.2.2.9.3 Autoimmune sera 
A number of whole sera from well documented patients were used, in addition to the 
specific antibodies: 
2429 
93-1 
2109 
123 
92-1 , C2 
Sjorgen' s syndrome. Immunodiffusion (ID) positive for SSA. 
ELISA positive for native 60kD Ro, recombinant 52kD Ro, 
recombinant 60kD Ro and La. 
Glyburide induced SCLE. ID positive for SSA. 
Subacute cutaneous LE. 
Neonatal LE. Immunodiffusion positive for SSA. ELISA 
positive for native SSA, negative for recombinant 52kD Ro, 
recombinant 60kD Ro and La. 
Subacute cutaneous LE. Paired sera from same patient, one 
month apart. 
92-1: antinuclear factor (ANF) positive. 
C2: (ANF) negative, Ro +, +whole 52, +-52-1 , 52-2, -
whole 60, +-60-2, +60-4 
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5.2.3 Results 
5.2.3.1 Ultraviolet irradiation 
5.2.3.1.1 Viability 
Viability was excellent among the keratinocytes subjected to UVR, hormonal, drug or 
vitamin manipulations, see tables 3 and 4. On average, 99% of cells were viable 20 
hours after irradiation with UVB 1.5 mJ/cm2, with or without supplementation with 
varying doses of Hydrochlorothiazide, oestradiol, vit E or vit C. Viability was poor 
(9%) at the end of the 90 min. 42°C incubation, as measured by the ability of cells to 
exclude propidium iodide. Fewer cells were propidium iodide positive (33% able to 
exclude propidium iodide) at the end of a two hour 37°C recovery phase. I found that 
cells, although trypan blue negative, may be positive for propidium iodide. This 
propidium iodide positivity is much less after the recovery phase in the heat shock 
experiments, suggesting that these changes may be related to apoptosis. 
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Table 3: Viability of normal neonatal keratinocytes with varying doses of UVB 
at one or twenty hours post irradiation, as determined by the trypan Blue exclusion 
method. Expressed as number of dead cells per 500 cells counted. 
Table 4: Viability of cells after supplementation +/- UVB, at 20 hrs post 
irradiation 
Viability assessed by number of trypan blue staining cells. 100 cells counted in each 
comer of the chamber and 100 counted in the middle of the slide. This table shows 
the number of trypan blue positive cells per 500 cells. Donors refer to different 
normal neonatal keratinocyte cell lines. 
I l1jD0NOR9 i DONORll l ~D0NOR6 
oestradiol '', 2 0 0 ; 
oestradiol /UVB , 3 1 4 
HCZ 100 ng/ml 6 1 2 
HCZ 100 ng/ml /UVB 3 2 4 
HCZ 400 ng/ml 9 3 3 
HCZ 400 ng/ml /UVB 2 9 6 
vih: : 2 0 2 .. ,,,, : '"° II ,, 
vitc/UVB 6 10 4 .. .. . ··-- --
HCZ200 ng/ml 2 0 0 ' 
BCZ 200 ng/ml /UVB 0 4 4 
vite 12 3 3 
Vtte/UVB 4 3 4 
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5.2.3.1.2 Translocation / surface fluorescence 
The negative controls for translocation were established in chapter 4, from the work 
on the normal location of the 52 and 60 kD Ro autoantibodies in un-perturbed fixed 
keratinocytes, see figure 36. In addition, as previous work had used sera, a range of 
sera were additionally used as negative controls, see 5.2.2.9.3 Autoimmune sera 
pg.149, see figures 36 and 37. 
5.2.3.1.2.1 Manipulations 
Following UVA or UVB irradiation, with or without supplements, as described in 
methods, there was no surface staining for any of the comprehensive range of 
monospecific antibodies, suggesting no translocation of the 52 or 60 kD antigens to 
the keratinocyte surface. Some surface staining was found when whole sera was used, 
see figure 38, figure 39, figure 40. 
5.2.3.1.2.2 Heat shock 
No translocation of the 52 or 60 kD antigens occurred, following the heating or 
recovery phase of heat shock. The C2 whole sera did not show positive results either. 
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figure 36: Translocation / surface fluorescence negative controls. The negative 
controls for translocation were established in chapter 4, from the work on the normal 
location of the 52 and 60 kD Ro autoantibodies in un-perturbed fixed keratinocytes. 
In addition, as previous work had used sera, a range of sera were additionally used as 
negative controls, see 5.2.2.9.3 Autoimmune sera pg.149. Immunofluorescence of 
cultured un-perturbed human keratinocytes, fixed before incubation with serum C2, 
purified human anti-52 and anti-60 kD Ro and a 1:100 dilution of normal serum 
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figure 37: Translocation / surface fluorescence negative controls. The negative 
controls for translocation were established in chapter 4, from the work on the normal 
location of the 52 and 60 kD Ro autoantibodies in un-perturbed fixed keratinocytes. 
In addition, as previous work had used sera, a range of sera were additionally used as 
negative controls, see 5.2.2.9.3 Autoimmune sera pg.149. Immunofluorescence of 
cultured un-perturbed human keratinocytes, fixed before incubation with serum 2429. 
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figure 38: Translocation / surface fluorescence No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD Ro antigens. Some speckling of viable 
keratinocytes was found when incubated with serum 2429 after irradiation with UVB 
1. 5 mJ/cm2 and prior incubation with a 10-7 M solution of 17 p Oestradiol 
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figure 39: Translocation / surface fluorescence No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD antigens. Some speckling of viable 
keratinocytes was found when incubated with serum 2429 after prior incubation with 
Hydrochlorothiazide 100 ng/ml, as described in Methods. 
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figure 40: Translocation / surface fluorescence No supplements, with or without 
UVR, caused translocation of the 52 or 60 kD Ro antigens. Some speckling of viable 
keratinocytes was found when incubated with serum 123, 1 hour post UVB 1.5 mJ/m2, 
as described in Methods. 
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figure 41: Translocation / surface fluorescence No supplements, with or 
without UVR, caused translocation of the 52 or 60 kD Ro antigens. Some surface 
fluorescence of viable keratinocytes was found when incubated with whole 
autoimmune sera, as previously described. (2429: SS, ID+ Ro, ELISA+ n Ro60, + r 
Ro52, + r Ro 60kD, + La. 123: NLE, ID+ Ro, ELISA+ n Ro60, - r Ro52, - r 60kD, -
La. 2109: SCLE,, ID+ Ro, ELISA - n Ro60, - r Ro52, - r 60kD, + La.) Number of 
keratinocytes (y axis) showing surface fluorescence after varying doses of UVB in 
mJ/cm2 (x axis), at one and twenty hours after irradiation, expressed as UVB dose in 
mJ/cm2/duration post UVR after which cells were incubated with the secondary 
antibody or whole autoimmune serum. 
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5.2.3.1.2.3 ELISA to assess surface antigen expression 
There was no detectable surface binding one hour after 0, 1.5, 4.5 or 20, 160 mJ/cm2 
UVB, using antibodies directed against two different recombinant 52 proteins or a 
recombinant 60 kD protein or whole sera 2429 and 123, with or without supplemental 
Oestradiol, HCZ, Vit C or Vit E. 
5.2.4 Discussion 
As previous work has described translocation of Ro to the keratinocyte surface, under 
the influence of a number of agents (LeFeber et al 1984; Furukawa et al 1990; Golan 
et al 1992; Lee et al 1989; Edwards et al 1991; Furukawa et al 1994) I thought this 
would be an ideal model, to further unravel the role of the different Ro antigens. As 
these studies used poorly characterised monospecific Ro sera, it remained to be 
determined whether the 52-kD Ro, 60-kD Ro or both proteins were so translocated. 
With my panel of Ro autoantibodies, I have found that neither the 52 nor 60kD Ro 
antigens change position in normal human keratinocytes under the influence of 
physiological doses of UVB or UV A, with or without the additional influences of 
oestrogen, Vit E or C, Hydrochlorothiazide, a drug clinically causing SCLE, or heat. 
This is not all together surprising, given that most of the previous studies relied on a 
single monospecific autoimmune sera and/ or anti-sera with anti-52 or anti-60 kD Ro 
activity; the specificity of these reagents was often not well defined. 
Furukawa el al, used only four sera for immunofluorescence, one with La ( 43kD) 
reactivity, two with reaction to a 60 kD protein (Ro) and one with reactivity to both 
Ro and La (Furukawa et al 1988). However the 52kD Ro antigen was not addressed. 
They found augmentation of antibody binding on keratinocyte cellular surfaces 24 
hours after the addition of oestradiol, maintained for 3 to 4 days. The highest 
159 
Chapter 5 
Do the Ro antibodies cause cutaneous disease? 
incidence (24%) was seen on day 2, with the both La and Ro-reactive serum. This 
was double that observed with just Ro reactive sera alone (13%). Using flow 
cytometry, these figures were confirmed: higher (21.4%) for both Ro and La reactive 
serum than for just Ro (13.1%) or just La (14.4%). However, by immunoblotting, 
comparing the extracts of cultures treated with oestradiol with control cultures, the 
amount of La was augmented but Ro levels were inadequate for detection (Furukawa 
et al 1988). 
Jones showed that the percentage of keratinocytes expressing cell-surface Ro antigen 
after exposure to hydrogen peroxide showed no increase above control slides, despite 
the fact that the concentrations used did induce injury and at higher doses, the death of 
a proportion of the cells (Jones, 1992a). None of the other stimuli tested, induced any 
consistent change in cell-surface antigen expression, compared with controls. None of 
stimuli, when tested in conjunction with UV A, led to any increase in antigen 
expression over the background levels exhibited with UV A alone. When UVB was 
tested with and without the various stimuli in the culture medium, the results were 
similar. Most stimuli induced no significant up or down regulation of the antigen 
expression as produced by UVB alone. The one exception was the addition of 17-13 
oestradiol to the culture medium prior to UVB exposure. Alone, it induced no 
increase in cell-surface antigen expression. When used in conjunction with UVB, it 
produced a two-fold increase over that induced by UVB alone. This increased 
expression did not show any dose dependence, being induced equally by all 
concentrations used. There was, however, a correlation with the time of pre-
incubation prior to UVB irradiation, expression being greater at the 24-and 48-time 
points than the 12-h time point (Jones, 1992a). This work suggested that cell injury 
alone is not enough to produce cell-surface antigen expression. 
My findings contrast with those of Furukawa et al (Furukawa et al 1988) who found 
that oestradiol at concentrations of 10-5 - 10-7 M augmented cell-surface antigen 
expression using a similar test system. The reasons for these differences are uncertain 
and cannot be explained on the basis of differences of experimental technique. 
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Furukawa does add that the issue of cross-reactivity of anti-Ro or anti-La antibodies 
with other antigen cannot be ignored (Furukawa et al 1988). Especially in 
autoimmune sera, the presence of autoantibodies with widely cross-reactive 
specificities has been appreciated. 
This is especially interesting, since clinical studies have shown that 70% of patients 
with Ro precipitating antibodies also have rheumatoid factor (Mamula et al 1986). In 
SS, the rheumatoid factor titre and the concentration of anti-Ro are closely related. In 
addition, rheumatoid factor and antinuclear antibody contribute to Ro precipitation by 
double diffusion. In other disorders, selected rheumatoid factors (some restricted to 
particular idiotypes) have been shown to bind to non-lgG cellular components 
including histones, DNA and bacterial peptidoglycan and nitrophenyl groups. In a 
study comparing the binding characteristics of heteroimmune anti-Ro generated in a 
rabbit host with human autoimmune anti-Ro, it was found that both autoimmune and 
heteroimmune anti-Ro not only bind the Ro protein but also react with lgG (Mamula 
et al 1986). Affinity purification of the IgG and Ro-binding fractions of the rabbit 
anti-Ro, demonstrated that both the anti-Ro and anti-IgG activities were concentrated 
in these fractions. Therefore, Ro and IgG share epitopes that are bound by anti-Ro 
antibody. Inhibition experiments suggest that this antibody is found in most human 
anti-Ro autoimmune sera and that the epitope (s) are found in the F(ab'h fragment of 
IgG (Mamula et al 1986). It was therefore postulated that the anti-Ro component of 
sera may contribute to the detection of positive rheumatoid factors. 
The same group analysed the fine specificity of anti-Ro for the IgG molecule. They 
concluded that the lg G cross-reactivity of anti-Ro does not resemble conventional 
rheumatoid factors, since Fe regions of IgG are not bound by anti-Ro (Mamula & 
Harley, 1992). The anti-Ro antibody has binding specificity for the F(ab'h heavy 
chain region oflgG. The 52k.D Ro protein does not possess the cross-reactive epitope. 
These cross-reactive antibodies are most likely to appear as the anti-Ro responses 
mature and become high-titered in the patient (Mamula & Harley, 1992). 
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Additionally, the UVB dose described has been somewhat inconsistent. My doses of 
UVB and UVA are physiological, terrestrial doses. Likewise, those used by Le Feber 
at 2-20 J/m2 (LeFeber et al 1984), Jones at 10 - 40 J/m2(Jones, 1992b) and Kawashima 
at 50 - 150 J/m2 (Kawashima et al 1994) were physiological.. However, Furukawa 
used 2000 J/m2 (Furukawa et al 1990) and Golan used 200 - 2500 J/m2 (Golan et al 
1992), representing up to 50-fold mean erythema doses for Caucasian skin. It has 
been established that irradiation of neonatal keratinocytes with 1 650 J/m2 generates 
apoptotic cells within 6 hours (Cascio la-Rosen et al 1994 ). This group has shown that 
the Ro antigen is clustered in two discrete populations of blebs at the surface of 
apoptotic cells (Casciola-Rosen et al 1994). The previous papers may therefore have 
been describing changes with apoptosis, rather than cell surface translocation of Ro 
with physiological doses ofUVR. 
It is interesting that Furukawa et al make the observation that oestradiol doubled the 
incidence of small or cuboidal cells showing cell surface IgG binding. In contrast, the 
percentage of large or polygonal cells binding IgG decreased from 39% to 21 % by 
oestradiol stimulation. The relative percentage of medium-sized cells binding IgG 
was not changed by oestradiol stimulation. Looking at their figures and with the 
benefit of hindsight and all the work done by Casciola-Rosen et al on apoptosis, these 
cells (small, polygonal) were probably apoptotic. They suggested that these 
differences may relate to differentiation but then went on to find that strontium, which 
produces uniform, small, cuboidal cell colonies, did not enhance cell surface antigen 
expression (Furukawa et al 1988). 
It has been felt that the translocation occurred in viable cells, on the basis of Trypan 
blue exclusion. However I have found that the cells showing these changes with 
whole sera, although Trypan blue negative, are positive for Propidium iodide. This 
propidium iodide positivity is much less after the recovery phase in the heat shock 
experiments. This suggests that these changes may be related to apoptosis. This is 
supported by the work of Kawashima et al (Kawashima et al 1994) who analysed 
Ro/SSA surface binding using fluorescence activated cell sorter analysis (F ACS), by 
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which dead cells are gated out by propidium iodide staining. They found there was no 
plasma membrane expression of the 52 and 60k.D antigens in transformed 
keratinocytes. In addition, Le Feher (Lefeber et al 1984) found that their 
keratinocytes showing granular Ro/SSA staining, stained positively but less intensely 
with fluorescein diacetate (FD) than did cells without granular Ro/SSA. This 
confirms that these cells were viable but apparently injured. In fact, they found no Ro 
staining in the 25 - 35% of "live" cells, namely cells which avidly hydrolyzed and 
retained FD. 
Casciola-Rosen et al have shown a conspicuous movement of cytoplasmic Ro to small 
surface blebs early in apoptosis (Casciola-Rosen et al 1994). Ro is also found in the 
apoptotic nucleus (Casciola-Rosen et al 1994). Much of this nuclear Ro is 
reorganised during apoptosis. Ro is excluded from the nucleoplasm as the chromatin 
becomes condensed. It becomes concentrated around the rim of apoptotic bodies after 
nuclear fragmentation. After forming within the cell, the apoptotic bodies move to the 
surface where they give rise to a population of larger surface structures containing 
fragmented DNA. These apoptotic bodies also contain a distinct cluster of 
autoantigens that are targeted in patients with lupus, including nucleosomes (Mohan et 
al 1993; Burlingame et al 1993), Ro, La and snRNPs. 
Other work on the anti-phospholipid autoantibodies has shown that apoptotic, not 
viable thymocytes may be the natural immunogen and/or target for anti-phosphlipid 
autoantibodies. In addition, this group suggested that the interaction of P2-
glycoprotein 1 with redistributed anionic phospholipid may itself generate a novel 
ligand by which apoptotic cells are recognised directly for phagocytic clearance (Price 
et al 1996). 
Previous work has shown a great deal of inter individual keratinocyte donor 
variability. Percentages of translocation have been quoted as varying from 3 - 17% in 
one report (Jones, 1992b). The percentage of cell showing granular staining increased 
significantly with each increase in dose of UVB, although the expression did not vary 
significantly when assessed at the different time points after irradiation (Jones, 
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1992b). This study showed an increase in both injured and dead cells with higher 
doses of UVB. In addition, this work showed that blocking protein synthesis with 
cycloheximide, induced a dose dependent reduction in the percentage of cell-surface 
antigen expression as induced by UVB. Le Feber (Lefeber et al 1984) found 10 -
20%. Golan (Golan et al 1992) showed a maximum of 8.2% for the combined anti-
Ro/anti-La probe. However this level was still extremely low, the cell line showing 
the highest positive number of fluorescent cells showed a doubling of the mean 
percentage of Ro positive normal keratinocytes from 4 to 8% after 1 600 - 2 500 J/m2 
UVB. UV A light at doses of 50 -200 kJ/m2 had no effect on cell viability or 
autoantibody binding. In addition, in 10/12 SLE derived keratinocyte cell lines, this 
Ro/La surface expression was higher than normal controls. This was UVB dose 
dependent, although expression varied between cell lines, ranging from about 4% in 2, 
to 60% in one. This study in addition, was done using autoimmune patient sera, rather 
than purified antibodies. They used a serum with both Ro and La combined, rather 
than one specific for either. They admit that they could not exclude the possibility 
that their sera could also contain antibodies that could have bound to other antigens or 
to neoantigens created by UVR (Golan et al 1992). Golan (Golan et al 1992) used 
one single anti - SSA/SSB (Ro/La) antiserum from a patient with primary Sjogrens 
syndrome, which did not bind to other proteins on irnmunoblotting. Their results may 
be due to La translocation, as described by Bachmann (Bachmann et al 1990). 
Bachmann et al (Bachmann et al 1990) have shown that the La antigen translocates 
from the nucleus to the cytoplasm of human keratinocytes. This shuttling includes a 
translocation to the cell surface. Their method differed somewhat from those of Le 
Feher et al (who incubated antisera for an unspecified period and examined cells 8 
and 24 hours after irradiation) (Lefeber et al 1984), in incubating irradiated viable 
cells for 5 minutes with the antibody at 1 hr, 5 hrs and 24 hrs post UVB. They found 
that anti-La stained in a punctate manner on the cell surface at 1 hour after UVB but 
that this staining disappeared during further incubation, being absent at 5 hours. 
Golan (Golan et al 1992) incubated the LE keratinocytes for one hour with the 
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primary antibody at 20 hours post irradiation, having found this the best time point 
after assessing surface expression at 4, 8, 16, 20 and 24 hours after irradiation. 
Furukawa et al in their work on UVR irradiated keratinocytes (Furukawa et al 1990), 
commented that since the degree of UVL-augmented antibody binding varied with 
different cell sources, the cell source was carefully selected and cells from the same 
source were used for all experiments. However in their results the lowest scoring cell 
lines are not recorded. Rather, results represent the mean of positive cells from four 
experiments, rather than different cell lines, which would more likely resemble the 
situation in the real world. In vivo Ro augmentation on the keratinocyte surface was 
examined in suction blister roofs, 24 hours post 100 and 200 mJ/cm2• Anti-Ro serum 
bound to epidermal keratinocytes but was also seen to bind to cytoplasm and nucleus. 
This report states in the first line of discussion that their work verified that of Le Feher 
et al, that antibodies specific for Ro were induced to bind to the cell surface by UVB. 
However, it is interesting that no comment was made on the very differing doses of 
UVB used! In addition, by using "monospecific" whole sera rather than purified 
antibodies, it is possible that cross-reacting antibodies or other antibodies not detected 
by immunoblotting, CIE, or immunodiffusion might be responsible for the IgG 
binding to keratinocytes. 
Furukawa in continuing his USA work in Japan, described lupus keratinocytes as 
showing a higher susceptibility to single-dose UVB compared to those of normal 
individuals. They however give no indication of the magnitude of this upregulation 
and in addition their figures do not convince (Edwards et al 1991 ). 
A further study, using only two cell lines, one from a patient with NLE and a normal 
neonatal control, suggested that NLE keratinocytes were more likely to show surface 
expression than the normal, although they did not differentiate between Ro or La. A 
dose of 200 mJ/cm2 UVB irradiation on NLE keratinocytes induced a 2.5-3-fold 
increase in Ro/SSA and La/SSB expression compared to non-irradiated cells. Sera 
derived from both the NLE patient and from his mother exhibited a cytotoxic effect on 
NLE keratinocytes, but not on control cells, in the presence of complement. 
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Furthermore, the cytotoxicity of the sera was enhanced on UVB-irradiated NLE 
keratinocytes, whereas it had no cytotoxic effects on UVB-irradiated control cells (Yu 
et al 1996). 
It has been suggested that 52kD Ro and La may be membrane expressed by TNF 
alpha. Normal neonatal keratinocytes were treated with tumour necrosis factor alpha 
(TNF alpha) and incubated with antibodies to 52 kD Ro isolated and purified from 
patients with systemic hJpus erythematosus or Sjogren's syndrome, with mouse 
monoclonal antibody to La, normal sera and a mouse monoclonal antibody to UlRNP 
68 kDa. Membrane expression of 52 kD Ro and La was detected using cyto ELISA, 
laser scanning microscopy and indirect immunofluorescence. After incubation with 
TNF alpha, cyto ELISA revealed an increased membrane binding of 52 kD Ro 
antibodies at a maximum of two hours, followed by enhanced 52 kD Ro expression 
during the subsequent 24 hours. The La antigen was expressed rapidly after TNF 
alpha treatment (within one hour), with a fast decrease to the pre-incubation value 
within three hours. Indirect immunofluorescence with fixed normal human 
keratinocytes confirmed increased 52 kD Ro and La antigen expression after the 
incubation with TNF (Domer et al 1995). 
Some SCLE patients describe cutaneous exacerbations with heat (Sontheimer, 1985) 
Heat shock like proteins can be translocated to cell surfaces where they may 
participate in immune mediated cell injury. More recently, a group studied the 
quantitative and qualitative changes of Ro induced by stress, such as with heat shock 
and UV irradiation, and found that only Ro52 could be expressed on the cell surface 
of human peripheral lymphocytes by either heat shock or UV irradiation. Flow 
cytometric analysis showed that heat shock-treated and UV-treated lymphocytes could 
be stained with patient sera (Igarashi et al 1995). In my model, I could find no 
keratinocyte surface expression of the 52 or 60kD Ro under the influence of heat 
shock. 
The importance of using monospecific antibodies is emphasised by a paper published 
concurrently with my work (Kawashima et al 1994). They studied the effect of UVB 
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irradiation on the expression of 60k0 Ro, 52k0 Ro and calreticulin in A431 cells, a 
transformed human epidermal keratinocyte cell line. Total cellular and cell surface 
expression of each antigenic polypeptide was examined by a whole cell ELISA and 
F ACS using rabbit anti-synthetic peptide antisera as probes. They found that both 
total cellular and cell surface calreticulin but not the 60 and 52 kD Ro polypeptides 
was increased after 100J/m2 of UVB irradiation. The mean fluorescence intensity of 
cells that had been irradiated with UVB 24 hrs earlier and then stained with the anti-
calreticulin antiserum, was approximately 50% greater than control levels. No such 
differences were noted with the 60 and 52k0 Ro peptide antisera. 
I have systematically examined the influence of physiological, rather than apoptosis -
inducing doses of UVB and UV A in a number of normal neonatal human keratinocyte 
cell lines. I have additionally documented the effect of oestradiol, Vit E and C, 
Hydrochlorothiazide and heat shock on the expression of the 52 and 60 kD Ro 
antigens. I conducted my experiments on viable keratinocytes at a whole range of 
incubation durations and intervals post UVR to include all those previously described. 
I could find no translocation of these Ro antigens to the cell surface. 
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5.3 POSSIBLE ROLES PLAYED BY THE Ro ANTIGENS 
The functions of the 52- and 60-kD Ro proteins remain unknown. There is 
convincing data that the 60kD Ro protein associates with cellular h Y RNA as a 
ribonucleoprotein complex. It has also been argued that the 52-kD Ro protein is also 
a component of this complex (Peek et al 1993) but others dispute this claim (Slobbe et 
al 1992; Kelekar et al 1994). My findings indicate that the majority of 52- and 60-kD 
Ro proteins are not complexed together. I would have to add, that given some 
similarities in distribution, it is possible that some 52- and 60-kD Ro molecules are 
components of the same ribonucleoprotein particles. Cell fractionation methods and 
h Y RNA and Ro protein injection studies have demonstrated that the Ro 
ribonucleoprotein complex is located primarily in the cytoplasm (Peek et al 1994; 
Peek et al 1993). My localisation of the 60-kD Ro protein predominantly to the 
nucleus, would therefore indicate that only a minority of the total cellular 60-kD Ro 
protein is complexed with cytoplasmic h Y RNA. Peek et al have reported that the 
majority of 60-kD Ro is in fact located in the cytoplasm but antibodies cannot detect it 
because of epitope masking when the protein is part of the ribonucleoprotein particles 
(Peek et al 1993). It is possible that my IF methods of fixation and / or 
permeabilisation may have failed to preserve and / or unmask epitopes on the 
cytoplasmic form of 60-kD Ro. This is less likely, however, as I used antibodies 
reactive with at least 3 different 60-kD Ro epitopes. In addition, other investigators, 
using different IF techniques, have also found a predominantly nuclear distribution of 
the 60-kD Ro antigen (Lopez-Robles et al 1986; Ben-Chetrit et al 1988; Casciola-
Rosen et al 1994; V eldhoven et al 1995). 
It has been suggested that Ro may play a part in the control of the distribution of 
mRNAs into translationally active or inactive forms (Wolin & Steitz, 1983). It has 
also been reported that the Ro antigen may be a part of a cellular complex possessing 
endoribonuclease VII activity (Bachmann et al 1987). The fact that the 60k0 Ro 
protein contains a zinc finger, potentially capable of binding DNA, in addition to the 
putative RNA-binding domains RNPl and RNP2 may suggest that the 60kD Ro 
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resembles transcription factor Illa. This is able to bind both DNA and RNA (Miller et 
al 1985) and may therefore play a role in transcriptional regulation. 
The conspicuous movement of cytoplasmic Ro to small surface blebs early in 
apoptosis, implies that cytoplasmic Ro has an affinity for the other components in 
these blebs. It suggests that Ro has a function that is performed at the site of ER-
ribosome interaction. Such functions might include a role in protein synthesis and 
control of translational protein translocation into the ER (Peek et al 1993; Slobbe et al 
1991). 
At present very little is known about the 52kD protein but it would be interesting to 
speculate that the 52kD Ro may be involved in regulating RoRNP function. This 
regulation may be manifest at the level of protein-DNA interaction. To test this 
hypothesis, the human gene which encodes this protein was cloned in a baculovirus 
and expressed in Spodoptera frugipoda cells. Extracts from these infected insect cells 
were used as a source of protein for this study. The protein is similar in size and 
antigenicity to that expressed in human cells. This protein binds to DNA at a 
physiological temperature and is eluted with high concentrations of sodium chloride. 
Striking similarities were found between the sequence in, and adjacent to, the nucleic 
acid-binding motifs of 52 kD Ro and a growing family of zinc finger proteins which 
have been shown to bind to DNA or regulate gene expression (Frank et al 1995). 
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Skin manifestations are some of the most common symptoms and signs in the 
multifactorial autoimmune disease of SLE. Genetic factors determine the inherited 
baseline, on which environmental, hormonal and infectious triggers act to produce 
autoantibodies. 
Ro I SS-A antibodies are considered pathogenic in SCLE and NLE. Ro autoantibodies 
react with at least two distinct proteins. The 52 and 60 kD Ro antigens have been 
cloned and are structurally dissimilar. Immunoaffinity purified anti-52 and 60kD Ro 
antibodies directed against all major epitopes, are expressed in keratinocytes, with no 
cross-reaction between the two. There are differences in the position of the 52 and 60 
kD Ro proteins. The Ro52 is predominantly cytoplasmic, with the Ro60 mainly 
nuclear. 
There is, as yet, little evidence to implicate a specific Ro protein or Ro epitope in a 
particular type of Ro autoantibody-associated autoimmune disorder. Anti-Ro 
antibodies are incapable of penetrating normal viable human keratinocytes. Ro 
antigens are not translocated to the surface of normal keratinocytes under 
physiological stress, although other work has shown a wide variation in cell surface 
expression related to presumed UVB induced apoptosis. Certainly, SLE patients show 
double the concentration of surface Ro than do keratinocytes from normal individuals 
(Golan et al 1992). Autologous sera from SLE patients sometimes increased the level 
and percentage of binding, supporting the possibility that autoantibodies or cytokines 
in patients' sera might prime cells for this UVR effect. 
There is evidence of at least two forms of the 60kD Ro encoding gene (Rader et al 
1989; Deutscher et al 1988; Ben-Chetrit et al 1989). Kutsch et al have reported 
variability in Ro displacement to the keratinocyte membrane after treatment with 
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calcium ionophore or tumour necrosis factor alpha, which they suggest may arise from 
genetic differences in the keratinocyte (Kutsch et al 1991 ). It is possible that certain 
forms of a Ro protein may be more immunogenic, expressed at higher levels, or more 
easily displaced to the cell surface where it could participate in immune mediated 
injury. I used anti-60 and 52-Ro antibodies, in addition to using at least 3 different 
donors. 
In addition, other authors have shown a striking variation in the expression of the Ro 
antigen in normal human skin between different individuals, by more than 2 000-fold 
(Niimi et al 1995). This difference in expression does not appear to be related to age 
or sex, nor due to regional differences in expression, as occurs with bullous 
pemphigoid or pemphigus antigens. There was no difference in Ro and La antibody 
binding between sun-exposed and sun-protected skin. Whatever the cause, the 
heterogeneity in expression of Ro antigens is not a unique phenomenon, since 
individual variability in the expression of other keratinocyte components, such as that 
of La, cytokines, or UV light-induced intercellular adhesion molecule 1, has been 
described (Norris, 1993). 
In the course of characterising the gene encoding the human 52kD Ro protein, a 
restriction fragment length polymorphism (RFLP) was shown. Homozygosity for this 
1.5kb RFLP was strongly associated with lupus in African Americans (Frank et al 
1993 ). This polymorphism, though present in White and Japanese populations, was 
not associated with SLE in these two populations. The structure of this gene has been 
shown to be six exons spanning over 5.5kb of the human genome (Tsugu et al 1994). 
This was considered to be in the promoter region. This would be an interesting 
polymorphism, as it is present in a gene encoding an autoantigen but the association is 
with the disease as a whole, rather than with the presence of anti-52kD Ro antibodies. 
In addition, it is restricted to African-American lupus patients. However, Tsugu et al 
did not report the 5' most exon, as reported earlier (Chan et al 1991a). Therefore the 
RFLP was not in the promoter region but in the first intron (Chan et al 1995). 
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Differences in the presence of particular anti-Ro antibodies between patients may be 
based on the ability of that patient's immune system to process and recognize epitopes 
which are unique to each form of the Ro polypeptide. Given the complexity of this 
antigenic system, a reevaluation of polymorphisms of the immune response genes of 
patients with anti-Ro antibodies is in order. It is possible that polymorphisms of the 
52kD Ro gene, contribute to the SLE disease process. SLE associated polymorphisms 
of the 52kD Ro antigen may affect response to UV radiation and cell surface 
expression. This would explain the controversy surrounding the effect of UV · 
irradiation on this antigen in normal keratinocytes. It would therefore be sensible to 
detect SLE associated 52kD Ro gene polymorphisms and to define their role in the 
autoimmune disease process. This could be achieved by detecting polymorphisms in 
both the 52kD Ro gene and its promotor by SSCP and characterising these 
polymorphisms by sequencing. PCR based methods could then be designed to assign 
polymorphism frequency in both normal controls and SLE patients. It would then be 
necessary to determine functional differences due to disease associated 
polymorphisms 
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7. PROTOCOLS 
DESCRIBED 
NOT PREVIOUSLY 
Protocol 22: POLYVINYL ALCOHOL (PV A) MOUNTING MEDIUM FOR IF 
PV A (Sigma P 8136) 
Glycerin 
ddH20 
4.8g (crystalline type II) 
12.0g 
12 ml 
Tris Buffer (0.1 M, pH 8.5) 
1. 21g Tris base in 95 ml ddH20 and 3 ml lN HCl (Adjust pH as necessary) 
Place 12g glycerol in a small beaker. Add 4.8g PVA and stir well without getting 
PVA into the sides of the tube. To stop the PVA from clumping, mix the 
glycerol and PV A thoroughly before adding the ddH20. Stir well and incubate 
for 4 hours at room temperature. Then add 24 ml Tris buffer and place tube in 
a water bath (50°C) for about 10 mins with occasional stirring to dissolve the 
PV A. Clear the reagent by centrifuging at 200 for 10 mins. Store in dropper 
bottles at 4 °C. 
Appendix 
Protocol 23: BUFFERS USED FOR WESTERN BLOTTING 
The following Tris-Glycine stock solutions and buffer systems were used: 
30% acrylamide: dissolve 30g acrylamide and 0.8g bis-acrylamide (30.8%T, 2.6% 
C) in ddH20 to a final volume of 100 ml. 
Electrophoresis buffer: dissolve 3.03g Tris base, 14.4 glycine and lg SDS in 11 
ddH20 
10% Ammonium persulphate: dissolve 100 mg Ammonium persulphate in 1 ml 
ddH20. Store the solution at 4°C. Discard after 24hrs. 
Sample buffer X 2: mix 1 ml glycerol, 0.5 ml 2-mercaptoethanol, 0.3g SDS, 0.25 
ml 0.05%(w/v) bromophenol blue and 1.25 ml Upper Tris (4X) buffer. Add 
ddH20 to a final volume of 5 ml 
1.5M Tris-HCl pH 8.8: dissolve 36.34g Tris base and 0.8 SDS in 150 ml ddH20. 
Titrate to pH 8.8 with 6N HCl. Add ddH20 to final volume of 200 ml 
.SM Tris-HCl pH 6.8: dissolve 12.1 lg Tris base and 0.8g SDS in 150 ml ddH20. 
Titrate to pH 6.8 with 6N HCI. Add ddH20 to final volume of200 ml. 
20% SDS: Avoid creating dust and wear a mask. Dissolve 200g electrophoresis 
grade SDS on 800 ml ddH20. Heat to 68°C with magnetic stir bar mixer. 
Adjust pH to 7.2 by adding a few drops of concentrated HCI. Adjust volume 
to 1 I. No need to sterilize. 
Loading buffer: 0.5M Tris HCl (6.8) 2 ml+ ddH20 1.6 ml+ 10% SDS 3.2 ml+ 
2-6-mercaptoethanol 0.8 ml 
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Protocol 24: BUFFERS USED FOR ELISA 
ELISA 
Materials: 
1. antigens 
a) recombinant Ro protein 
b) control protein 
2. antisera 
a) human Ro/SSA autoimmune sera 
Appendix 
b) goat anti-human imrnunoglobulin conjugated to alkaline phosphatase (SIGMA 
A3150 - gamma chain specific) 
3. buffers/solutions 
a) coating buffer 
b) diluting buffer 
c) PBS 
d) wash buffer 
e) alkaline phosphatase wash solution 
f) substrate solution 
a)Coating buffer 
O.lM carbonate buffer, pH 9.6 = 
stock A= 0.2M: 21.2 g Na2C03 (anhydrous) per liter H20 
stock B=0.2M: 16.8 g NaHC03 per liter H20 
80 ml stock A+ 170 ml stock 8 + 250 ml H20 
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b)Diluting buffer 0.5 ml Tween 20 + 2.5 g bovine serum albumin (BSA 0.25%) + 
1.0 g goat gamma globulin (0.1%) + 1.0 g sodium azide (0.1%) + 1 X PBS to 1 liter 
( dilute 1 OX PBS 1: 10 in H20). Filter sterilize 
c)lO X PBS phosphate buffered saline, pH- 7.3 = 80 g NaCl + 2 g KCl + 11.5 g 
Na2HP04•7 H20 + 2 g KH2P04 + H20 to I liter. pH to - 7.4 with a few drops of cone. 
HCl, then autoclave. 
d)Wash buffer 0.5 ml Tween 20 0.05%) in 1 liter sterile 1 X PBS 
e) Alkaline phosphatase wash solution 
10 mM diethanolamine, pH 9.5, containing 0.5 mM MgCh 
1 OX stock solution = 0.53 gm diethanolamine + 0.05 gm MgCh/6 H20 in 50 cc 
ddH20 , pH with 1 OM NaOH (- 100-150 ul) and filter sterilise 
For IX working solution, add 5 cc to 45 cc sterile H20 
f) Substrate solution 
prepare just before use 
10 mM ethanolamine HCl, pH 9.8, containing 0.5 mM MgCh 
1 OX stock solution = 0.49 gm diethanolamine + 0.05 gm MgCb/6 H20 in 50 cc 
ddH20 , pH with lOM NaOH (- 100-150 ul) and filter sterilise 
For lX working solution, add 5 cc to 45 cc sterile H20 
add a 5 mg p-nitrophenyl phosphate tablet (sigma #N9389)to 5 cc of IX working 
solution to get enough substrate for 96 wells 
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STRIPPING AN ELISA PLATE 
Wash the plate 2-3 times with wash buffer 
150µ1 stripping buffer at room temperature in the hood into each well . Leave for 
2 hours at 37°C (molecular biology room) 
Wash buffer 6-10 times, until no smell remains 
Add DTT to Tl and T-lb wells, 100µ1/well overnight 
Wash 3-4 times to remove DTT 
Use a new plate to titre accurately 
ELISA PROTOCOL 
1. Designate the protein and sera to be placed in each well on the blank grid 
form. 
2. Dissolve each recombinant protein antigen and control protein in coating 
buffer. The final concentration of each protein in coating buffer should be 
- 5 µg/ml for each batch of protein. Some proteins are already dissolved in 
coating buffer and stored in the -70°C freezer. 
3. Coat wells with protein according to grid sheet: 
a) Add 50 µl of control antigen in coating buffer to as many wells as needed. 
b) Do the same for each recombinant protein antigen to be tested. 
c) Leave one row or column of wells empty as BLANKS. 
4. Cover plate with saran wrap and incubate overnight at 4°C. 
5. a) Shake plate over sink to remove coating buffer and pat·semi-dry on a paper 
towel. 
b) Without delay, add 100 µl of diluting buffer to each well and let plate 
incubate X 1 hr. on shaker at room temperature. Use this time to make the 
serum dilutions (see 6 below). 
c) Empty plate, add I 00 µl wash buffer and empty. 
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6. Dilute sera: 
a) Determine the amount of serum needed, as determined by the number of 
wells loaded (50µ1 each) and the serum dilution to be tested. Overestimate 
the amount of serum needed to ensure that you have a little extra to make up 
for possible pipetting errors. 
b) Add 50 µI of dilute sera to each designated well. 
7. Cover plate with saran wrap and incubate on a shaker bed at room temperature 
for 1 - 2 hours. While plate is incubating, dilute 1 µl of goat anti-human 
immunoglobulin (lgG, A or M) in 999 µl of diluting buffer for every -19 wells 
that have been coated). 
8. Empty and wash wells at least twice with 100 µl of wash buffer. 
9. Add 50 µI of goat anti-human immunoglobulin ( diluted 1: 1000 in dilution 
buffer) to each well, cover with saran wrap and incubate at room temperature 
for - 1 hour on shaker. 
IO. Wash wells: 
a) Shake plate out over the sink and wash each well X 3 with 100 - 200µ1 
wash buff er. 
b) Then wash each well once with 100 µI of alkaline wash solution. 
11. Add 50 µI of substrate solution to each well, cover with foil, place on shaker 
platform and watch closely for colour change (this usually takes between 15 -
30 minutes). 
12. As the wells darken, check the ODs at 405 nM frequently until the darkest well 
has an OD - 1.5 to 1.9 OD units. 
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